

WEST Search History

[Hide Items](#) | [Restore](#) | [Clear](#) | [Cancel](#)

DATE: Thursday, March 03, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L25	L24 AND brain tumor	35
<input type="checkbox"/>	L24	L23 AND L13 AND L14	360
<input type="checkbox"/>	L23	L22 AND L19	542
<input type="checkbox"/>	L22	adoptive immunotherapy	1317
<input type="checkbox"/>	L21	(514/2.CCLS.)	6623
<input type="checkbox"/>	L20	L12 AND L13 AND L14 AND L19 AND brain tumor	11
<input type="checkbox"/>	L19	(lymphokine-activated killer cells OR LAK)	4806
<input type="checkbox"/>	L18	L17 AND brain tumor	28
<input type="checkbox"/>	L17	= 2002	231
<input type="checkbox"/>	L16	L15 AND tumor	264
<input type="checkbox"/>	L15	L12 AND L13 AND L14	326
<input type="checkbox"/>	L14	prolonged OR slowly OR slow OR dilute OR low-dosage	1342158
<input type="checkbox"/>	L13	interleukin-2 OR IL-2	24916
<input type="checkbox"/>	L12	424/93.1,93.7,529,530,534.CCLS.	2784
<input type="checkbox"/>	L11	Svadovskiy-A-I.IN.	3
<input type="checkbox"/>	L10	Svadovskiy-A.IN.	0
<input type="checkbox"/>	L9	Svadovskiy-Aleksandr.IN.	0
<input type="checkbox"/>	L8	Svadovskiy-Aleksandr-I.IN.	0
<input type="checkbox"/>	L7	(Svadovskiy-Aleksandr-Igorevich.IN.)	4
<input type="checkbox"/>	L6	Svadovskiy.IN.	8
<input type="checkbox"/>	L5	Svadovskiy-I.IN.	0
<input type="checkbox"/>	L4	Svadovskiy-I-A.IN.	0
<input type="checkbox"/>			

	L3	Svadovskiy-Igorevich.IN.	0
<input checked="" type="checkbox"/>	L2	Svadovskiy-Igorevich-A.IN.	0
<input type="checkbox"/>	L1	(Svadovskiy-Igorevich-Aleksandr.IN.)	0


END OF SEARCH HISTORY

Untitled


5449522
5840770
6203787
6207147
6666213
6716425
5837233
6136306
6190656
6251385
6277368
4690915
4808151
4832686
4849329
5002879
5041289
5108760
5126132
5425940
5696079
5800810
5837231
5837233
5840770
5843435
5846827
5919700
5962318
6013659
6022538
6136306
6190656
6203787
6251385
6277368
6503503
6716425

US20020187130
US20030039650
US20030095955
US20030068306
US20010038841
US20010036458
US20030014055
US20030034038
US20030044387
US20030068298
US20030105507

AU009050726A
RU 2185106C



National
Library
of Medicine NLM



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journa

Search [PubMed]

for yeast IL-2 AND tumor

Go

Clear

Sa

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)
[Display](#) [Summary](#)

Show: 500

Sort

Send to

Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed
Services

Journals

Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

My NCBI

(Cubby)

Related
Resources
Order

Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

All: 54 Review: 1

Items 1 - 54 of 54

On

1: Chiapello LS, Baronetti JL, Aoki MP, Gea S, Rubinstein H, Masih DT. [Related Article](#)

Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan.

Immunology. 2004 Nov;113(3):392-400.
PMID: 15500627 [PubMed - indexed for MEDLINE]

2: Maffei CM, Mirels LF, Sobel RA, Clemons KV, Stevens DA. [Related Article](#)

Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis.

Infect Immun. 2004 Apr;72(4):2338-49.
PMID: 15039359 [PubMed - indexed for MEDLINE]

3: Lilic D, Gravenor I, Robson N, Lammas DA, Drysdale P, Calvert JE, Cant AJ, Abinun M. [Related Article](#)

Deregulated production of protective cytokines in response to *Candida albicans* infection in patients with chronic mucocutaneous candidiasis.

Infect Immun. 2003 Oct;71(10):5690-9.
PMID: 14500490 [PubMed - indexed for MEDLINE]

4: Biondo C, Beninati C, Bombaci M, Messina L, Mancuso G, Midiri A, Galbo R, Teti G. [Related Article](#)

Induction of T helper type 1 responses by a polysaccharide deacetylase from *Cryptococcus neoformans*.

Infect Immun. 2003 Sep;71(9):5412-7.
PMID: 12933895 [PubMed - indexed for MEDLINE]

□ 5: [Farah CS, Gotjamano T, Seymour GJ, Ashman RB.](#) Related Article

□ Cytokines in the oral mucosa of mice infected with *Candida albicans*.
Oral Microbiol Immunol. 2002 Dec;17(6):375-8.
PMID: 12485329 [PubMed - indexed for MEDLINE]

□ 6: [Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, Kuroki M, Kuroki M.](#) Related Article

□ Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
Anticancer Res. 2002 Jul-Aug;22(4):2001-7.
PMID: 12174877 [PubMed - indexed for MEDLINE]

□ 7: [Johnson LM, Too CK.](#) Related Article

□ Prolactin, interleukin-2 and FGF-2 stimulate expression, nuclear distribution and DNA-binding of rat homolog of pombe Cdc5 in Nb2 T lymphoma cells.
Mol Cell Endocrinol. 2001 Nov 26;184(1-2):151-61.
PMID: 11694351 [PubMed - indexed for MEDLINE]

□ 8: [Abe Y, Matsumoto S, Wei S, Nezu K, Miyoshi A, Kito K, Ueda N, Shigemoto K, Hitsumoto Y, Nikawa J, Enomoto Y.](#) Related Article

□ Cloning and characterization of a p53-related protein kinase expressed in interleukin-2-activated cytotoxic T-cells, epithelial tumor cell lines, and the testes.
J Biol Chem. 2001 Nov 23;276(47):44003-11. Epub 2001 Sep 06
PMID: 11546806 [PubMed - indexed for MEDLINE]

□ 9: [Ohnmacht GA, Phan GQ, Mavroukakis SA, Steinberg SM, Shea YR, Witebsky FG, McIntyre LS, Goodwin RS, Muehlbauer PM, Morton KE, Rogers-Freezer LJ, Seipp CA, Rosenberg SA, Marincola FM.](#) Related Article

□ A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2.
J Immunother. 2001 Mar-Apr;24(2):188-92.
PMID: 11265777 [PubMed - indexed for MEDLINE]

□ 10: [Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G.](#) Related Article

Seborrhoeic dermatitis and Pityrosporum (*Malassezia*) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry.
Br J Dermatol. 2001 Mar;144(3):549-56.
PMID: 11260013 [PubMed - indexed for MEDLINE]

□ 11: [Rajagopal K, Sommers CL, Decker DC, Mitchell EO, Korthauer U, Sperling AI, Kozak CA, Love PE, Bluestone JA.](#) Related Article

RIBP, a novel Rlk/Txk- and itk-binding adaptor protein regulates T cell activation.
J Exp Med. 1999 Dec 6;190(11):1657-68.
PMID: 10587356 [PubMed - indexed for MEDLINE]

□ 12: [Talluri G, Marella VK, Shirazian D, Wise GJ.](#) Related Article

Immune response in patients with persistent candiduria occult candidemia.
J Urol. 1999 Oct;162(4):1361-4.
PMID: 10492197 [PubMed - indexed for MEDLINE]

□ 13: [Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, van Zanten-Przybysz I, Hummel P, Nijman HW, Kenemans P, Hilgers J.](#) Related Article

Cellular and humoral immune responses to MUC1 muc tandem-repeat peptides in ovarian cancer patients and controls.
Cancer Immunol Immunother. 1999 Apr;48(1):47-55.
PMID: 10235488 [PubMed - indexed for MEDLINE]

□ 14: [Dhillon S, Saxena RK.](#) Related Article

Tumor specific boosting of IL-2 induced NK activation paraformaldehyde fixed tumor cells.
Immunol Lett. 1998 Oct;63(3):153-8.
PMID: 9840684 [PubMed - indexed for MEDLINE]

□ 15: [Zanetta JP, Bonaly R, Maschke S, Strecker G, Michalski JC.](#) Related Article

Differential binding of lectins IL-2 and CSL to candida albicans and cancer cells.

Glycobiology. 1998 Mar;8(3):221-5.
PMID: 9451031 [PubMed - indexed for MEDLINE]

□ 16: Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT. Related Article.

□ Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res. 1995;1:53-71. Review.
PMID: 9552353 [PubMed - indexed for MEDLINE]

□ 17: Estrada A, Yun CH, Van Kessel A, Li B, Hauta S, Laarveld B. Related Article.

□ Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol Immunol. 1997;41(12):991-8.
PMID: 9492185 [PubMed - indexed for MEDLINE]

□ 18: Vecchiarelli A, Retini C, Monari C, Casadevall A. Related Article.

□ Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T-cell proliferation. Infect Immun. 1998 Mar;66(3):1244-7.
PMID: 9488420 [PubMed - indexed for MEDLINE]

□ 19: Vazquez N, Walsh TJ, Friedman D, Chanock SJ, Lyman CA. Related Article.

□ Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against *Candida albicans*. Infect Immun. 1998 Jan;66(1):145-50.
PMID: 9423851 [PubMed - indexed for MEDLINE]

□ 20: Grazziutti ML, Rex JH, Cowart RE, Anaissie EJ, Ford A, Savary CA. Related Article.

□ Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis. 1997 Dec;176(6):1579-83.
PMID: 9395370 [PubMed - indexed for MEDLINE]

□ 21: Buchanan KL, Murphy JW. Related Article.

□ Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity.

reaction.

Immunology. 1997 Feb;90(2):189-97.

PMID: 9135546 [PubMed - indexed for MEDLINE]

□ 22: Brunn GJ, Williams J, Sabers C, Wiederrecht G, Related Article
Lawrence JC Jr, Abraham RT.

□ Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
EMBO J. 1996 Oct 1;15(19):5256-67.
PMID: 8895571 [PubMed - indexed for MEDLINE]

□ 23: Meyer CF, Wang X, Chang C, Templeton D, Related Article
Tan TH.

□ Interaction between c-Rel and the mitogen-activated protein kinase kinase kinase 1 signaling cascade in mediating kappaB enhancer activation.
J Biol Chem. 1996 Apr 12;271(15):8971-6.
PMID: 8621542 [PubMed - indexed for MEDLINE]

□ 24: Kondo Y, Uchino J, Sawaguchi Y, Shirato H, Related Article
Gondo H, Hase T, Saito I, Higashi T, Hosokawa M, Kobayashi H.

□ Evaluation of multi skin test in colorectal cancer patients
effects of serum immunosuppressive factor and cytokin production of peripheral mononuclear cells.
Am J Clin Oncol. 1996 Apr;19(2):159-63.
PMID: 8610641 [PubMed - indexed for MEDLINE]

□ 25: Ashman RB, Bolitho EM, Fulurija A, Related Article

□ Cytokine mRNA in brain tissue from mice that show strain dependent differences in the severity of lesions induced by systemic infection with Candida albicans yeast.
J Infect Dis. 1995 Sep;172(3):823-30.
PMID: 7658077 [PubMed - indexed for MEDLINE]

□ 26: Wang X, Fiscus RR, Yang L, Mathews HL, Related Article

□ Suppression of the functional activity of IL-2-activated lymphocytes by CGRP.
Cell Immunol. 1995 Apr 15;162(1):105-13.
PMID: 7704898 [PubMed - indexed for MEDLINE]

Grinev MV, Tsibin JuN, Tarelkina MN.

□ 27: [Gromov MI, Shirokov DM, Pivovarova LP, Erolov GM, Razumova NK, Masiianskaia TI, Ariskina OB.](#) Related Article
[A first trial of the use of human recombinant interleukin (rIL-2) in patients with tumorous diseases]
Vestn Khir Im I I Grek. 1995;154(2):57-60. Russian.
PMID: 8540190 [PubMed - indexed for MEDLINE]

□ 28: [Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM.](#) Related Article
Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.
Nature. 1994 Dec 8;372(6506):570-3.
PMID: 7990932 [PubMed - indexed for MEDLINE]

□ 29: [Duan X, Ackerly M, Vivier E, Anderson P.](#) Related Article
Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function.
Cell Immunol. 1994 Sep;157(2):393-402.
PMID: 8069924 [PubMed - indexed for MEDLINE]

□ 30: [Sjogren-Jansson E, Gustafsson C, Jeansson S, Karlsson U, Lycke N.](#) Related Article
Production of large amounts of recombinant interleukin cDNA transfected mouse myeloma cells cultured in dialysis tubing.
J Immunol Methods. 1994 Jan 12;168(1):131-6.
PMID: 8288889 [PubMed - indexed for MEDLINE]

□ 31: [Gomez MJ, Torosantucci A, Quinti I, Testa U, Peschle C, Cassone A.](#) Related Article
Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
Cell Immunol. 1993 Dec;152(2):530-43.
PMID: 8258154 [PubMed - indexed for MEDLINE]

□ 32: [Murphy JW.](#) Related Article
Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response.

Infect Immun. 1993 Nov;61(11):4750-9.

PMID: 8406874 [PubMed - indexed for MEDLINE]

□ 33: Ausiello CM, Urbani F, Gessani S, Spagnoli GC, Gomez MJ, Cassone A. Related Article

 Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from *Candida albicans*.

Infect Immun. 1993 Oct;61(10):4105-11.

PMID: 8406799 [PubMed - indexed for MEDLINE]

□ 34: Kimura L. Related Article

 Immunologic aspects of kampo medicine.
Ann N Y Acad Sci. 1993 Jun 23;685:529-42. No abstract available
PMID: 8363262 [PubMed - indexed for MEDLINE]

□ 35: Levitz SM, Dupont MP. Related Article

 Phenotypic and functional characterization of human lymphocytes activated by interleukin-2 to directly inhibit growth of *Cryptococcus neoformans* in vitro.

J Clin Invest. 1993 Apr;91(4):1490-8.

PMID: 7682573 [PubMed - indexed for MEDLINE]

□ 36: Wei S, Blanchard DK, Liu JH, Leonard WJ, Djeu JY. Related Article

 Activation of tumor necrosis factor-alpha production from human neutrophils by IL-2 via IL-2-R beta.

J Immunol. 1993 Mar 1;150(5):1979-87.

PMID: 8436829 [PubMed - indexed for MEDLINE]

□ 37: Djeu JY, Liu JH, Wei S, Rui H, Pearson CA, Leonard WJ, Blanchard DK. Related Article

 Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against *Candida albicans* by IL-2.

J Immunol. 1993 Feb 1;150(3):960-70.

PMID: 8380826 [PubMed - indexed for MEDLINE]

□ 38: Sakata T, Iwagami S, Tsuruta Y, Teraoka H, Suzuki S, Suzuki R. Related Article

 Role of colony-stimulating factor-1 in macrophage activation in tumor-bearing mice.

J Immunol. 1992 Dec 15;149(12):4002-8.

PMID: 1281198 [PubMed - indexed for MEDLINE]

□ 39: Levitz SM.

[Related Article](#)



Activation of human peripheral blood mononuclear cell interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun. 1991 Oct;59(10):3393-7.
PMID: 1894353 [PubMed - indexed for MEDLINE]

□ 40: Quinti I, Palma C, Guerra EC, Gomez MJ, Mezzaroma I, Aiuti F, Cassone A.

[Related Article](#)



Proliferative and cytotoxic responses to mannoproteins Candida albicans by peripheral blood lymphocytes of H infected subjects. Clin Exp Immunol. 1991 Sep;85(3):485-92.
PMID: 1893630 [PubMed - indexed for MEDLINE]

□ 41: Miura K, Itoh Y, Kadokawa Y, Kagaya M, Sasaki M, Shioya T, Miura M.

[Related Article](#)



Reaction of mononuclear cells from patients with bronc asthma to Candida albicans. Tohoku J Exp Med. 1991 May;164(1):1-12.
PMID: 1926141 [PubMed - indexed for MEDLINE]

□ 42: Lindemann RA, Franker CK.

[Related Article](#)



Phagocyte-mediated killing of Candida tropicalis. Mycopathologia. 1991 Feb;113(2):81-7.
PMID: 1903513 [PubMed - indexed for MEDLINE]

□ 43: Ausiello CM, Palma C, Maleci A, Spagnoli GC, Amici C, Antonelli G, Casciani CU, Cassone A.

[Related Article](#)



Cell mediated cytotoxicity and cytokine production in peripheral blood mononuclear cells of glioma patients. Eur J Cancer. 1991;27(5):646-50.
PMID: 1711354 [PubMed - indexed for MEDLINE]

□ 44: Scaringi L, Cornacchione P, Rosati E, Boccanera M, Cassone A, Bistoni F, Marconi P.

[Related Article](#)



Induction of LAK-like cells in the peritoneal cavity of r by inactivated Candida albicans. Cell Immunol. 1990 Sep;129(2):271-87.
PMID: 2166624 [PubMed - indexed for MEDLINE]

□ 45: Hockertz S.

[Related Article](#)

 [Immunomodulating effect of lysed immunoactive fraction of selected Escherichia coli strains on the macrophage system. An in vitro study]
Arzneimittelforschung. 1990 Sep;40(9):1068-72. German.
PMID: 2080945 [PubMed - indexed for MEDLINE]

□ 46: Ausiello CM, Palma C, Spagnoli GC, Piazza A, [Related Article](#)
Casciani CU, Cassone A.

 Cytotoxic effectors in human peripheral blood mononuclear cells induced by a mannoprotein complex of Candida albicans: a comparison with interleukin 2-activated killer cells.
Cell Immunol. 1989 Jul;121(2):349-59.
PMID: 2661020 [PubMed - indexed for MEDLINE]

□ 47: Zunich KM, Kirkpatrick CH. [Related Article](#)

 Methionine-enkephalin as immunomodulator therapy in human immunodeficiency virus infections: clinical and immunological effects.
J Clin Immunol. 1988 Mar;8(2):95-102.
PMID: 2967309 [PubMed - indexed for MEDLINE]

□ 48: Maleci A, Ausiello C, Gagliardi FM, Guidetti B, [Related Article](#)
Cassone A.

 The response of peripheral blood mononuclear cells of glioma-bearing patients to stimulation with microbial agents and IL-2: proliferation and IFN-gamma production.
Acta Neurochir Suppl (Wien). 1988;43:130-4.
PMID: 3145674 [PubMed - indexed for MEDLINE]

□ 49: Baccarini M, Hao L, Decker T, Lohmann- Matthes ML. [Related Article](#)

 Macrophage precursors as natural killer cells against tumor cells and microorganisms.
Nat Immun Cell Growth Regul. 1988;7(5-6):316-27.
PMID: 2906114 [PubMed - indexed for MEDLINE]

□ 50: Djeu JY, Blanchard DK. [Related Article](#)

 Regulation of human polymorphonuclear neutrophil (PMN) activity against Candida albicans by large granular

lymphocytes via release of a PMN-activating factor.
J Immunol. 1987 Oct 15;139(8):2761-7.
PMID: 2443572 [PubMed - indexed for MEDLINE]

□ 51: Ausiello CM, Spagnoli GC, Antonelli G, Malavasi F, Dianzani F, Casciani CU, Cassone A. Generation and characterization of cytotoxic activity ag tumor cell lines in human peripheral blood mononuclea stimulated "in vitro" by a glucomannan-protein prepara of *Candida albicans*. J Biol Regul Homeost Agents. 1987 Apr-Jun;1(2):59-68. PMID: 3142217 [PubMed - indexed for MEDLINE]

□ 52: Shaw AR, Bleackley RC, Merryweather JP, Barr PJ. Modulation of human natural killer cell activity by recombinant human interleukin 2. Cell Immunol. 1985 Mar;91(1):193-200. PMID: 3871664 [PubMed - indexed for MEDLINE]

□ 53: Shaw AR, Bleackley RC, Merryweather JP, Barr PJ. Modulation of human natural killer cell activity by recombinant human interleukin 2. Cell Immunol. 1985 Feb;90(2):547-54. PMID: 3881192 [PubMed - indexed for MEDLINE]

□ 54: Nag S, Sharma A, Talukder G. Differential action of mitogens on human lymphocytes cancer patients. Indian J Pathol Microbiol. 1983 Jul;26(3):145-51. No abstract available. PMID: 6365761 [PubMed - indexed for MEDLINE]

Display [Summary](#) Show: 500 [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)


[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Search [PubMed]

for Roncoleukin

Go

Clear

Save

Limits Preview/Index History Clipboard Details
 Display Summary Show: 20 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed

Services

Journals

Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

My NCBI

(Cubby)

Related

Resources

Order

Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

All: 5 Review: 0

Items 1 - 5 of 5

On

- 1: [Skvortsova LA, Pavlova MV, Vinogradova TI, Archakova LI.](#) Related Article
- [Combined therapy of pulmonary tuberculosis by using recombinant interleukins] Probl Tuberk Bolezn Legk. 2003;(10):9-12. Russian. PMID: 14669620 [PubMed - indexed for MEDLINE]
- 2: [Lebedev VF, Kozlov VK, Gavrilin SV.](#) Related Article
- [Immunopathogenesis of severe wounds and traumas: possibilities of immune correction] Vestn Khir Im I I Grek. 2002;161(4):85-90. Russian. PMID: 12577564 [PubMed - indexed for MEDLINE]
- 3: [Ostanin AA, Zainutdinov IuG, Strel'tsova EI, Ovechkin AV, Ageev NL, Leplina OIu, Tikhonova MA, Chernykh ER.](#) Related Article
- [Surgical sepsis. II. Effectiveness of immune therapy with recombinant interleukin-2] Vestn Khir Im I I Grek. 2002;161(4):79-84. Russian. PMID: 12577563 [PubMed - indexed for MEDLINE]
- 4: [Ismail-zade RS, Buglova SE, Potapnev MP, Sachivko NV, Semenov AS, Rud'ko VS, Shman TV, Zhavrid EA.](#) Related Article
- [Salvage thermochemotherapy in advanced refractory malignant tumors in children] Vopr Onkol. 2002;48(3):351-5. Russian. PMID: 12455361 [PubMed - indexed for MEDLINE]
- 5: [Knoring BE, El'kin AV, Smirnov MN, Sakharova Il'a, Basek TS.](#) Related Article

 [Roncoleukin immunomodulation in pulmonary tubercul
Probl Tuberk. 1999;(5):26-9. Russian.
PMID: 10565213 [PubMed - indexed for MEDLINE]

Display [Summary](#) Show: 20 Sort Send to [Text](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)


[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine



All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Search PubMed

for interleukin-2 AND prolonged infusion

Go

Clear

Save

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)
Display Show: Sort Send to Text

About Entrez

[Text Version](#)

Items 1 - 77 of 77

On

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed

Services

Journals

Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

My NCBI

(Cubby)

Related

Resources

Order

Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

All: 77 Review: 4

Items 1 - 77 of 77

1: [Donckier V, Troisi R, Toungouz M, Colle I, Van Vlierberghe H, Jacquy C, Martiat P, Stordeur P, Zhou L, Boon N, Lambermont M, Schandene L, Van Laethem JL, Noens L, Gelin M, de Hemptinne B, Goldman M.](#) Related Article

2: [Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-liver graft.](#) Transpl Immunol. 2004 Sep-Oct;13(2):139-46.
PMID: 15380544 [PubMed - indexed for MEDLINE]

3: [Kelsen J, Agnholt J, Falborg L, Nielsen JT, Romer JL, Hoffmann HJ, Dahlerup JE.](#) Related Article

4: [Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show detectable homing to the gut in vivo.](#) Clin Exp Immunol. 2004 Oct;138(1):66-74.
PMID: 15373907 [PubMed - indexed for MEDLINE]

5: [Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.](#) Related Article

6: [Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.](#) Clin Cancer Res. 2004 Jul 15;10(14):4839-47.
PMID: 15269160 [PubMed - indexed for MEDLINE]

7: [Praditpornsilpa K, Avihingsanon Y, Kupatawintu P, Songpanich S, Pisitkul T, Kansanabuch T, Eiam-Ong S, Chusil S, O-Charoen R, Tungsanga](#) Related Article

K.

 Monitoring of T-cell subsets in patients treated with anti-25 antibody.

Transplant Proc. 2004 Mar;36(2 Suppl):487S-491S.

PMID: 15041394 [PubMed - indexed for MEDLINE]

 **5:** Linn YC, Hui KM. Related Article

 Cytokine-induced killer cells: NK-like T cells with cytotoxic specificity against leukemia.

Leuk Lymphoma. 2003 Sep;44(9):1457-62. Review.

PMID: 14565644 [PubMed - indexed for MEDLINE]

 **6:** Stepkowski SM. Related Article

 Preclinical results of sirolimus treatment in transplant models.

Transplant Proc. 2003 May;35(3 Suppl):219S-226S. Review.

PMID: 12742499 [PubMed - indexed for MEDLINE]

 **7:** Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C, Bordignon C, Bonini C. Related Article

 Immunologic potential of donor lymphocytes expressing suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003 Feb 15;101(4):1290-8. Epub 2002 Oct 03.

PMID: 12393508 [PubMed - indexed for MEDLINE]

 **8:** Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R. Related Article

 Treatment of Raynaud's phenomenon with intravenous prostaglandin E1 alpha-cyclodextrin improves endothelial injury in systemic sclerosis.

J Rheumatol. 2001 Apr;28(4):786-94.

PMID: 11327251 [PubMed - indexed for MEDLINE]

 **9:** Clemons-Miller AR, Chatta GS, Hutchins L, Angtuaco EJ, Ravaggi A, Santin AD, Cannon MJ. Related Article

 Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.

Clin Cancer Res. 2001 Mar;7(3 Suppl):917s-924s.

PMID: 11300492 [PubMed - indexed for MEDLINE]

Zhang JL, Yamaguchi Y, Mori K, Okabe K,

□ 10: [Hidaka H, Ohshiro H, Uchino S, Ishihara K, Furuhashi T, Yamada S, Ogawa M.](#) Related Article.
A serine protease inhibitor, N-alpha-tosyl-l-lysine chloromethyl ketone, prolongs rat hepatic allograft survival. *J Surg Res.* 2001 Apr;96(2):296-303.
PMID: 11266287 [PubMed - indexed for MEDLINE]

□ 11: [Helmy SA, Al-Attiyah RJ.](#) Related Article.
The immunomodulatory effects of prolonged intravenous infusion of propofol versus midazolam in critically ill surgical patients. *Anaesthesia.* 2001 Jan;56(1):4-8.
PMID: 11167428 [PubMed - indexed for MEDLINE]

□ 12: [Safar M, Junghans RP.](#) Related Article.
Interleukin 2 maintains biologic stability and sterility over prolonged time. *Immunopharmacology.* 2000 Sep;49(3):419-23.
PMID: 10996039 [PubMed - indexed for MEDLINE]

□ 13: [Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM.](#) Related Article.
Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) CD8(+) T cells in human immunodeficiency virus-infected subjects. *Blood.* 2000 Aug 1;96(3):785-93.
PMID: 10910888 [PubMed - indexed for MEDLINE]

□ 14: [Dillman RO, Wiemann MC, Bury MJ, Church C, DePriest C.](#) Related Article.
Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II study of the National Biotherapy Study Group. *Cancer Biother Radiopharm.* 1997 Feb;12(1):5-11.
PMID: 10851441 [PubMed - indexed for MEDLINE]

□ 15: [Bordin V, Giani L, Meregalli S, Bukovec R, Vaghi MM, Mandala M, Paolorossi F, Ardizzoia A, Tancini G, Barni S, Frigerio F,](#) Related Article.

Fumagalli L, Bordoni A, Valsuani G, Di Felice G, Lissoni P.

Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Urol Int. 2000;64(1):3-8.
PMID: 10782024 [PubMed - indexed for MEDLINE]

16: Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T. Related Article
Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Cancer J Sci Am. 2000 Feb;6 Suppl 1:S93-8.
PMID: 10685667 [PubMed - indexed for MEDLINE]

17: Fisher RI, Rosenberg SA, Fyfe G. Related Article
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
Cancer J Sci Am. 2000 Feb;6 Suppl 1:S55-7.
PMID: 10685660 [PubMed - indexed for MEDLINE]

18: Schiphorst PP, Chang PC, Clar N, Schoemaker RC, Osanto S. Related Article
Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer.
Ann Oncol. 1999 Nov;10(11):1381-3.
PMID: 10631470 [PubMed - indexed for MEDLINE]

19: Chakraborty N, Bilgrami S, Maness L, Guo C, Perez-Diez A, Mukherji B, Tutschka P. Related Article
Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: immunologic consequences affecting clinical outcome.
Bone Marrow Transplant. 1999 Oct;24(8):837-43.
PMID: 10516693 [PubMed - indexed for MEDLINE]

20: Lu L, Li W, Zhong C, Qian S, Fung JJ, Thomson AW, Starzl TE. Related Article
Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with

prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L m
Transplantation. 1999 Sep 27;68(6):747-57.
PMID: 10515374 [PubMed - indexed for MEDLINE]

□ 21: Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J. Related Article

□ Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar;2(3):493-9.
PMID: 9816195 [PubMed - indexed for MEDLINE]

□ 22: Nicolini A, Carpi A, Ferrari P, Sagripanti A, Anselmi L. Related Article

□ A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. Biomed Pharmacother. 1998;52(7-8):311-6.
PMID: 9809175 [PubMed - indexed for MEDLINE]

□ 23: Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S. Related Article

□ Donor blood monocytes but not T or B cells facilitate long term allograft survival after total lymphoid irradiation. Transplantation. 1998 Sep 15;66(5):585-93.
PMID: 9753336 [PubMed - indexed for MEDLINE]

□ 24: Gorczyński RM, Chen Z, Zeng H, Gorczyński L, Terzioglu E. Related Article

□ Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells with or without additional anti-cytokine monoclonal antibodies. Immunology. 1998 Feb;93(2):221-9.
PMID: 9616372 [PubMed - indexed for MEDLINE]

□ 25: Mourad GJ, Preffer FI, Wee SL, Powelson JA, Kawai T, Delmonico FL, Knowles RW, Cosimi B. Related Article

AB, Colvin RB.

 Humanized IgG1 and IgG4 anti-CD4 monoclonal antibody effects on lymphocytes in the blood, lymph nodes, and allografts in cynomolgus monkeys.
Transplantation. 1998 Mar 15;65(5):632-41.
PMID: 9521196 [PubMed - indexed for MEDLINE]

 **26:** Vey N, Viens P, Fossat C, Olive D, Sainty D, Baume D, Stoppa AM, Bouabdallah R, Brandely M, Gastaut JA, Maraninchi D, Blaise D.
Clinical and biological effects of gamma interferon and combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
Eur Cytokine Netw. 1997 Dec;8(4):389-94.
PMID: 9459619 [PubMed - indexed for MEDLINE]

 **27:** Edwards RP, Gooding W, Lemmersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldissari M, Kirkwood JM, Herberman RB.
Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer platinum: twenty-four-hour versus 7-day infusion.
J Clin Oncol. 1997 Nov;15(11):3399-407.
PMID: 9363872 [PubMed - indexed for MEDLINE]

 **28:** Fehniger TA, Carson WE, Mrozek E, Caligiuri MA.
Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.
Blood. 1997 Nov 1;90(9):3647-53.
PMID: 9345049 [PubMed - indexed for MEDLINE]

 **29:** Saxton ML, Longo DL, Wetzel HE, Tribble H, Alvord WG, Kwak LW, Leonard AS, Ullmann CD, Curti BD, Ochoa AC.
Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Blood. 1997 Apr 1;89(7):2529-36.

PMID: 9116299 [PubMed - indexed for MEDLINE]

□ 30: [Yim CY, Lee CW, Choi SM, Park SS, Lee SJ, Kim JH, Song JS, Yoo WH, Kwak JY, Sohn MH.](#) Related Article

Effects of nitric oxide (NO) synthesis inhibition on anti responses during interleukin-2 (IL-2) treatment of mice
Korean J Intern Med. 1996 Jun;11(2):93-100.
PMID: 8854644 [PubMed - indexed for MEDLINE]

□ 31: [Meloni G, Vignetti M, Andrizzi C, Capria S, Eoa R, Mandelli F.](#) Related Article

Effects of nitric oxide (NO) synthesis inhibition on anti responses during interleukin-2 (IL-2) treatment of mice
Korean J Intern Med. 1996 Jun;11(2):93-100.
Leuk Lymphoma. 1996 May;21(5-6):429-35.
PMID: 9172807 [PubMed - indexed for MEDLINE]

□ 32: [Chung SW, Gould B, Gorczynski R.](#) Related Article

Effects of nitric oxide (NO) synthesis inhibition on anti responses during interleukin-2 (IL-2) treatment of mice
Korean J Intern Med. 1996 Jun;11(2):93-100.
Leuk Lymphoma. 1996 May;21(5-6):429-35.
PMID: 8803613 [PubMed - indexed for MEDLINE]

□ 33: [Goey SH, Eggermont AM, Oskam R, Wiggers T, Bolhuis RL, Stoter G.](#) Related Article

Effects of nitric oxide (NO) synthesis inhibition on anti responses during interleukin-2 (IL-2) treatment of mice
Korean J Intern Med. 1996 Jun;11(2):93-100.
Leuk Lymphoma. 1996 May;21(5-6):429-35.
PMID: 8740799 [PubMed - indexed for MEDLINE]

□ 34: [Raspadori D, Lauria F, Ventura MA, Tazzari PL, Ferrini S, Miggiano MC, Rondelli D, Tura S.](#) Related Article

Effects of nitric oxide (NO) synthesis inhibition on anti responses during interleukin-2 (IL-2) treatment of mice
Korean J Intern Med. 1996 Jun;11(2):93-100.
Leuk Lymphoma. 1996 May;21(5-6):429-35.
PMID: 7578523 [PubMed - indexed for MEDLINE]

□ 35: [Harris TJ, Waltman TJ, Carter SM, Maisel AS.](#) Related Article

-  Effect of prolonged catecholamine infusion on immunoregulatory function: implications in congestive failure.
J Am Coll Cardiol. 1995 Jul;26(1):102-9.
PMID: 7797738 [PubMed - indexed for MEDLINE]
- 36:** Patselas T, Thomas F, Araneda D, Marchman W. [Related Article](#)
 Role of natural killer and killer cells in concordant xenograft rejection.
Transplant Proc. 1995 Feb;27(1):262-3.
PMID: 7878995 [PubMed - indexed for MEDLINE]
- 37:** Schiller JH, Morgan-Ihrig C, Levitt ML. [Related Article](#)
 Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer.
Am J Clin Oncol. 1995 Feb;18(1):47-51.
PMID: 7847259 [PubMed - indexed for MEDLINE]
- 38:** Merrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B, Moskovtchenko JF, Tolstoshev P, Moen R, Philip T, et al. [Related Article](#)
 Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
J Clin Oncol. 1995 Feb;13(2):410-8.
PMID: 7844602 [PubMed - indexed for MEDLINE]
- 39:** Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J. [Related Article](#)
 Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer.
Clin Exp Immunol. 1995 Feb;99(2):143-7.
PMID: 7531626 [PubMed - indexed for MEDLINE]
- 40:** Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM. [Related Article](#)
 Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody rituximab.
J Clin Oncol. 1995 Feb;13(2):419-26.
PMID: 7844603 [PubMed - indexed for MEDLINE]

CLB-CD19.

Cancer Immunol Immunother. 1995 Jan;40(1):37-47.
PMID: 7530170 [PubMed - indexed for MEDLINE]

□ 41: Hellstrand K, Naredi P, Lindner P, Lundholm K, Rudenstam CM, Hernodsson S, Asztely M, Hafstrom L. Related Article
Histamine in immunotherapy of advanced melanoma: a study.
Cancer Immunol Immunother. 1994 Dec;39(6):416-9.
PMID: 8001030 [PubMed - indexed for MEDLINE]

□ 42: Parent JM, Lowenstein DH. Related Article
Treatment of refractory generalized status epilepticus w continuous infusion of midazolam.
Neurology. 1994 Oct;44(10):1837-40.
PMID: 7936232 [PubMed - indexed for MEDLINE]

□ 43: Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F. Related Article
Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.
Blood. 1994 Oct 1;84(7):2158-63.
PMID: 7919330 [PubMed - indexed for MEDLINE]

□ 44: Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH. Related Article
Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release v increasing IL-4/IL-10 production.
J Surg Res. 1994 Jun;56(6):579-85.
PMID: 8015314 [PubMed - indexed for MEDLINE]

□ 45: Janssen RA, Buter J, The TH, Mulder NH, de Leij L. Related Article
Prolonged continuous infusion of low-dose rIL-2.
Br J Cancer. 1994 May;69(5):976-7. No abstract available.
PMID: 8180034 [PubMed - indexed for MEDLINE]

□ 46: Deehan DJ, Heys SD, Simpson W, Herriot R, Broom J, Eremin O. Related Article
Correlation of serum cytokine and acute phase reactant with alterations in weight and serum albumin in patient:

receiving immunotherapy with recombinant IL-2.
Clin Exp Immunol. 1994 Mar;95(3):366-72.
PMID: 7511074 [PubMed - indexed for MEDLINE]

□ 47: Vlasveld LT, Horenblas S, Hekman A, Hilton AM, Dubbelman AC, Melief CJ, Rankin EM. Related Article
Phase II study of intermittent continuous infusion of low dose recombinant interleukin-2 in advanced melanoma renal cell cancer.
Ann Oncol. 1994 Feb;5(2):179-81.
PMID: 8186163 [PubMed - indexed for MEDLINE]

□ 48: Astoul P, Bertault-Peres P, Durand A, Catalin J, Vignal F, Boutin C. Related Article
Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion.
Cancer. 1994 Jan 15;73(2):308-13.
PMID: 8293393 [PubMed - indexed for MEDLINE]

□ 49: MacArthur CA, Isaacs H Jr, Miller JH, Ozkaynak F. Related Article
Pediatric renal cell carcinoma: a complete response to recombinant interleukin-2 in a child with metastatic disease at diagnosis.
Med Pediatr Oncol. 1994;23(4):365-71.
PMID: 8058009 [PubMed - indexed for MEDLINE]

□ 50: Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JG, Voordouw AC, Sein JJ, Delleijn TA, Rodenhuis S, Melief CJ. Related Article
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell carcinoma Part II: Immunological aspects.
Br J Cancer. 1993 Sep;68(3):559-67.
PMID: 8353046 [PubMed - indexed for MEDLINE]

□ 51: Harada Y, Yahara I. Related Article
Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals.
Int Rev Exp Pathol. 1993;34 Pt A:37-55.
PMID: 8454416 [PubMed - indexed for MEDLINE]

□ 52: Gambacorti-Passerini C, Hank JA, Albertini M. Related Article

MR, Borchert AA, Moore KH, Schiller JH,
Bechhofer R, Borden EC, Storer B, Sondel PM.

 A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
J Immunother. 1993 Jan;13(1):43-8.
PMID: 8435431 [PubMed - indexed for MEDLINE]

 53: Jones M, Philip T, Palmer P, von der Maase H, Related Article
Vinke J, Elson P, Franks CR, Selby P.

 The impact of interleukin-2 on survival in renal cancer: multivariate analysis.
Cancer Biother. 1993 Winter;8(4):275-88.
PMID: 7804369 [PubMed - indexed for MEDLINE]

 54: Caligiuri MA, Murray C, Robertson MJ, Wang Related Article
E, Cochran K, Cameron C, Schow P, Ross ME,
Klumpp TR, Soiffer RJ, et al.

 Selective modulation of human natural killer cells in vitro after prolonged infusion of low dose recombinant interleukin-2.
J Clin Invest. 1993 Jan;91(1):123-32.
PMID: 7678599 [PubMed - indexed for MEDLINE]

 55: Thompson JA, Shulman KL, Benyunes MC, Related Article
Lindgren CG, Collins C, Lange PH, Bush WH
Jr, Benz LA, Fefer A.

 Prolonged continuous intravenous infusion interleukin-2-lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
J Clin Oncol. 1992 Jun;10(6):960-8.
PMID: 1588376 [PubMed - indexed for MEDLINE]

 56: Vlasveld LT, Rankin EM, Hekman A, Related Article
Rodenhuis S, Beijnen JH, Hilton AM,
Dubbelman AC, Vyth-Dreese FA, Melief CJ.

 A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell carcinoma: Part I: Clinical aspects.
Br J Cancer. 1992 May;65(5):744-50.
PMID: 1586602 [PubMed - indexed for MEDLINE]
Soiffer RJ, Murray C, Cochran K, Cameron C,

□ 57: [Wang E, Schow PW, Daley JF, Ritz J.](#) Related Article
Clinical and immunologic effects of prolonged infusion low-dose recombinant interleukin-2 after autologous and cell-depleted allogeneic bone marrow transplantation.
Blood. 1992 Jan 15;79(2):517-26.
PMID: 1730094 [PubMed - indexed for MEDLINE]

□ 58: [Palmer PA, Vinke J, Evers P, Pourreau C, Oskam R, Roest G, Vleminc F, Becker L, Loriaux E, Franks CR.](#) Related Article
Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for treatment of advanced renal cell carcinoma.
Eur J Cancer. 1992;28A(6-7):1038-44.
PMID: 1627369 [PubMed - indexed for MEDLINE]

□ 59: [Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo D, et al.](#) Related Article
Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
J Clin Oncol. 1991 Dec;9(12):2110-9.
PMID: 1960552 [PubMed - indexed for MEDLINE]

□ 60: [Lamers HJ, Gratama JW, van Putten WL, Stoter G, Bolhuis RL.](#) Related Article
Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocyte.
Cancer Res. 1991 May 1;51(9):2324-8.
PMID: 2015597 [PubMed - indexed for MEDLINE]

□ 61: [Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, Mier J, Sparano J, Fisher RI, Weiss G, et al.](#) Related Article
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
J Clin Oncol. 1991 Apr;9(4):641-8.
PMID: 2066760 [PubMed - indexed for MEDLINE]

□ 62: [Lim SH, Giles FJ, Smith MP, Goldstone AH.](#) Related Article

-  Bacterial infections in lymphoma patients treated with recombinant interleukin-2.
Acta Haematol. 1991;85(3):135-8.
PMID: 2042446 [PubMed - indexed for MEDLINE]
-  **63:** Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Related Article
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.
Cancer Invest. 1991;9(1):35-48. Review.
PMID: 2012995 [PubMed - indexed for MEDLINE]
-  **64:** Sweep F, Rijnkels C, Hermus A. Related Article
Activation of the hypothalamus-pituitary-adrenal axis by cytokines.
Acta Endocrinol (Copenh). 1991;125 Suppl 1:84-91. Review.
PMID: 1801507 [PubMed - indexed for MEDLINE]
-  **65:** Ikemoto S, Kamizuru M, Wada S, Nishio S, Kishimoto T, Maekawa M. Related Article
Combined effect of interleukin 2 and bacillus Calmette-Guerin in the therapy of mice with transitional cell carcinoma.
Urol Int. 1991;47(4):250-4.
PMID: 1781111 [PubMed - indexed for MEDLINE]
-  **66:** Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, et al. Related Article
Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation.
Blood. 1990 Sep 15;76(6):1092-7.
PMID: 2400805 [PubMed - indexed for MEDLINE]
-  **67:** Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM. Related Article
Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.
Cancer Immunol Immunother. 1990;31(1):53-9.

PMID: 2306756 [PubMed - indexed for MEDLINE]

□ 68: Goldstein D, Sosman JA, Hank JA, Weil-
Hillman G, Moore KH, Borchert A, Bechhofer
R, Storer B, Kohler PC, Levitt D, et al. Related Article
 Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity. Cancer Res. 1989 Dec 1;49(23):6832-9.
PMID: 2819723 [PubMed - indexed for MEDLINE]

□ 69: Creekmore SP, Harris JE, Ellis TM, Braun DP, Cohen II, Bhopalam N, Jassak PF, Cahill MA, Canzoneri CL, Fisher RI. Related Article
 A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. J Clin Oncol. 1989 Feb;7(2):276-84.
PMID: 2783732 [PubMed - indexed for MEDLINE]

□ 70: Eberlein TJ, Schoof DD, Jung SE, Davidson D, Gramolini B, McGrath K, Massaro A, Wilson RE. Related Article
 A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity. Arch Intern Med. 1988 Dec;148(12):2571-6.
PMID: 3264142 [PubMed - indexed for MEDLINE]

□ 71: Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al. Related Article
 Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity T-cell mitogenic response with long-term administration of rIL-2. J Biol Response Mod. 1988 Oct;7(5):457-72.
PMID: 3263471 [PubMed - indexed for MEDLINE]

□ 72: Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ. Related Article
 Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988 Sep 1;48(17):5007-10.

PMID: 3261630 [PubMed - indexed for MEDLINE]

□ 73: [Aronson FR, Libby P, Brandon EP, Janicka MW, Mier JW.](#) Related Article

□ IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury.

J Immunol. 1988 Jul 1;141(1):158-63.

PMID: 3259966 [PubMed - indexed for MEDLINE]

□ 74: [Naito K, Pellis NR, Kahan BD.](#) Related Article

□ Effect of continuous administration of interleukin 2 on T-cell specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.

Cancer Res. 1988 Jan 1;48(1):101-8.

PMID: 3257158 [PubMed - indexed for MEDLINE]

□ 75: [Okuno K, Ohnishi H, Takagi H, Nakamura T, Kokudo S, Yasutomi M.](#) Related Article

□ [Injection of interleukin-2 (IL-2) into the tumor-bearer's spleen augments lymphokine-activated killer (LAK) activity in vitro and inhibits tumor metastasis]

Nippon Geka Gakkai Zasshi. 1987 Jul;88(7):802-7. Japanese.

PMID: 3499562 [PubMed - indexed for MEDLINE]

□ 76: [Kupiec-Weglinski JW, Diamantstein T, Tilney NL, Strom TB.](#) Related Article

□ Therapy with monoclonal antibody to interleukin 2 selectively spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

Proc Natl Acad Sci U S A. 1986 Apr;83(8):2624-7.

PMID: 2939456 [PubMed - indexed for MEDLINE]

□ 77: [Chang AE, Hyatt CL, Rosenberg SA.](#) Related Article

□ Systemic administration of recombinant human interleukin-2 in mice.

J Biol Response Mod. 1984 Oct;3(5):561-72.

PMID: 6334141 [PubMed - indexed for MEDLINE]

Display

Summary

Show:

500

Sort

Send to


Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine
NLM

M:
[Sign In]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search for

Limits	Preview/Index	History	Clipboard	Details
Display	Abstract	Show: 20	Sort	Send to
All: 1 Review: 0				

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)

[PubMed Services](#)
[Journals](#)
[Database](#)
[MeSH Database](#)
[Single Citation Matcher](#)
[Batch Citation Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI \(Cubby\)](#)

[Related Resources](#)
[Order](#)
[Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)

Systemic administration of recombinant human interleukin-2 in mice.

Chang AE, Hyatt CL, Rosenberg SA.

The production of recombinant human interleukin-2 (RIL) in large amounts has made possible studies of the in vivo effects of this lymphokine in the normal murine host. We have studied a variety of routes of administration of RIL-2 in mice to maximize the bioavailability of this lymphokine. The serum half-life after intravenous administration was 1.6 +/- 0.3 hr (mean +/- SEM, n = 3). Intraperitoneal and subcutaneous administration resulted in RIL-2 serum levels greater than or equal to 10 units/ml for 3-5 h, and was prolonged by gelatinous 7-11 h. Continuous infusion of RIL-2 was accomplished via osmotic pumps placed intraperitoneally or subcutaneously and resulted in RIL-2 serum levels greater than or equal to 8 units/ml for greater than 4 days. RIL-2 given intraperitoneally three times daily for 3 days enhanced natural killer activity of splenocytes as measured by lysis of YAC cells. Specific augmentation of C57BL/6 splenocyte cytotoxicity to a secondary challenge of irradiated allogeneic P815 was found in mice receiving RIL-2 intraperitoneally three times daily for 4 days. The continuous administration of RIL-2 over a 4-day period resulted in the in vivo generation of lymphokine-activated killer cells in the spleen and peritoneal exudate.

exogenous administration of RIL-2 in the normal murine enhances three different cell-mediated cytotoxic mechanisms and has potential applications in the treatment of tumors and immunodeficient conditions.

PMID: 6334141 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) [▼](#) Show: [20](#) [▼](#) Sort [▼](#) Send to [Text](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42

National
Library
of Medicine
NLM[All Databases](#) [PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [OMIM](#) [PMC](#) [Journals](#)Search [PubMed](#)

for



Clear

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)[Display](#) [Abstract](#) [Show: 20](#) [Sort](#) [Send to](#) [Text](#)[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)[PubMed](#)
[Services](#)
[Journals](#)
[Database](#)
[MeSH Database](#)
[Single Citation](#)
[Matcher](#)
[Batch Citation](#)
[Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI](#)
(Cubby)[Related](#)
[Resources](#)
[Order](#)
[Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)[1: Cancer Res. 1988 Jan 1;48\(1\):101-8.](#) [Related Article](#)

Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen cyclophosphamide.

Naito K, Pellis NR, Kahan BD.

Department of Surgery, University of Texas Medical School, Houston 77030.

Injection of purified human interleukin 2 (IL-2) directly into the spleen has been shown to potentiate the effect of specific chemoimmunotherapy, using butanol-extracted tumor-specific transplantation antigen (TSTA) and cyclophosphamide (CY) in a C3H/HeJ murine methylcholanthrene-induced fibrosarcoma model. Since IL-2 has a relatively short half-life in serum, continuous infusion of this lymphokine via the intrasplenic (i.s.), i.v., or i.p. routes was administered in an attempt to maintain therapeutic tissue levels. Primary hosts bearing 7T1 (4-mm) or 14-day (greater than 10-mm) established s.c. methylcholanthrene F tumors were treated with weekly s.c. doses of 1 micrograms 1-butanol-extracted, isoelectrophoretically purified TSTA, the first of which was combined with a single i.p. injection of 20 mg/kg CY, and a 10-day continuous infusion of 120 units IL-2/day by one of three routes. IL-2 delivered by all routes either by continu-

infusion or by bolus injection augmented the chemoimmunotherapeutic efficacy of TSTA/CY against 7 established tumors. On the other hand, the outcome of 14. (greater than 10-mm) established tumors depended upon the method and route of administration of IL-2: continuous infusion via the i.v., i.p., or i.s. route prolonged host survival beyond that obtained by bolus administration. Continuous i.s.-IL-2 infusion greatly prolonged, continuous i.p.-IL-2 (120 units/day) slightly extended, and continuous i.v.-IL-2 had no effect on host survival. In a spontaneous pulmonary metastasis model following amputation of a tumor-bearing limb, only the regimen of TSTA/CY/i.s.-IL-2 decreased the number of lung colonies and prolonged host survival. Continuous infusion of IL-2 (120 units/day, 10 days) combined with TSTA/CY induced tumor-specific cytotoxic T-cells, as documented by *in vitro* 51chromium release cytolytic and *in vivo* local adoptive transfer assays. Based upon the residual local adoptive transfer assay activity of spleen cells depleted of specific lymphocyte subpopulations using monoclonal antibodies, the immune effectors generated by i.s.-IL-2 plus TSTA/CY bear the T-Lyt2+ phenotype and those by i.p. or i.v.-IL-2 plus TSTA bear the Thy+, L3T4+ markers. Thus continuous i.s.-IL-2 infusion appears to augment cytotoxic T-cell induction in tumor-bearing hosts undergoing stimulation of helper elements by TSTA and inhibition of suppressor cells by CY.

PMID: 3257158 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42

National
Library
of Medicine
 My
[\[Sign In\]](#) [Re...]
[\[Help\]](#)[All Databases](#) [PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [OMIM](#) [PMC](#) [Journals](#)Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)[PubMed](#)
[Services](#)
[Journals](#)
[Database](#)
[MeSH Database](#)
[Single Citation](#)
[Matcher](#)
[Batch Citation](#)
[Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI](#)
[\(Cubby\)](#)[Related](#)
[Resources](#)
[Order](#)
[Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphoactivated killer cells.

Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ.

Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115.

The adoptive transfer of recombinant-methionyl human interleukin 2 (rIL-2)-activated autologous peripheral blood mononuclear lymphokine-activated killer (LAK) cells to cancer patients is being evaluated as an alternative to conventional cancer therapy. We have independently developed an alternative regimen to previously reported adoptive immunotherapy protocols using rIL-2 and LAK cells which features the prolonged administration of low-dose rIL-2 (30,000 units), and an automated, entirely enclosed system of peripheral blood cell procurement, culture, harvest, and reinfusion of activated cells. The cell culture system was tested with a murine tumor model in which LAK cells generated in plastic culture bags were reinfused into tumor-bearing mice. Tumor regression was as effective with cells activated in the bags as in conventional culture flasks. Twenty-eight cancer patients were treated for consecutive days with low-dose rIL-2, followed by

leukapheresis, infusion of LAK cells, and prolonged IL-2 administration. At least 50% tumor regression was observed in 46% of all patients treated. These data imply that human peripheral blood mononuclear cells retain fully their capacity for rIL-2-induced activation and effector cell function under alternative approach, and further, that a low-dose rIL-2 regimen with markedly reduced toxicities can be as effective as high-dose rIL-2 regimens if low-dose rIL-2 is given for a prolonged period of time following LAK cell infusion.

PMID: 3261630 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) [▼](#) Show: [20](#) [▼](#) Sort: [▼](#) Send to: [Text](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)


[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine
NLM



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search for

Limits Preview/Index History Clipboard Details
Display Abstract Show: 20 Sort Send to Text

About Entrez

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)

[PubMed Services](#)
[Journals](#)
[Database](#)
[MeSH Database](#)
[Single Citation](#)
[Matcher](#)
[Batch Citation](#)
[Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI](#)
[\(Cubby\)](#)

[Related Resources](#)
[Order](#)
[Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)

A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.


Eberlein TJ, Schoof DD, Jung SE, Davidson D, Gramzow B, McGrath K, Massaro A, Wilson RE.

Department of Surgery, Brigham & Women's Hospital, Boston, MA 02115.

Adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer (LAK) cells has proved to be successful in the treatment of some patients with metastatic cancer, but not without a significant degree of associated toxic effects. The primary goal of this study was to substantially reduce the toxicity of this complex and expensive treatment while maintaining or improving efficacy. To this end, 29 patients were treated with LAK cells in conjunction with a high-dose regimen of interleukin 2 and a prolonged period of administration following LAK cell infusion. This protocol resulted in a considerable reduction in toxicity, as compared with that described in previous studies, without compromising the efficacy. This study offers further confirmation that active immunotherapy of metastatic cancer can be clinically beneficial to patients for whom no other effective therapy is presently available.



National
Library
of Medicine
NLM



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search [PubMed]

for

[Go]

[Clear]

Limits Preview/Index History Clipboard Details

Display Abstract

Show: 20

Sort

Send to

Text

About Entrez

All: 1 Review: 0

Text Version

1: J Clin Oncol. 1989 Feb;7(2):276-84.

Related Article

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed

Services

Journals

Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

My NCBI

(Cubby)

Related

Resources

Order

Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.

Creekmore SP, Harris JE, Ellis TM, Braun DP, Cohen RJ, Bhoopalam N, Jassak PF, Cahill MA, Canzoneri CL, Johnson RI.

Biological Resources Branch, NCI, Frederick, MD 21701

Recombinant interleukin-2 (rIL-2) (NSC# 600664; Hoffmann-La Roche, Inc., Nutley, NJ) was studied in a phase I clinic trial in 33 patients with advanced, measurable cancer of colon or malignant melanoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and no prior chemotherapy or radiotherapy. The goal of the study was to identify a dose and schedule of IL-2 to generate maximal immune modulation with tolerable toxicity. Such a regimen might allow the addition of other treatment modalities and prolonged treatment duration in later trials. Each patient received IL-2 as a continuous 24-hour infusion once weekly for 4 weeks and then twice weekly for 4 weeks. Five treatment groups received from 10(3) U/m² to 3 x 10(7) U/m² per 24-hour infusion. The maximal tolerated dose was 3 x 10(7) U/m²/d twice weekly. Patients treated twice weekly at 1 x and 3 x 10(7) U/m²/d had immune modulation in terms of lymphocytosis, eosinophilia, increased natural killer (NK)

activity, and elevated numbers of peripheral blood monon cells expressing CD16, OKT10/Leu-17, and Leu-19 surface markers. Endogenous generation of peripheral blood lymphokine-activated killer (LAK) activity was demonstrated by lysis of NK-resistant Daudi targets, in patients treated at 3×10^7 U/m²/d. Biochemical and hematological abnormalities were moderate and reversible. Clinical toxicity included hypotension, myalgia, arthralgia, stomatitis, fever, fatigue, nausea, headache, chills, diarrhea, and oliguria at high doses. Cardiovascular toxicity was tolerable for most patients and reversed after IL-2 was stopped. Two of six melanoma patients at 3×10^7 U/m²/d achieved partial responses by the end of the eighth week. This IL-2 schedule appears to produce potentially clinically useful immune enhancement with tolerable toxicities.

PMID: 2783732 [PubMed - indexed for MEDLINE]

Show:


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)


[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine
NLM



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search for

Limits Preview/Index History Clipboard Details
Display Abstract Show: 20 Sort Send to Text

About Entrez

All: 1 Review: 0

Text Version

1: J Clin Oncol. 1991 Dec;9(12):2110-9. Related Article

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed
Services
Journals
Database
MeSH Database
Single Citation
Matcher
Batch Citation
Matcher
Clinical Queries
LinkOut
My NCBI
(Cubby)

Related
Resources
Order
Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.

Caligiuri MA, Murray C, Soiffer RJ, Klumpp TR, Seiden M, Cochran K, Cameron C, Ish C, Buchanan L, Perillo AL.

Dana-Farber Cancer Institute, Boston, MA 02115.

In previous clinical trials, recombinant interleukin-2 (rIL-2) has been infused at high doses over short periods of time to generate lymphokine-activated killer (LAK) cells in vivo. These trials have been limited by severe toxicities, and the immunologic effects of rIL-2 have been transient. The present study was designed to assess the toxicity and immunologic effects of prolonged administration of low doses of rIL-2. In this phase I study, patients with advanced cancer were scheduled to receive an intravenous (IV) infusion of rIL-2 without interruption for 12 months in an outpatient setting. Twenty-one patients received rIL-2 at doses ranging from 0.5×10^5 to 6.0×10^5 U/m²/d. Treatment was extremely well tolerated, and no patient experienced grade 3 or grade 4 toxicity. The lowest dose (0.5×10^5 U/m²/d) did not have demonstrable immunologic activity. At doses of 1.5×10^5 and 4.5×10^5 U/m²/d, one infusion resulted in the specific expansion of natural-kille

cells (sixfold and ninefold increases, respectively, at these dose levels) without any changes in B cells, T cells, neutrophils or monocytes. Grade 2 toxicity was observed at the dose of $1 \times 10(5)$ U/m²/d, as three patients required interruption of therapy and two patients who completed therapy developed transient hypothyroidism. In patients with increased NK cell numbers, enhancement of non-major histocompatibility complex (MHC) restricted cytotoxicity and increased generation of LAK cells *in vitro* were also demonstrated. Therapy with low-dose rIL-2 can be given safely in an uninterrupted fashion for prolonged periods of time in an outpatient setting. This results in selective expansion of NK cells *in vivo* with minimal toxicity. Further investigation of this schedule for immunomodulation in various disease states should be pursued in phase II studies of both malignant and immunodeficient disease states.

PMID: 1960552 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) [...
Show:](#) [20](#) [Sort](#) [Send to:](#) [Text](#)


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42

National
Library
of Medicine

[Sign In] [Re]

[All Databases](#) [PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [OMIM](#) [PMC](#) [Journals](#)Search [PubMed](#)

for

[Go](#)[Clear](#)[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)
[Display](#) [Abstract](#) Show: [20](#) [Sort](#) [Send to](#) [Text](#)

All: 1 Review: 0

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)[PubMed Services](#)
[Journals](#)
[Database](#)
[MeSH Database](#)
[Single Citation Matcher](#)
[Batch Citation Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI \(Cubby\)](#)[Related Resources](#)
[Order](#)
[Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)[1: Eur J Cancer. 1992;28A\(6-7\):1038-44.](#) [Related Article](#)

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.

Palmer PA, Vinke J, Evers P, Pourreau C, Oskam R, J G, Vlems F, Becker L, Loriaux E, Franks CR.

Medical Department, EuroCetus BV, Amsterdam, The Netherlands.

Data have been analysed for 327 patients with advanced renal cell carcinoma receiving a continuous infusion of recombinant interleukin 2 (rIL-2) alone (225 patients) or rIL-2 plus lymphokine activated killer (LAK) cells (102) on a normal oncology ward. Eligibility criteria were uniform across protocols, all patients having advanced progressive disease with an ambulatory performance status. The baseline characteristics of patients receiving rIL-2 alone did not differ significantly from those receiving LAK, with the exception that the LAK treated patients had a better performance status. Despite similar treatment intensity, toxicity was more severe in the patients receiving LAK. The addition of LAK did not improve higher response rates or to prolonged response duration, progression-free survival or survival. This review confirms the activity of rIL-2 for the treatment of advanced renal cell carcinoma.

carcinoma and demonstrates that the addition of LAK cell not lead to increased efficacy.

PMID: 1627369 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine NLM

Me
[Sign In] [Re]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search PubMed

for

Go Clear

Limits Preview/Index History Clipboard Details

Display Abstract

Show: 20 Sort

Send to Text

About Entrez

[Text Version](#)

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed
Services
Journals
Database
MeSH Database
Single Citation
Matcher
Batch Citation
Matcher
Clinical Queries
LinkOut
My NCBI
(Cubby)

Related
Resources
Order
Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 1 Review: 0

1: J Clin Oncol. 1992 Jun;10(6):960-8.

[Related Article](#)

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

**Thompson JA, Shulman KL, Benyunes MC, Lindgren
Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A.**

Department of Medicine, University of Washington School
Medicine, Seattle.

PURPOSE: Two consecutive protocols of continuous intravenous (CIV) infusion interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells were carried out in patients with metastatic renal cell carcinoma (RCC) to determine the response rate and toxicity. **PATIENTS AND METHODS:** In both protocols, patients received induction IL-2 at 6×10^6 U/m²/d on days 1 to 5, and underwent leukapheresis on days 7 to 9 at the peak of rebound lymphocytosis. LAK cells were generated by a 5-day incubation with IL-2 at 1,000 U/mL, and were infused on days 12 to 16. For the first 20 patients (protocol A), maintenance IL-2 was administered at 6×10^6 U/m²/d on days 12 to 16. On the assumption that less IL-2 might be required to maintain rather than to induce LAK activity, and that a longer duration of maintenance IL-2 might enhance LAK survival and function in vivo, the protocol for the subsequent 22 patients (protocol

was altered so that the maintenance phase consisted of a lower dose of IL-2 (2×10^6 U/m²/d) administered for a longer period of time (days 10 to 20). RESULTS: In protocol A, there were two complete responses (CRs) and three partial responses (PRs), for a total response rate of 25%. One PR was surgically converted into a CR. The durations of the CRs are 36+, 18+, and 18+ months. Hypotension and capillary leak were more severe during maintenance, which limited the median duration of maintenance IL-2 to 4 days. In protocol B, no patient experienced severe hypotension, and the median duration of maintenance IL-2 was 9 days. Two patients exhibited a CR, seven a PR, for a total response rate of 41%. Two PRs were surgically converted to CRs. The durations of CR are 14+, 14+, 6+, and 5+ months. In both protocols, the CIV induction regimen resulted in marked rebound lymphocytosis (mean, 11,097/microL) and LAK-cell yield (mean, 18.1×10^{10}) and cumulative response rate was 14 of 42 patients, or 33% (95% confidence interval, 19% to 47%). CONCLUSION: These results demonstrate that both protocols of CIV IL-2 plus IL-2 cells have substantial antitumor activity, and that a longer maintenance phase of IL-2 at a lower dose is associated with significantly less toxicity without a loss of therapeutic efficacy.

Publication Types:

- Clinical Trial

PMID: 1588376 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42

National
Library
of Medicine
NLMMy
[Sign In] [Re][All Databases](#) [PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [OMIM](#) [PMC](#) [Journals](#)Search [PubMed](#)

for

[Go](#)[Clear](#)[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)
[Display](#) [Abstract](#) Show: [20](#) [Sort](#) [Send to](#) [Text](#)
All: 1 Review: 0[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)[PubMed Services](#)
[Journals](#)
[Database](#)
[MeSH Database](#)
[Single Citation Matcher](#)
[Batch Citation Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI \(Cubby\)](#)[Related Resources](#)
[Order Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)[1: J Clin Invest. 1993 Jan;91\(1\):123-32.](#) [Related Article](#)[Full Text Article
in PubMed Central](#)**Selective modulation of human natural killer cell vivo after prolonged infusion of low dose recombinant interleukin 2.****Caligiuri MA, Murray C, Robertson MJ, Wang E, Co K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiff et al.**

Dana-Farber Cancer Institute, Department of Medicine, H Medical School, Boston, Massachusetts 02115.

The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum concentrations of cytokine were investigated. rIL-2 in doses of $0.5-6.0 \times 10^6$ U/m² per d (3.3-40 micrograms/m² per d) was administered by continuous intravenous infusion for 90 consecutive days to patients with advanced cancer. IL-2 concentrations (25 +/- and 77 +/- 64 pM, respectively) that selectively saturate high affinity IL-2 receptors (IL-2R) were achieved in the serum of patients receiving rIL-2 infusions of 10 micrograms/m² per d and 30 micrograms/m² per d. A gradual, progressive expansion of natural killer (NK) cells was seen in the peripheral blood of these patients with no evidence of a plateau effect during 9 mo of therapy. A preferential expansion of CD56bright NK cells was consistently evident. NK cytotoxicity against tu

targets was only slightly enhanced at these dose levels. However, brief incubation of these expanded NK cells *in vitro* induced potent lysis of NK-sensitive, NK-resistant antibody-coated targets. Infusions of rIL-2 at 40 micrograms per day produced serum IL-2 levels (345 +/- 381 pM) sufficient to engage intermediate affinity IL-2R p75, which is constitutively expressed by human NK cells. This did not result in great cell expansion compared to the lower dose levels, but did produce *in vivo* activation of NK cytotoxicity, as evidenced by lysis of NK-resistant targets. There was no consistent change in the numbers of CD56- CD3+ T cells, CD56+ CD3+ MHC unrestricted T cells, or B cells during infusions of rIL-2 at all of the dosages used. This study demonstrates that prolonged infusions of rIL-2 in doses that saturate only high affinity receptors can selectively expand human NK cells for an extended period of time with only minimal toxicity. Further activation of NK cytolytic activity can also be achieved *in vivo*, but it requires higher concentrations of IL-2 that bind intermediate affinity IL-2R p75. Clinical trials are underway attempting to exploit the differing effects of various concentrations of IL-2 on human cells *in vivo*.

Publication Types:

- Clinical Trial

PMID: 7678599 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42



National
Library
of Medicine
NLM

My
[Sign In] [Re]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search **PubMed**

for

[Go] [Clear]

Limits Preview/Index History Clipboard Details
Display Abstract Show: 20 Sort Send to Text
All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed

Services

Journals

Database

MeSH Database

Single Citation

Matcher

Batch Citation

Matcher

Clinical Queries

LinkOut

My NCBI

(Cubby)

Comment on:

- [Br J Cancer. 1993 Sep;68\(3\):559-67.](#)

Prolonged continuous infusion of low-dose rIL-2

Janssen RA, Buter J, The TH, Mulder NH, de Leij L.

Publication Types:

- Comment
- Letter

PMID: 8180034 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

Related
Resources

Order

Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central



National
Library
of Medicine
NLM

My
[Sign In] [Re]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals

Search PubMed

for

Go

Clear

Limits Preview/Index History Clipboard Details

Display Abstract

Show: 20

Sort

Send to

Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed
Services
Journals
Database
MeSH Database
Single Citation
Matcher
Batch Citation
Matcher
Clinical Queries
LinkOut
My NCBI
(Cubby)

Related
Resources
Order
Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Clin Cancer Res. 1996 Mar;2(3):493-9. Related Article

Expansion and manipulation of natural killer ce patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.

Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier Lazo S, Ritz J.

Divisions of Hematologic Malignancies and Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.

Interleukin 2 (IL-2) administered at low doses for prolonged periods can markedly expand the number of CD56(+) natural killer (NK) cells in patients with metastatic cancer. The cytotoxic capacity of NK cells obtained from patients receiving IL-2 in vivo can be dramatically augmented by additional exposure to IL-2 in vitro. These observations formed the basis of a clinical trial in which patients with metastatic cancer were treated with low-dose continuous daily infusions of IL-2 to increase the number of their NK cells in conjunction with intermittent boluses of additional IL-2 to stimulate this expanded pool of cytotoxic cells. Twenty-three patients were registered to receive IL-2 at 4.5×10^5 units/m²/day for 4 weeks by continuous i.v. infusion. After 4 weeks of "priming" with low-dose continuous infusion IL-2, cohorts of three 1

patients received 5 weekly 2-h boluses of IL-2 at doses ranging from 2.5×10^5 units/m² to 1.0×10^6 units/m². Low-dose continuous infusion IL-2 was usually well tolerated; 2-h bolus infusions of IL-2 were often associated with high fevers and constitutional symptoms that resolved after several hours. High-dose continuous infusion IL-2 resulted in the progressive expansion of circulating CD56(+)CD3(-) NK cells. In contrast, each bolus infusion of IL-2 resulted in an immediate dramatic decrease in both the number of NK cells and activated T lymphocytes with recovery noted within 24 h. Bolus doses of IL-2 as low as 2.5×10^5 units/m² were capable of producing these effects. Cytolytic activity against NK-sensitive and NK-resistant targets correlated with the presence of circulating activated NK cells. Our results demonstrate that NK cells expanded by low-dose continuous infusions of IL-2 can be further activated *in vivo* by exposure to very low doses of IL-2 as a 2-h i.v. bolus. This capacity to manipulate human NK cells *in vivo* through varying the dose and schedule of IL-2 administration may help in defining the therapeutic potential of these cytotoxic effectors in the treatment of both neoplastic and infectious diseases.

PMID: 9816195 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) [-](#) Show: [20](#) [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Mar 2 2005 14:57:42

Welcome to STN International! Enter x:x

* * * * * * * * * * Welcome to STN International * * * * * * * * * *
* * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:15:44 ON 03 MAR 2005

=> FIL STNGUIDE

FILE 'ADISCTI' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:17:18 ON 03 MAR 2005

FILE 'ANABSTR' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:17:18 ON 03 MAR 2005
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOPMERCE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved.

FILE 'BIOENG' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 16:17:18 ON 03 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:17:18 ON 03 MAR 2005

FILE 'CAPLUS' ENTERED AT 16:17:18 ON 03 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (c) 2005 DECHEMA eV

FILE 'CEN' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:17:18 ON 03 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOTBASE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:17:18 ON 03 MAR 2005

FILE 'FOMAD' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:17:18 ON 03 MAR 2005

FILE 'HEALSAFE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:17:18 ON 03 MAR 2005

FILE 'KOSMET' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:17:18 ON 03 MAR 2005

FILE 'NIOSHTIC' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:17:18 ON 03 MAR 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 16:17:18 ON 03 MAR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:17:18 ON 03 MAR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHARMAML' ENTERED AT 16:17:18 ON 03 MAR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHIN' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PROMT' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:17:18 ON 03 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 16:17:18 ON 03 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:17:18 ON 03 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 16:17:18 ON 03 MAR 2005
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S adoptive immunotherapy
38 FILES SEARCHED...
L1 30471 ADOPTIVE IMMUNOTHERAPY

=> S L1 AND brain tumor
25 FILES SEARCHED...
53 FILES SEARCHED...
L2 580 L1 AND BRAIN TUMOR

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2
L3 316 DUP REM L2 (264 DUPLICATES REMOVED)

=> S L3 AND PY<=2001
'2001' NOT A VALID FIELD CODE
4 FILES SEARCHED...
9 FILES SEARCHED...
12 FILES SEARCHED...
15 FILES SEARCHED...
20 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
26 FILES SEARCHED...
31 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
38 FILES SEARCHED...
46 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
48 FILES SEARCHED...
53 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
59 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
65 FILES SEARCHED...
71 FILES SEARCHED...
L4 196 L3 AND PY<=2001

=> D L4 1-196

L4 ANSWER 1 OF 196 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
STN
AN 1996:34604 ADISCTI
DN 807103751
TI ***Adoptive*** ***immunotherapy*** using lymphokine-activated
killer (LAK) cells and interleukin-2 for recurrent malignant primary
brain ***tumors***

CS SK Sankhla, Royal Preston Hosp, J-5, Staff Village, Sharoe Green Lane,
Preston PR2 4HT, Lancs, England.
SO Journal of Neuro Oncology (Feb 1, 1996), Vol. 27, pp. 133-140
DT Citation
RE Cancer Chemotherapy
FS Citation
LA English

L4 ANSWER 2 OF 196 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved.
(2005) on STN
AN 91:78280 AGRICOLA
DN IND91042221
TI ***Adoptive*** ***immunotherapy*** of ***brain***
tumors in dogs.
AU Ingram, M.; Jacques, D.B.; Freshwater, D.B.; Skillen, R.; Techy, G.B.; Shelden, C.H.
CS Huntington Medical Research Institutes, Pasadena, CA
AV DNAL (SF601.V4742)
SO Veterinary medicine report, ***Fall 1990.*** Vol. 2, No. 4. p. 398-402
Publisher: St. Louis, Mo. : Mosby-Year Book, Inc.
ISSN: 0895-7703
NTE Includes references.
DT Article
FS U.S. Imprints not USDA, Experiment or Extension
LA English

L4 ANSWER 3 OF 196 BIOENG COPYRIGHT 2005 CSA on STN
AN 2004401601 BIOENG
DN 4769628
TI Recycled addition of CD4+ T cell-rich population for induction of human autologous cytotoxic T lymphocytes: A practically efficient method
AU Saijo, K; Tsurushima, H; Tsuboi, K; Nose, T; Oki, A; Ohno, T*
CS RIKEN Cell Bank, The Institute of Physical and Chemical Research (RIKEN), 3-1-1 Koyadai, Tsukuba Science City, Ibaraki 305-0074, Japan, [mailto:tad-ohno@rtc.riken.go.jp]
SO Cytotechnology [Cytotechnology]. Vol. 34, no. 1-2, pp. 101-110. Oct 2000.
Published by: Kluwer Academic Publishers
ISSN: 0920-9069
DT Journal
LA English
SL English
OS Medical and Pharmaceutical Biotechnology Abstracts

L4 ANSWER 4 OF 196 BIOENG COPYRIGHT 2005 CSA on STN
AN 2004199477 BIOENG
DN 2712516
TI The combined effect of lymphokine activated killer cell and radiation therapy on rat ***brain*** ***tumor*** in vitro.
AU Nakagawa, K; Omori, N; Hashimoto, K; Yamamoto, T; Tsunoda, T; Nose, T
CS Dep. Neurol. Surg., Inst. Clin. Med., Univ. Tsukuba, Tsukuba, Ibaraki 305, Japan
SO Biotherapy, vol. 4, no. 2, pp. 109-115, 1992
ISSN: 0921-299X
DT Journal
LA English
SL English
OS Immunology Abstracts; Biotechnology Research Abstracts (through 1992)

L4 ANSWER 5 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:530804 BIOSIS
DN PREV200000530804
TI The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant ***brain*** ***tumors*** and traffics through brain tissue: Implications for local ***adoptive*** ***immunotherapy*** .
AU Kruse, Carol A. [Reprint author]; Visonneau, Sophie; Kleinschmidt-DeMasters, Bette K.; Gup, Carol J.; Gomez, German G.; Paul, David B.; Santoli, Daniela

SO 4200 East Ninth Avenue, Denver, CO, 80262, USA
Cancer Research, (October 15, 2000) Vol. 60, No. 20, pp. 5731-5739. print.
CODEN: CNREA8. ISSN: 0008-5472.

DT Article
LA English
ED Entered STN: 6 Dec 2000
Last Updated on STN: 11 Jan 2002

L4 ANSWER 6 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 2000:33723 BIOSIS
DN PREV200000033723
TI Immunotherapy of malignant ***brain*** ***tumors*** in children
and adults: From theoretical principles to clinical application.
AU Zeltzer, Paul M. [Reprint author]; Moilanen, Brita; Yu, John S.; Black,
Keith L.
CS Division of Neurosurgery, Maxine Dunitz Neurosurgical Institute,
Cedars-Sinai Medical Center, 8631 West Third Street, Suite 800 E, Los
Angeles, CA, 90048, USA
SO Child's Nervous System, (Oct., 1999) Vol. 15, No. 10, pp. 514-528. print.
ISSN: 0256-7040.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 19 Jan 2000
Last Updated on STN: 31 Dec 2001

L4 ANSWER 7 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1999:99416 BIOSIS
DN PREV199900099416
TI Effects of OK-432 on the proliferation and cytotoxicity of
lymphokine-activated killer (LAK) cells.
AU Yamamoto, Kiyoshi [Reprint author]; Tanaka, Ryuichi; Yoshida, Seiichi;
Ono, Koji; Mori, Hiroshi; Taniguchi, Yoshinori; Oda, Tazunu; Watanabe,
Toru
CS Dep. Neurosurg., Brain Res. Inst., Niigata Univ., 1 Asahimachi, Niigata
951, Japan
SO Journal of Immunotherapy, (Jan., 1999) Vol. 22, No. 1, pp. 33-40. print.
DT Article
LA English
ED Entered STN: 4 Mar 1999
Last Updated on STN: 4 Mar 1999

L4 ANSWER 8 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1998:498873 BIOSIS
DN PREV199800498873
TI Intracerebral bispecific-antibody conjugate increases survival of animals
bearing endogenously arising ***brain*** ***tumors***.
AU Patrick, Todd A.; Kranz, David M.; Zachary, James F.; Roy, Edward J.
[Reprint author]
CS Dep. Biochem., Univ. Ill., 600 S. Mathews Ave., Urbana, IL 61801, USA
SO International Journal of Cancer, (Nov. 9, 1998) Vol. 78, No. 4, pp.
470-479. print.
CODEN: IJCNAW. ISSN: 0020-7136.
DT Article
LA English
ED Entered STN: 18 Nov 1998
Last Updated on STN: 18 Nov 1998

L4 ANSWER 9 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1998:362819 BIOSIS
DN PREV199800362819
TI Systemic T cell ***adoptive*** ***immunotherapy*** of malignant
gliomas.
AU Plautz, Gregory E.; Barnett, Gene H.; Miller, David W.; Cohen, Bruce H.;
Prayson, Richard A.; Krauss, John C.; Luciano, Mark; Kangisser, Debra B.;
Shu, Suyu [Reprint author]

SO Cleveland, OH 44195, USA
Journal of Neurosurgery, (July, 1998) Vol. 89, No. 1, pp. 42-51. print.
CODEN: JONSAC. ISSN: 0022-3085.

DT Article

LA English

ED Entered STN: 27 Aug 1998

Last Updated on STN: 27 Aug 1998

L4 ANSWER 10 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1998:13801 BIOSIS

DN PREV199800013801

TI ***Adoptive*** ***immunotherapy*** .

AU Ballen, Karen; Stewart, F. Marc

CS Univ. Mass. Med. Cent., Hematology/Oncology Div., 55 Lake Ave. North,
Worcester, MA 01655, USA

SO Current Opinion in Oncology, (Nov., 1997) Vol. 9, No. 6, pp. 579-583.
print.

ISSN: 1040-8746.

DT Article

LA English

ED Entered STN: 5 Jan 1998

Last Updated on STN: 5 Jan 1998

L4 ANSWER 11 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1997:395050 BIOSIS

DN PREV199799694253

TI ***Adoptive*** ***immunotherapy*** of intracranial tumors by
systemic transfer of tumor-draining lymph node cells (Review).

AU Plautz, Gregory E. [Reprint author]; Shu, Suyu

CS Cent. Surgery Res., FF508, Cleveland Clinic Foundation, Cleveland, OH
44195, USA

SO International Journal of Oncology, (1997) Vol. 11, No. 2, pp. 389-395.
ISSN: 1019-6439.

DT Article

General Review; (Literature Review)

LA English

ED Entered STN: 10 Sep 1997

Last Updated on STN: 10 Sep 1997

L4 ANSWER 12 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1997:207398 BIOSIS

DN PREV199799506601

TI Cellular and molecular neurosurgery: Pathways from concept to reality-Part
I: Target disorders and concept approaches to gene therapy of the central
nervous system.

AU Zlokovic, Berislav V. [Reprint author]; Apuzzo, Michael L. J.

CS 2025 Zonal Ave., RMR 506, Los Angeles, CA 90033, USA

SO Neurosurgery (Baltimore), (1997) Vol. 40, No. 4, pp. 789-804.

ISSN: 0148-396X.

DT Article

General Review; (Literature Review)

LA English

ED Entered STN: 12 May 1997

Last Updated on STN: 12 May 1997

L4 ANSWER 13 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1996:540357 BIOSIS

DN PREV199699262713

TI The cytocidal activity of OK-432-activated mononuclear cells against human
glioma cells is partly mediated through the Fas ligand/Fas system.

AU Toda, Keisuke; Shiraishi, Tetsuya; Hirotsu, Tatsumi; Fukuyama, Kouzou;
Mineta, Toshihiro; Kawaguchi, Shojiro; Tabuchi, Kazuo

CS Dep. Neurosurg., Saga Med. Sch., 5-1-1 Nabeshima, Saga 849, Japan

SO Japanese Journal of Cancer Research, (1996) Vol. 87, No. 9, pp. 972-976.
CODEN: JJCREP. ISSN: 0910-5050.

DT Article

ED Entered STN: 10 Dec 1996
Last Updated on STN: 10 Dec 1996

L4 ANSWER 14 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1996:126580 BIOSIS
DN PREV199698698715
TI Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme.
AU Tsurushima, Hideo; Liu, Shu Qin; Tsuboi, Koji; Yoshii, Yoshihiko; Nose, Tadao; Ohno, Tadao [Reprint author]
CS RIKEN Cell Bank, 3-1-1 Koyadai, Tsukuba Science City 305, Japan
SO Journal of Neurosurgery, (1996) Vol. 84, No. 2, pp. 258-263.
CODEN: JONSAC. ISSN: 0022-3085.

DT Article
LA English
ED Entered STN: 27 Mar 1996
Last Updated on STN: 27 Mar 1996

L4 ANSWER 15 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1996:63778 BIOSIS
DN PREV199698635913
TI Gene therapy for cancer: A trend of research.
AU Niitsu, Yoshiro; Koshita, Yoshikazu
CS 4th Dep. Internal Med., Sapporo Med. Univ., Sapporo, Japan
SO Journal of Japan Society for Cancer Therapy, (1995) Vol. 30, No. 10, pp. 1703-1713.
CODEN: NGCJAK. ISSN: 0021-4671.

DT Article
LA Japanese
ED Entered STN: 9 Feb 1996
Last Updated on STN: 9 Feb 1996

L4 ANSWER 16 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1995:496481 BIOSIS
DN PREV199598520031
TI Unique characteristics associated with systemic ***adoptive*** ***immunotherapy*** of experimental intracerebral tumors.
AU Sussman, Jeffrey J.; Wahl, Wendy L.; Chang, Alfred E.; Shu, Suyu [Reprint author]
CS Cent. Surg. Res./FF50, Cleveland Clin. Found., 9500 Euclid Ave., Cleveland, OH 44195, USA
SO Journal of Immunotherapy with Emphasis on Tumor Immunology, (1995) Vol. 18, No. 1, pp. 35-44.
ISSN: 1067-5582.

DT Article
LA English
ED Entered STN: 29 Nov 1995
Last Updated on STN: 29 Nov 1995

L4 ANSWER 17 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1995:385776 BIOSIS
DN PREV199598400076
TI The effects of allogeneic tumor specific cytotoxic T-lymphocytes on in-situ 9L gliosarcoma ***brain*** ***tumors*** in the Fischer rat.
AU Wall, N. R.; Redd, J. M.
CS Walla Walla College, College Place, WA, USA
SO 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY. (1995) pp. 874. The 9th International Congress of Immunology.
Publisher: 9th International Congress of Immunology, San Francisco, California, USA.
Meeting Info.: Meeting Sponsored by the American Association of Immunologists and the International Union of Immunological Societies. San Francisco, California, USA. July 23-29, 1995.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

ED Entered STN: 1 Sep 1995
Last Updated on STN: 1 Sep 1995

L4 ANSWER 18 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1995:373821 BIOSIS
DN PREV199598388121
TI Cancer Chemotherapy and Biological Response Modifiers Annual, 15.
AU Pinedo, H. M. [Editor, Reprint author]; Longo, D. L. [Editor]; Chabner, B. A. [Editor]
CS The Free Univ., Amsterdam, Netherlands
SO Pinedo, H. M. [Editor]; Longo, D. L. [Editor]; Chabner, B. A. [Editor].
Cancer Chemotherapy and Biological Response Modifiers Annual, (1994) pp. xv+715p. Cancer Chemotherapy and Biological Response Modifiers Annual.
Publisher: Elsevier Science Publishers B.V., PO Box 211, Sara Burgerhartstraat 25, 1000 AE Amsterdam, Netherlands; Elsevier Science Publishing Co., Inc., P.O. Box 882, Madison Square Station, New York, New York 10159-2101, USA. Series: Cancer Chemotherapy and Biological Response Modifiers Annual.
ISSN: 0921-4410. ISBN: 0-444-82056-6.

DT Book
LA English
ED Entered STN: 1 Sep 1995
Last Updated on STN: 1 Sep 1995

L4 ANSWER 19 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1995:37931 BIOSIS
DN PREV199598052231
TI ***Adoptive*** ***immunotherapy*** of ***brain***
tumors
AU Kikuchi, Tetsuro [Reprint author]; Nakamura, Norio; Abe, Toshiaki; Watanabe, Michiko; Ohno, Tsuneya
CS Dep. Neurosurg., Jikei Univ. Sch. Med., 3-25-8 Nishi-Shinbashi, Minato-Ku, Tokyo 105, Japan
SO Jikeikai Medical Journal, (1994) Vol. 41, No. 3, pp. 317-323.
CODEN: JMEJAS. ISSN: 0021-6968.
DT Article
LA English
ED Entered STN: 25 Jan 1995
Last Updated on STN: 25 Jan 1995

L4 ANSWER 20 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1994:317409 BIOSIS
DN PREV199497330409
TI ***Adoptive*** ***immunotherapy*** of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells.
AU Wahl, Wendy L.; Sussman, Jeffrey J.; Shu, Suyu; Chang, Alfred E. [Reprint author]
CS 2920 Taubman Cent., Univ. Michigan Med. Cent., 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA
SO Journal of Immunotherapy With Emphasis on Tumor Immunology, (1994) Vol. 15, No. 4, pp. 242-250.
ISSN: 1067-5582.
DT Article
LA English
ED Entered STN: 26 Jul 1994
Last Updated on STN: 26 Jul 1994

L4 ANSWER 21 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1994:79378 BIOSIS
DN PREV199497092378
TI Adjuvant ***adoptive*** ***immunotherapy*** for pediatric recurrent ***brain*** ***tumors***
AU Lillehei, Kevin O. [Reprint author]; Johnson, Stephen D.; McCleary, Edward L.; Mitchell, Dawn H. [Reprint author]; Schiltz, Patric M. [Reprint author]; Kruse, Carol A.
CS Neurosurg. Div., Univ. Colorado Health Sci. Center, Denver, CO 80262, USA

DT Letter

LA English

ED Entered STN: 22 Feb 1994

Last Updated on STN: 22 Feb 1994

L4 ANSWER 22 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1993:334139 BIOSIS

DN PREV199345028864

TI Systemic T cell ***adoptive*** ***immunotherapy*** of experimental
brain ***tumors***

AU Sussman, J.; Wahl, W.; Chang, A.; Shu, S.

CS Dep. Surgery, Univ. Mich., Ann Arbor, MI 48109, USA

SO Journal of Immunology, (1993) Vol. 150, No. 8 PART 2, pp. 176A.

Meeting Info.: Joint Meeting of the American Association of Immunologists
and the Clinical Immunology Society. Denver, Colorado, USA. May 21-25,
1993.

CODEN: JOIMA3. ISSN: 0022-1767.

DT Conference; (Meeting)

LA English

ED Entered STN: 16 Jul 1993

Last Updated on STN: 16 Jul 1993

L4 ANSWER 23 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1993:322159 BIOSIS

DN PREV199396030509

TI Generation of cellular immune responses against a glioma-associated
antigen(s).

AU Holladay, Frank P.; Wood, Gary W. [Reprint author]

CS Dep. Pathol., University Kansas Med. Center, 39th Rainbow Blvd., Kansas
City, KS 66160-7410, USA

SO Journal of Neuroimmunology, (1993) Vol. 44, No. 1, pp. 27-32.

CODEN: JNRIDW. ISSN: 0165-5728.

DT Article

LA English

ED Entered STN: 12 Jul 1993

Last Updated on STN: 12 Jul 1993

L4 ANSWER 24 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1993:158712 BIOSIS

DN PREV199344077512

TI Effect of dexamethasone on the efficacy of chemo- ***adoptive***
immunotherapy or rat ***brain*** ***tumor***AU Frank, J. A. [Reprint author]; Eule, J. M.; Demasters, B. K.; Kong, Q.;
Mitchell, D. H.; Lillehei, K. O.; Kruse, C. A.

CS Univ. Colo. Health Sci. Cent., Denver, CO, USA

SO Clinical Research, (1993) Vol. 41, No. 1, pp. 31A.

Meeting Info.: Joint Meeting of the Western Society for Clinical
Investigation, Western Section American Federation for Clinical Research,
Western Society for Pediatric Research, Western Region Society for
Investigative Dermatology, and the Western Student Medical Research
Committee. Carmel, California, USA. February 17-20, 1993.

CODEN: CLREAS. ISSN: 0009-9279.

DT Conference; (Meeting)

LA English

ED Entered STN: 19 Mar 1993

Last Updated on STN: 20 Mar 1993

L4 ANSWER 25 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN

AN 1992:434685 BIOSIS

DN PREV199294086810; BA94:86810

TI CHARACTERIZATION OF IMMOBILIZED ANTI-CD3 ANTIBODY-ACTIVATED T LYMPHOCYTES
FOR USE IN ***ADOPTIVE*** ***IMMUNOTHERAPY*** OF PATIENTS WITH
BRAIN ***TUMORS***

AU YAMAZAKI T [Reprint author]; SEKINE T

JPN
SO Neurologia Medico-Chirurgica, (1992) Vol. 32, No. 5, pp. 255-261.
ISSN: 0387-2572.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 22 Sep 1992
Last Updated on STN: 22 Sep 1992

L4 ANSWER 26 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1992:237305 BIOSIS
DN PREV199293125330; BA93:125330
TI ALLOGENEIC TUMOR-SPECIFIC CYTOTOXIC T LYMPHOCYTES.
AU REDD J M [Reprint author]; LAGARDE A C; KRUSE C A; BELLGRAU D
CS DEP MICROBIOLOGY IMMUNOLOGY, UNIVERSITY COLORADO HEALTH SCI CENTER, BOX B
140, DENVER, COLO 80262, USA
SO Cancer Immunology Immunotherapy, (1992) Vol. 34, No. 5, pp. 349-354.
CODEN: CIIMDN. ISSN: 0340-7004.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 10 May 1992
Last Updated on STN: 10 May 1992

L4 ANSWER 27 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1992:191180 BIOSIS
DN PREV199293102130; BA93:102130
TI TREATMENT OF MURINE PRIMARY ***BRAIN*** ***TUMORS*** WITH SYSTEMIC
INTERLEUKIN-2 AND TUMOR-INFILTRATING LYMPHOCYTES.
AU SARIS S C [Reprint author]; SPIESS P; LIEBERMAN D M; LIN S; WALBRIDGE S;
OLDFIELD E H
CS NATL INST HEALTH, 9000 ROCKVILLE PIKE, BLDG 10 ROOM 5D-37, BETHESDA, MD
20892, USA
SO Journal of Neurosurgery, (1992) Vol. 76, No. 3, pp. 513-519.
CODEN: JONSAC. ISSN: 0022-3085.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 13 Apr 1992
Last Updated on STN: 13 Apr 1992

L4 ANSWER 28 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1992:73909 BIOSIS
DN PREV199293042364; BA93:42364
TI IMMUNOMODULATORY EFFECTS OF INTERFERONS ON TARGET HUMAN GLIOSARCOMA CELLS
IN THE TUMOR-SPECIFIC CTL AND LAK-MEDIATED CYTOLYSIS.
AU MIYATAKE S-I [Reprint author]; KONDOU S; AOKI T; IWASAKI K; OHYAMA K;
OOTSUKA S-I; ODA Y; KIKUCHI H
CS DEP NEUROSURG, FAC MED, KYOTO UNIV, JPN
SO Neurological Surgery, (1991) Vol. 19, No. 11, pp. 1053-1059.
CODEN: NOKGB6. ISSN: 0301-2603.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 2 Feb 1992
Last Updated on STN: 2 Feb 1992

L4 ANSWER 29 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1991:298209 BIOSIS
DN PREV199192019224; BA92:19224
TI PHENOTYPE AND FUNCTIONAL ACTIVITY OF TUMOR-INFILTRATING LYMPHOCYTES
ISOLATED FROM IMMUNOGENIC AND NONIMMUNOGENIC RAT ***BRAIN***
TUMORS
AU TZENG J-J [Reprint author]; BARTH R F; OROSZ C G; JAMES S M
CS 165 HAMILTON HALL, 1645 NEIL AVE, COLUMBIA, OH 43210, USA
SO Cancer Research, (1991) Vol. 51, No. 9, pp. 2373-2378.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 25 Jun 1991
Last Updated on STN: 25 Jun 1991

L4 ANSWER 30 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1991:116366 BIOSIS
DN PREV199191063756; BA91:63756
TI LONG-TERM FOLLOW-UP OF PATIENTS WITH RECURRENT MALIGNANT GLIOMAS TREATED
WITH ADJUVANT ***ADOPTIVE*** ***IMMUNOTHERAPY***
AU LILLEHEI K O [Reprint author]; MITCHELL D H; JOHNSON S D; MCCLEARY E L;
KRUSE C A
CS DENVER BRAIN TUMOR RESEARCH GROUP, NEUROSURG DIV UNIV COLORADO HEALTH SCI
CENTER, ST JOSEPH HOSP, DENVER, COLO, USA
SO Neurosurgery (Baltimore), (1991) Vol. 28, No. 1, pp. 16-23.
ISSN: 0148-396X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 27 Feb 1991
Last Updated on STN: 27 Feb 1991

L4 ANSWER 31 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1990:520010 BIOSIS
DN PREV199090137286; BA90:137286
TI AN EXPERIMENTAL APPROACH TO SPECIFIC ***ADOPTIVE***
IMMUNOTHERAPY FOR MALIGNANT ***BRAIN*** ***TUMORS***
AU YAMASAKI T [Reprint author]; KIKUCHI H
CS DEP NEUROSURGERY, SHIMANE MEDICAL UNIVERSITY, ENYA-CHO 89-1, IZUMO 693,
JPN
SO Archiv fuer Japanische Chirurgie, (1989) Vol. 58, No. 6, pp. 485-492.
CODEN: NIGHAE. ISSN: 0003-9152.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1990
Last Updated on STN: 19 Nov 1990

L4 ANSWER 32 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1990:482699 BIOSIS
DN PREV199039106720; BR39:106720
TI POTENTIAL OF ALLOGENEIC TUMORICIDAL CYTOTOXIC T LYMPHOCYTES IN
BRAIN ***TUMOR*** ***ADOPTIVE*** ***IMMUNOTHERAPY***
AU FLESHNER M [Reprint author]; WATKINS L R; KRUSE C A; BELLGRAU D
CS DEP PSYCH, UNIV COLO-BOULDER, BOULDER, COLO 80309, USA
SO Journal of Cellular Biochemistry Supplement, (1990) No. 14 PART B, pp. 95.
Meeting Info.: SYMPOSIUM ON CELLULAR IMMUNITY AND THE IMMUNOTHERAPY OF
CANCER HELD AT THE 19TH ANNUAL UCLA (UNIVERSITY OF CALIFORNIA-LOS ANGELES)
SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, PARK CITY, UTAH, USA, JANUARY
27-FEBRUARY 3, 1990. J CELL BIOCHEM SUPPL.
ISSN: 0733-1959.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 30 Oct 1990
Last Updated on STN: 30 Oct 1990

L4 ANSWER 33 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1990:473852 BIOSIS
DN PREV199090113272; BA90:113272
TI ***ADOPTIVE*** ***IMMUNOTHERAPY*** AGAINST ***BRAIN***
TUMORS
AU KIKUCHI T [Reprint author]; SAKAI H; NAKAMURA N; MOROOKA S; KANDA R;
WATANABE M; OHNO T
CS DEP NEUROSURGERY, JIKEI UNIVERSITY SCH MED, JAPAN

CODEN: TJIDAH. ISSN: 0375-9172.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 25 Oct 1990
Last Updated on STN: 25 Oct 1990

L4 ANSWER 34 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1990:428519 BIOSIS
DN PREV199090089320; BA90:89320
TI ANALYSIS OF LOCAL IMMUNORESPONSES IN LOCAL APPLICATION OF VARIOUS EFFECTOR
CELLS IN A RAT ***BRAIN*** ***TUMOR*** MODEL.
AU KAWAHARA T [Reprint author]
CS DEP NEUROSURG, SAPPORO MED COLL
SO Sapporo Medical Journal, (1990) Vol. 59, No. 3, pp. 201-214.
CODEN: SIZSAR. ISSN: 0036-472X.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 22 Sep 1990
Last Updated on STN: 22 Sep 1990

L4 ANSWER 35 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1990:199703 BIOSIS
DN PREV199089106374; BA89:106374
TI HIGH YIELDING CULTURE OF LAK CELLS BY THE CONCENTRATION ROTARY TISSUE
CULTURE SYSTEM AND ITS CLINICAL APPLICATION.
AU PARK K-C [Reprint author]; SHIMIZU K; TAMARA K; YAMADA M; MATSUI Y;
MABUCHI E; MORIUCHI S; MOGAMI H
CS DEP NEUROSURG, OSAKA UNIV MED SCH
SO Journal of Japan Society for Cancer Therapy, (1989) Vol. 24, No. 10, pp.
2349-2354.
CODEN: NGCJAK. ISSN: 0021-4671.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 24 Apr 1990
Last Updated on STN: 24 Apr 1990

L4 ANSWER 36 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1990:71966 BIOSIS
DN PREV199089039792; BA89:39792
TI ***ADOPTIVE*** ***IMMUNOTHERAPY*** FOR PATIENTS WITH
MEDULLOBLASTOMA BY LAK CELLS.
AU SHIMIZU K [Reprint author]; TAMURA K; YAMADA M; OKAMOTO Y; MIYAO Y; PARK
K; MATSUI Y; HAYAKAWA T; TAKIMOTO H; MOGAMI H
CS DEP NEUROSURGERY, OSAKA UNIV MED SCH, 1-1-50 FUKUSHIMA, FUKUSHIMA-KU,
OSAKA, JPN
SO Brain and Nerve (Tokyo), (1989) Vol. 41, No. 10, pp. 991-995.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 23 Jan 1990
Last Updated on STN: 23 Jan 1990

L4 ANSWER 37 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1989:183919 BIOSIS
DN PREV198987095185; BA87:95185
TI INTRALESIONAL INFUSION OF LYMPHOKINE-ACTIVATED KILLER LAK CELLS AND
RECOMBINANT INTERLEUKIN-2 RIL-2 FOR THE TREATMENT OF PATIENTS WITH
MALIGNANT ***BRAIN*** ***TUMOR***
AU MERCHANT R E [Reprint author]; MERCHANT L H; COOK S H S; MCVICAR D W;
YOUNG H F
CS VA COMMONWEALTH UNIV, MED COLL VA, DEP ANATOMY, MCV STATION, BOX 709,
RICHMOND, VA 23298-0709, USA

ISSN: 0148-396X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 9 Apr 1989
Last Updated on STN: 9 Apr 1989

L4 ANSWER 38 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:463305 BIOSIS
DN PREV198886105024; BA86:105024
TI STUDY ON ***ADOPTIVE*** ***IMMUNOTHERAPY*** FOR THE EXPERIMENTAL
BRAIN ***TUMOR***
AU TAKAI N [Reprint author]
CS DEP NEUROSURGERY, BRAIN RES INST, NIIGATA UNIV, 1-757 ASAHI MACHI-DORI,
NIIGATA 951, JAPAN
SO Brain and Nerve (Tokyo), (1988) Vol. 40, No. 7, pp. 689-695.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 18 Oct 1988
Last Updated on STN: 18 Oct 1988

L4 ANSWER 39 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:462917 BIOSIS
DN PREV198886104636; BA86:104636
TI LOCAL ADMINISTRATION OF AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELLS AND
RECOMBINANT INTERLEUKIN 2 TO PATIENTS WITH MALIGNANT ***BRAIN***
TUMORS
AU YOSHIDA S [Reprint author]; TANAKA R; TAKAI N; ONO K
CS DEP NEUROSURG, BRAIN RES INST, NIIGATA UNIV, NIIGATA 951, JPN
SO Cancer Research, (1988) Vol. 48, No. 17, pp. 5011-5016.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 18 Oct 1988
Last Updated on STN: 18 Oct 1988

L4 ANSWER 40 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:266964 BIOSIS
DN PREV198886006208; BA86:6208
TI OBSERVATIONS ON THE LOCAL ADMINISTRATION OF AUTOLOGOUS LYMPHOKINE
ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN 2 TO PATIENTS WITH
MALIGNANT GLIOMAS.
AU YOSHIDA S [Reprint author]; TAKAI N; ONO K; SAITO T; TANAKA R
CS DEP NEUROSURGERY, BRAIN RES INST, NIIGATA UNIV, 1 ASAHI MACHI-DORI, NIIGATA
951, JPN
SO Brain and Nerve (Tokyo), (1988) Vol. 40, No. 2, pp. 119-125.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 2 Jun 1988
Last Updated on STN: 2 Jun 1988

L4 ANSWER 41 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:246036 BIOSIS
DN PREV198885124438; BA85:124438
TI IN-VIVO AND IN-VITRO EFFECT OF ***ADOPTIVE*** ***IMMUNOTHERAPY***
OF EXPERIMENTAL MURINE ***BRAIN*** ***TUMORS*** USING
LYMPHOKINE-ACTIVATED KILLER CELLS.
AU TAKAI N [Reprint author]; TANAKA R; YOSHIDA S; HARA N; SAITO T
CS DEP NEUROSURG, BRAIN RES INST, NIIGATA UNIV, NIIGATA 951, JPN
SO Cancer Research, (1988) Vol. 48, No. 8, pp. 2047-2052.
CODEN: CNREA8. ISSN: 0008-5472.

FS BA
LA ENGLISH
ED Entered STN: 16 May 1988
Last Updated on STN: 16 May 1988

L4 ANSWER 42 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:137078 BIOSIS
DN PREV198885071905; BA85:71905
TI EFFECTS OF PHENYTOIN ON CELL-MEDIATED IMMUNITY.
AU OKAMOTO Y [Reprint author]; SHIMIZU K; TAMURA K; MIYAO Y; YAMADA M; MATSUI
Y; TSUDA N; MOGAMI H
CS DEP NEUROSURG, OSAKA UNIV MED SCH, 1-1-50 FUKUSHIMA, FUKUSHIMA-KU, OSAKA
553, JPN
SO Brain and Nerve (Tokyo), (1987) Vol. 39, No. 10, pp. 931-936.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 12 Mar 1988
Last Updated on STN: 12 Mar 1988

L4 ANSWER 43 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:114183 BIOSIS
DN PREV198885059653; BA85:59653
TI ***ADOPTIVE*** ***IMMUNOTHERAPY*** FOR THE EXPERIMENTAL
BRAIN ***TUMOR*** IN RATS INDUCTION OF LAK CELLS AND THEIR
BIOLOGICAL CHARACTERISTIC.
AU TAKAI N [Reprint author]; TANAKA R; YOSHIDA S; HARA N; SAITO T
CS DEP NEUROSURG, BRAIN RES INST, NIIGATA UNIV, 1-757 ASAHI MACHI-DORI,
NIIGATA 951, JPN
SO Brain and Nerve (Tokyo), (1987) Vol. 39, No. 9, pp. 879-884.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 23 Feb 1988
Last Updated on STN: 23 Feb 1988

L4 ANSWER 44 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1988:73153 BIOSIS
DN PREV198885039452; BA85:39452
TI FUNCTIONAL ANALYSIS OF INTERLEUKIN 2 IN IMMUNE SURVEILLANCE AGAINST
BRAIN ***TUMORS***
AU YOSHIDA S [Reprint author]; TAKAI N; TANAKA R
CS DEP NEUROSURGERY, BRAIN RES INST, NIIGATA UNIV, 1 ASAHI MACHI, NIIGATA 951,
JPN
SO Neurosurgery (Baltimore), (1987) Vol. 21, No. 5, pp. 627-630.
ISSN: 0148-396X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 27 Jan 1988
Last Updated on STN: 27 Jan 1988

L4 ANSWER 45 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on
STN
AN 1987:59398 BIOSIS
DN PREV198732029619; BR32:29619
TI THE ***ADOPTIVE*** ***IMMUNOTHERAPY*** OF HUMAN ***BRAIN***
TUMORS WITH LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT
INTERLEUKIN-2.
AU OKAMOTO Y [Reprint author]; SHIMIZU K; MIYAO Y; MATSUI Y; YAMADA M; TSUDA
N; MOGAMI M
CS DEP NEUROSURG, OSAKA UNIV, OSAKA, JPN
SO (1986) pp. 144. UICC (UNION INTERNATIONALE CONTRE LE CANCER, INTERNATIONAL
UNION AGAINST CANCER). 14TH INTERNATIONAL CANCER CONGRESS, BUDAPEST,
HUNGARY, AUG. 21-27, 1986. ABSTRACTS, LECTURES, SYMPOSIA AND FREE

XVI+479P. (VOL. 1); XVI+298P. (VOL. 2); XVI+531P. (VOL. 3); 15P. (LATE ABSTRACTS); 40P. (REGISTER) S. KARGER AG: BASEL, SWITZERLAND; NEW YORK, N.Y., USA; AKADEMIAI KIADO: BUDAPEST, HUNGARY. PAPER.
ISBN: 3-8055-4434-0 (KARGER), 963-05-4422-9 (VOL. 1), 963-05-4423-7 (VOL. 2), 963-05-4424-5 (VOL. 3), 963-05-4439-3 (LATE ABSTRACTS), 963-05-4425-3 (REGISTER), 963-05-4421-0 (GENERAL).

DT Book
FS Conference; (Meeting)
LA BR

ED Entered STN: 17 Jan 1987
Last Updated on STN: 17 Jan 1987

L4 ANSWER 46 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1986:419231 BIOSIS

DN PREV198682094765; BA82:94765

TI CLINICAL STUDIES OF ***ADOPTIVE*** ***IMMUNOTHERAPY*** OF HUMAN DISSEMINATED ***BRAIN*** ***TUMORS*** WITH LYMPHOKINE-ACTIVATED KILLER CELLS AND RECOMBINANT INTERLEUKIN 2.

AU OKAMOTO Y [Reprint author]; SHIMIZU K; MIYAO Y; YAMADA M; USHIO Y; MATSUI Y; HAYAKAWA T; TAGO H; IKEDA H

CS DEP NEUROSURG, ITAMI CITY HOSP, UNIV MED SCH, 1-1-50 FUKUSHIMA, FUKUSHIMA-KU, OSAKA 553, JPN

SO Brain and Nerve (Tokyo), (1986) Vol. 38, No. 6, pp. 593-598.
CODEN: NOTOA6. ISSN: 0006-8969.

DT Article

FS BA

LA JAPANESE

ED Entered STN: 25 Oct 1986

Last Updated on STN: 25 Oct 1986

L4 ANSWER 47 OF 196 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1984:308659 BIOSIS

DN PREV198478045139; BA78:45139

TI EFFECT OF T CELL GROWTH FACTOR ON EXPERIMENTAL MALIGNANT GLIOMA SPECIFIC KILLER T CELL.

AU YAMASAKI T [Reprint author]; YAMASHITA J; HANDA H; NAMBA Y; HANAOKA M

CS DEP NEUROSURG, KYOTO UNIV, MED SCH, KYOTO, JPN

SO Neurological Surgery, (1984) Vol. 12, No. 2, pp. 141-150.
CODEN: NOKGB6. ISSN: 0301-2603.

DT Article

FS BA

LA JAPANESE

L4 ANSWER 48 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2001:33131198 BIOTECHNO

TI Strategies using the immune system for therapy of ***brain***
tumors

AU Virasch N.; Kruse C.A.

CS Dr. C.A. Kruse, Department of Immunology, Univ. of Colorado Health Sci. Ctr., 4200 E Ninth Avenue, Denver, CO 80262, United States.

E-mail: carol.kruse@uchsc.edu

SO Hematology/Oncology Clinics of North America, (***2001***), 15/6 (1053-1071), 104 reference(s)

CODEN: HCNAEQ ISSN: 0889-8588

DT Journal; General Review

CY United States

LA English

SL English

L4 ANSWER 49 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2001:33070980 BIOTECHNO

TI Dendritic cell therapy of primary ***brain*** ***tumors***

AU Soling A.; Rainov N.G.

CS A. Soling, Martin-Luther-University Halle, Department of Neurosurgery, Molec. Neurooncology Lab. (ZAMED), Heinrich-Damerow-Strasse 1, D-06097 Halle, Germany.

E-mail: ariane.soling@medizin.uni-halle.de

CODEN: MOMEE2 ISSN: 1076-1551

DT Journal; General Review

CY United States

LA English

SL English

L4 ANSWER 50 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2001:32959252 BIOTECHNO

TI Novel approaches to imaging ***brain*** ***tumors***

AU Matthews P.M.; Wylezinska M.; Cadoux-Hudson T.

CS P.M. Matthews, Ctr. for Func. Magnetic Reson., John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom.

E-mail: paul@fmrib.ox.ac.uk

SO Hematology/Oncology Clinics of North America, (***2001***), 15/4 (609-630), 118 reference(s)

CODEN: HCNAEQ ISSN: 0889-8588

DT Journal; General Review

CY United States

LA English

SL English

L4 ANSWER 51 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2001:32551987 BIOTECHNO

TI Adoptive cellular immunotherapy for the treatment of malignant gliomas

AU Hayes R.L.; Arbit E.; Odaimi M.; Pannullo S.; Scheff R.; Kravchinskiy D.; Zaroulis C.

CS R.L. Hayes, Department of Medicine, Sanford R. Nalitt Inst. for Cancer, Staten Island University Hospital, 256 Mason Avenue, Staten Island, NY 10305, United States.

SO Critical Reviews in Oncology/Hematology, (***2001***), 39/1-2 (31-42), 76 reference(s)

CODEN: CCRHEC ISSN: 1040-8428

PUI S1040842801001226

DT Journal; Conference Article

CY Ireland

LA English

SL English

L4 ANSWER 52 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30418761 BIOTECHNO

TI Exploitation of immune mechanisms in the treatment of central nervous system cancer

AU Pollack I.F.; Okada H.; Chambers W.H.

CS Dr. I.F. Pollack, Department of Neurosurgery, Children's Hospital of Pittsburgh, 3705 Fifth Ave, Pittsburgh, PA 15213, United States.

SO Seminars in Pediatric Neurology, (***2000***), 7/2 (131-143), 123 reference(s)

CODEN: SPNEFD ISSN: 1071-9091

DT Journal; Article

CY United States

LA English

SL English

L4 ANSWER 53 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29467815 BIOTECHNO

TI Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2

AU Glick R.P.; Lichtor T.; De Zoeten E.; Deshmukh P.; Cohen E.P.; Rock J.P.; Parsa A.T.; Bruce J.N.; Rutka J.T.; Piepmeyer J.M.

CS Dr. R.P. Glick, Department of Neurosurgery, Cook County Hospital, 1835 W. Harrison Street, Chicago, IL 60612, United States.

SO Neurosurgery, (***1999***), 45/4 (867-874), 25 reference(s)

CODEN: NRSRDY ISSN: 0148-396X

DT Journal; Article

CY United States

LA English

SL English

L4 ANSWER 54 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:28306213 BIOTECHNO

AU Herrlinger U.; Weller M.; Schabet M.
CS U. Herrlinger, Department of Neurology, University of Tuebingen,
Hoppe-Seyles-Str. 3, D-72076 Tuebingen, Germany.
SO Journal of Neuro-Oncology, (***1998***), 38/2-3 (233-239), 50
reference(s)
CODEN: JNODD2 ISSN: 0167-594X
DT Journal; Conference Article
CY United States
LA English
SL English

L4 ANSWER 55 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1995:25340306 BIOTECHNO
TI Novel biologic therapies for malignant gliomas: Antiangiogenesis,
immunotherapy, and gene therapy
AU Fine H.A.
CS Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, United
States.
SO Neurologic Clinics, (***1995***), 13/4 (827-846)
CODEN: NECLEG ISSN: 0733-8619
DT Journal; General Review
CY United States
LA English
SL English

L4 ANSWER 56 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1994:24146992 BIOTECHNO
TI New approaches in ***brain*** ***tumor*** therapy using gene
transfer and antisense oligonucleotides
AU Yung W.K.A.
CS Department of Neurology, Texas Univ. M.D. Anderson Can. Ctr., Box 100,
1515 Holcombe Boulevard, Houston, TX 77030, United States.
SO Current Opinion in Oncology, (***1994***), 6/3 (235-239)
CODEN: CUOOE8 ISSN: 1040-8746
DT Journal; General Review
CY United States
LA English
SL English

L4 ANSWER 57 OF 196 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1988:18201844 BIOTECHNO
TI An ***adoptive*** ***immunotherapy*** of patients with
medulloblastoma by lymphokine-activated killer cells (LAK)
AU Okamoto Y.; Shimizu K.; Tamura K.; Miyao Y.; Yamada M.; Matsui Y.; Tsuda
N.; Takimoto H.; Hayakawa T.; Mogami H.
CS Department of Neurosurgery, Osaka University Medical School,
Fukushima-ku, Osaka 553, Japan.
SO Acta Neurochirurgica, (***1988***), 94/1-2 (47-52)
CODEN: ACNUA5 ISSN: 0001-6268
DT Journal; Article
CY Austria
LA English
SL English

L4 ANSWER 58 OF 196 CANCERLIT on STN
AN 2002129955 CANCERLIT
DN 21543153 PubMed ID: 11686021
TI ***Adoptive*** ***immunotherapy*** of CNS malignancies.
AU Plautz G E; Shu S
CS Department of Pediatrics, 333 Cedar Street LMP 4087, Yale University
School of Medicine, New Haven, CT 06520-8064, USA.
SO CANCER CHEMOTHERAPY AND BIOLOGICAL RESPONSE MODIFIERS, *** (2001)*** 19
327-38. Ref: 33
Journal code: 8812385. ISSN: 0921-4410.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS MEDLINE; Priority Journals

EM 200204
ED Entered STN: 20020726
Last Updated on STN: 20020726

L4 ANSWER 59 OF 196 CANCERLIT on STN
AN 2002096900 CANCERLIT
DN 21446111 PubMed ID: 11561349
TI ***Adoptive*** ***immunotherapy*** for malignant ***brain***
tumors using human peripheral blood mononuclear cells activated by
the Streptococcal preparation OK-432.
AU Hirotsu T; Mineta T; Ichinose M; Toda K; Fukuyama K; Tabuchi K
CS Department of Neurosurgery, Saga Medical School, Saga, Japan.
SO NEUROLOGIA MEDICO-CHIRURGICA, ***(2001 Aug)*** 41 (8) 387-92.
Journal code: 0400775. ISSN: 0470-8105.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2001514036
EM 200201
ED Entered STN: 20020726
Last Updated on STN: 20020726

L4 ANSWER 60 OF 196 CANCERLIT on STN
AN 96625406 CANCERLIT
DN 96625406
TI Therapeutic effect of CTL from mice immunized with TNF-alpha gene-modified
tumor cells on established brain metastases (Meeting abstract).
AU Kazumoto K; Inoue K; Nishimura H; Hara E
CS Neurosurgery, Endocrinology, Thoracic Surgery Clinic, and Research
Institute Dept. of Biochemistry, Saitama Cancer Center, Saitama 362,
Japan.
SO Gene Ther, ***(1995)*** 2 (9) 689.
ISSN: 0969-7128.
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Institute for Cell and Developmental Biology
EM 199606
ED Entered STN: 19970509
Last Updated on STN: 19970509

L4 ANSWER 61 OF 196 CANCERLIT on STN
AN 96602235 CANCERLIT
DN 96602235
TI Treatment of experimental cerebral tumors by the systemic transfer of
superantigen-activated tumor-draining lymph node cells (Meeting abstract).
AU Inoue M; Plautz G E; Chang A E; Shu S
CS Department of Surgery, University of Michigan, Ann Arbor, MI 48109.
SO Proc Annu Meet Am Assoc Cancer Res, ***(1995)*** 36 A2944.
ISSN: 0197-016X.
DT (MEETING ABSTRACTS)
LA English
FS Institute for Cell and Developmental Biology
EM 199604
ED Entered STN: 19970509
Last Updated on STN: 19970509

L4 ANSWER 62 OF 196 CANCERLIT on STN
AN 94697322 CANCERLIT
DN 94697322
TI Successful ***adoptive*** ***immunotherapy*** of intracerebral
tumors with activated tumor-draining lymphocytes (Meeting abstract).
AU Wahl W L; Sussman J J; Shu S; Chang A E
CS Univ. of Michigan, Ann Arbor, MI.
SO Non-serial, ***(1993)*** Society of Surgical Oncology, 46th Annual
Cancer Symposium in Conjunction with Society of Head and Neck Surgeons.
March 18-21, 1993, Los Angeles, CA, p. 83, 1993..
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Institute for Cell and Developmental Biology

ED Entered STN: 19941107
Last Updated on STN: 19970509

L4 ANSWER 63 OF 196 CANCERLIT on STN
AN 94199197 CANCERLIT
DN 94199197 PubMed ID: 1344303
TI A 9L gliosarcoma transplantation model for studying ***adoptive***
immunotherapy into the brains of conscious rats.
AU Fleshner M; Watkins L R; Redd J M; Kruse C A; Bellgrau D
CS Department of Psychology, University of Colorado-Boulder 80309.
SO CELL TRANSPLANTATION, ***(1992)*** 1 (4) 307-12.
Journal code: 9208854. ISSN: 0963-6897.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 94199197
EM 199405
ED Entered STN: 19941107
Last Updated on STN: 19970509

L4 ANSWER 64 OF 196 CANCERLIT on STN
AN 91676359 CANCERLIT
DN 91676359
TI IMMUNOBIOLOGICAL AND IMMUNOTHERAPEUTIC ASPECTS OF TRANSPLANTABLE RAT
GLIOMAS.
AU Tzeng J
CS Ohio State Univ.
SO Diss Abstr Int [B], ***(1991)*** 51 (10) 4789.
ISSN: 0419-4217.
DT (THESIS)
LA English
FS Institute for Cell and Developmental Biology
EM 199111
ED Entered STN: 19941107
Last Updated on STN: 19970509

L4 ANSWER 65 OF 196 CANCERLIT on STN
AN 91676346 CANCERLIT
DN 91676346
TI DIFFERENTIAL EFFECTS OF CORTICOSTEROIDS AND GLIOMA ON CELLULAR
CYTOTOXICITY AND T-LYMPHOCYTE ACTIVATION.
AU McVicar D W
CS Virginia Commonwealth Univ.
SO Diss Abstr Int [B], ***(1991)*** 51 (10) 4766.
ISSN: 0419-4217.
DT (THESIS)
LA English
FS Institute for Cell and Developmental Biology
EM 199111
ED Entered STN: 19941107
Last Updated on STN: 19970509

L4 ANSWER 66 OF 196 CANCERLIT on STN
AN 91672620 CANCERLIT
DN 91672620
TI BIOLOGICAL RESPONSE MODIFIER THERAPIES FOR PATIENTS WITH MALIGNANT
GLIOMAS.
AU Gillespie G Y; Mahaley M S
CS Div. of Neurological Surgery, Univ. of Alabama at Birmingham, Birmingham,
AL 35294.
SO Non-serial, ***(1990)*** Neuro-oncology: Primary Malignant Brain
Tumours. Thomas DG, ed. Johns Hopkins Series in Contemporary Medicine and
Public Health. Baltimore, Johns Hopkins University Press, p. 242-82, 1990.
DT Book; (MONOGRAPH)
General Review; (REVIEW)
LA English
FS Institute for Cell and Developmental Biology
EM 199105

Last Updated on STN: 19970509

L4 ANSWER 67 OF 196 CANCERLIT on STN
AN 91127977 CANCERLIT
DN 91127977 PubMed ID: 1992912
TI Advances of BRM therapy of malignant ***brain*** ***tumors***
AU Nagai M
CS Dept. of Neurosurgery, Dokkyo University School of Medicine.
SO GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY],
(1991 Feb) 18 (2) 188-94.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA Japanese
FS MEDLINE; Priority Journals
OS MEDLINE 91127977
EM 199103
ED Entered STN: 19941107
Last Updated on STN: 19970509

L4 ANSWER 68 OF 196 CANCERLIT on STN
AN 90197716 CANCERLIT
DN 90197716 PubMed ID: 2180410
TI Immunobiology of ***brain*** ***tumors***
AU Sawamura Y; de Tribolet N
CS Department of Neurosurgery, University Hospital, Lausanne, Switzerland.
SO ADVANCES AND TECHNICAL STANDARDS IN NEUROSURGERY, ***(1990)*** 17
3-64. Ref: 323
Journal code: 7501064. ISSN: 0095-4829.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 90197716
EM 199005
ED Entered STN: 19990618
Last Updated on STN: 19990618

L4 ANSWER 69 OF 196 CANCERLIT on STN
AN 89265804 CANCERLIT
DN 89265804 PubMed ID: 2854899
TI Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant ***brain*** ***tumor***
AU Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
CS Department of Nuclear Medicine, School of Medicine, Hokkaido University, Japan.
SO RADIATION MEDICINE, ***(1988 Nov-Dec)*** 6 (6) 276-81.
Journal code: 8412264. ISSN: 0288-2043.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 89265804
EM 198906
ED Entered STN: 19941107
Last Updated on STN: 19941107

L4 ANSWER 70 OF 196 CANCERLIT on STN
AN 88645097 CANCERLIT
DN 88645097
TI CHEMOTHERAPY AND IMMUNOTHERAPY.
AU Anonymous
CS No affiliation given.
SO Dev Oncol, ***(1987)*** 52 353-448.
DT Book; (MONOGRAPH)
LA English

EM 198807
ED Entered STN: 19941107
Last Updated on STN: 19941107

L4 ANSWER 71 OF 196 CANCERLIT on STN
AN 88075976 CANCERLIT
DN 88075976 PubMed ID: 3318704
TI Efficacy of interferon-beta and interleukin-2 as cytokines for malignant ***brain*** ***tumor*** treatment.
AU Shitara N; Nakamura H; Genka S; Takakura K
CS Dept. of Neurosurgery, University of Tokyo.
SO GAN TO KAGAKU RYOH [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], *** (1987 Dec) *** 14 (12) 3235-44. Ref: 26
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS MEDLINE; Priority Journals
OS MEDLINE 88075976
EM 198801
ED Entered STN: 19941107
Last Updated on STN: 19941107

L4 ANSWER 72 OF 196 CANCERLIT on STN
AN 86267908 CANCERLIT
DN 86267908 PubMed ID: 3488031
TI Pharmacokinetics and toxicity of intrathecal administration of recombinant interleukin 2.
AU Miyatake S; Yamashita J; Tokuriki Y; Yamasaki T; Nishihara T; Handa Y;
Sugama K; Tsubai F; Hazama T; Handa H
SO GAN TO KAGAKU RYOH [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], *** (1986 Jul) *** 13 (7) 2393-8.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS MEDLINE; Priority Journals
OS MEDLINE 86267908
EM 198608
ED Entered STN: 19941107
Last Updated on STN: 19970509

L4 ANSWER 73 OF 196 CANCERLIT on STN
AN 79630217 CANCERLIT
DN 79630217
TI IMMUNOTHERAPY OF ***BRAIN*** ***TUMORS*** - IS THERE A FUTURE?.
AU Mahaley M S
CS Div. Neurosurgery, Univ. North Carolina, Clinical Sciences Building, 229 H, Chapel Hill, NC, 27514.
SO Clin Neurosurg, *** (1978) *** 25 382-387.
ISSN: 0069-4827.
DT (MEETING PAPER)
LA English
FS Institute for Cell and Developmental Biology
EM 197911
ED Entered STN: 19941107
Last Updated on STN: 19941107

L4 ANSWER 74 OF 196 CANCERLIT on STN
AN 77800962 CANCERLIT
DN 77800962
TI REVIEW AND NEW PROPOSALS FOR IMMUNOTHERAPY OF ***BRAIN*** ***TUMORS***
AU Blaylock R L; Kempe L G
CS Dept. Neurosurgery, Medical Univ. South Carolina, Charleston, SC.
SO Neurochirurgia (Stuttg), *** (1976) *** 19 10-21.
ISSN: 0028-3819.
DT Journal; Article; (JOURNAL ARTICLE)

FS Hiérarchical Classification of Proteins
EM 197702
ED Entered STN: 19941107
Last Updated on STN: 19941107

L4 ANSWER 75 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:37905 CAPLUS
DN 137:18959

TI Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse ***brain***
tumor

AU Aoki, Hideo; Mizuno, Masaaki; Natsume, Atsushi; Tsugawa, Takahiko; Tsujimura, Kunio; Takahashi, Toshitada; Yoshida, Jun

CS Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan

SO Cancer Immunology Immunotherapy (***2001***), 50(9), 463-468
CODEN: CIIMDN; ISSN: 0340-7004

PB Springer-Verlag

DT Journal

LA English

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 76 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:12748 CAPLUS
DN 136:198678

TI Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established ***brain*** ***tumors***

AU Iwadate, Yasuo; Yamaura, Akira; Sato, Yasuo; Sakiyama, Shigeru; Tagawa, Masatoshi

CS Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan

SO Cancer Research (***2001***), 61(24), 8769-8774
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 77 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:832565 CAPLUS
DN 136:117001

TI CD40 ligand promotes priming of fully potent antitumor CD4+ T cells in draining lymph nodes in the presence of apoptotic tumor cells

AU Fujita, Nanae; Kagamu, Hiroshi; Yoshizawa, Hirohisa; Itoh, Kazuhisa; Kuriyama, Hideyuki; Matsumoto, Naoya; Ishiguro, Takuro; Tanaka, Junta; Suzuki, Eiichi; Hamada, Hirofumi; Gejyo, Fumitake

CS Department of Medicine (II), Niigata University Medical School, Niigata, Japan

SO Journal of Immunology (***2001***), 167(10), 5678-5688
CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 78 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:732258 CAPLUS
DN 136:133137

TI Autologous vaccine and adoptive cellular immunotherapy as treatment for ***brain*** ***tumors***

AU Wood, Gary W.; Holladay, Frank P.

CS CAI Cent., Kansas City, MO, USA

SO Brain Tumor Immunotherapy (***2001***), 171-189. Editor(s): Liau, Linda M. Publisher: Humana Press Inc., Totowa, N. J.
CODEN: 69BWYU

DT Conference; General Review

RE.CNT 51

THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 79 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:732255 CAPLUS
DN 136:133135
TI Systemic T-cell immunotherapy for ***brain*** ***tumors***
AU Plautz, Gregory E.; Shu, Suyu
CS Dep. of Pediatrics, Yale Univ. Sch. of Med., New Haven, CT, USA
SO Brain Tumor Immunotherapy (***2001***), 133-148. Editor(s): Liau,
Linda M. Publisher: Humana Press Inc., Totowa, N. J.
CODEN: 69BWYU
DT Conference; General Review
LA English
RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 80 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:710528 CAPLUS
DN 133:361790
TI Immunological responsiveness to interleukin-2-producing ***brain***
tumors can be restored by concurrent subcutaneous transplantation
of the same tumors
AU Iwadate, Yasuo; Tagawa, Masatoshi; Namba, Hiroki; Oga, Masaru; Kawamura,
Kiyoko; Tasaki, Kentaro; Sakiyama, Shigeru; Yamaura, Akira
CS Department of Neurosurgery, School of Medicine, Chiba University, Chiba,
Japan
SO Cancer Gene Therapy (***2000***), 7(9), 1263-1269
CODEN: CGTHEG; ISSN: 0929-1903
PB Nature America Inc.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 81 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:708098 CAPLUS
DN 133:348849
TI Cross-presentation of tumor antigens to effector T cells is sufficient to
mediate effective immunotherapy of established intracranial tumors
AU Plautz, Gregory E.; Mukai, Shigehiko; Cohen, Peter A.; Shu, Suyu
CS Center for Surgery Research, The Cleveland Clinic Foundation, Cleveland,
OH, 44195, USA
SO Journal of Immunology (***2000***), 165(7), 3656-3662
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 82 OF 196 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:587335 CAPLUS
DN 132:77230
TI Novel immunotherapy against gliomas
AU Kikuchi, Tetsuro
CS Division of Oncology, The Institute of DNA Medicine and Department of
Neurosurgery, Jikei University School of Medicine, Tokyo, 105-8461, Japan
SO Shinkei Kenkyu no Shinpo (***1999***), 43(3), 443-450
CODEN: SKNSAF; ISSN: 0001-8724
PB Igaku Shoin Ltd.
DT Journal; General Review
LA Japanese

L4 ANSWER 83 OF 196 CIN COPYRIGHT 2005 ACS on STN
AN 22(52):53480S CIN
TI Japanese bionews
SO Genet. Eng. News, 15 Nov 1993 (931115), 13(20), p. 19. ISSN: 0270-6377;
CODEN: GENNDX.
LA English

L4 ANSWER 84 OF 196 CIN COPYRIGHT 2005 ACS on STN
AN 17(27):24470E CIN
SO Genet. Eng. News, Jun 1988 (880600), 8(6), p. 36. ISSN: 0270-6377; CODEN:
GENNDX.

LA English

L4 ANSWER 85 OF 196 DISSABS COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 90:25395 DISSABS Order Number: AAR9107163
TI DIFFERENTIAL EFFECTS OF CORTICOSTEROIDS AND GLIOMA ON CELLULAR CYTOTOXICITY AND T-LYMPHOCYTE ACTIVATION (CYTOTOXICITY)
AU MCVICAR, DANIEL WALTER [PH.D.]; MERCHANT, RANDALL E. [advisor]
CS VIRGINIA COMMONWEALTH UNIVERSITY (2383)
SO Dissertation Abstracts International, (***1990***) Vol. 51, No. 10B, p. 4766. Order No.: AAR9107163. 151 pages.

DT Dissertation

FS DAI

LA English

ED Entered STN: 19921118

Last Updated on STN: 19921118

L4 ANSWER 86 OF 196 DISSABS COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 90:24773 DISSABS Order Number: AAR9105228
TI IMMUNOBIOLOGICAL AND IMMUNOTHERAPEUTIC ASPECTS OF TRANSPLANTABLE RAT GLIOMAS
AU TZENG, JONE-JIUN [PH.D.]; BARTH, ROLF F. [advisor]
CS THE OHIO STATE UNIVERSITY (0168)
SO Dissertation Abstracts International, (***1990***) Vol. 51, No. 10B, p. 4789. Order No.: AAR9105228. 204 pages.

DT Dissertation

FS DAI

LA English

ED Entered STN: 19921118

Last Updated on STN: 19921118

L4 ANSWER 87 OF 196 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1999-33370 DRUGU P
TI Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.
AU Mukai S; Kagamu H; Shu S; Plautz G E
CS Cleveland-Clinic; Univ.Niigata

LO Cleveland, Ohio, USA; Niigata, Jap.
SO Cell.Immunol. (192, No. 2, 122-32, 1999) 8 Fig. 53 Ref.

CODEN: CLIMB8 ISSN: 0008-8749

AV Center for Surgery Research FF5, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, U.S.A. (G.E.P.).
LA English
DT Journal

FA AB; LA; CT

FS Literature

L4 ANSWER 88 OF 196 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1989-03477 DRUGU T
TI Clinical Applications of rIL-2 and LAK Cells in Patients with ***Brain*** ***Tumors***

AU Shumizu K; Tamura K; Okamoto Y; Miyao; Y; Yamada M; Matsui Y
LO Osaka, Japan
SO Int.J.Immunopharmacol. (10, Suppl. 1, 103, 1988)

CODEN: IJIMDS ISSN: 0192-0561

AV Department of Neurosurgery, Osaka University Medical School, Osaka, Japan. (8 authors).
LA English
DT Journal

FA AB; LA; CT

FS Literature

L4 ANSWER 89 OF 196 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1989-03393 DRUGU T P
TI Augmentation of the Cytocidal Effect of LAK Cells by OK-432.

LO Osaka, Japan
SO Int.J.Immunopharmacol. (10, Suppl. 1, 50, 1988)
CODEN: IJIMDS ISSN: 0192-0561
AV Department of Neurosurgery, Osaka University Medical School, Osaka,
Japan. (8 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L4 ANSWER 90 OF 196 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 2000251621 EMBASE
TI Immunotherapy of a murine T cell lymphoma localized to the brain.
AU Ghanta V.K.; Hiramoto N.S.; Gillespie G.Y.; Gauthier D.K.; Hiramoto R.N.
CS R.N. Hiramoto, Department of Microbiology, Univ. of Alabama at Birmingham,
148 Lyons-Harrison Research Bldg., 733 19th St. So., Birmingham, AL
35294-0007, United States. hiramoto@uab.edu
SO Journal of Neuro-Oncology, (2000) 47/1 (1-10).
Refs: 33
ISSN: 0167-594X CODEN: JNODD2
CY United States
DT Journal; Article
FS 008 Neurology and Neurosurgery
030 Pharmacology
016 Cancer
037 Drug Literature Index
LA English
SL English

L4 ANSWER 91 OF 196 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 97118364 EMBASE
DN 1997118364
TI ***Adoptive*** ***immunotherapy*** with bacterial superantigen SEA
activated T cells.
AU Inoue M.; Kato H.; Mukai S.; Kimura S.; Asai K.; Hashiramoto A.; Sano H.;
Yamamura Y.; Nakamura N.; Kondo M.
CS Dr. M. Inoue, Department of Internal Medicine, Meiji College of Oriental
Medicine, Honoda, Hiyoshi-cho, Funai-gun, Kyoto 629-03, Japan
SO Biotherapy, (1997) 11/3 (361-363).
Refs: 3
ISSN: 0914-2223 CODEN: BITPE
CY Japan
DT Journal; Conference Article
FS 016 Cancer
026 Immunology, Serology and Transplantation
LA Japanese
SL English; Japanese

L4 ANSWER 92 OF 196 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 96153233 EMBASE
DN 1996153233
TI ***Adoptive*** ***immunotherapy*** of experimental cerebral tumors
with bacterial superantigen-activated T cells.
AU Inoue M.; Kato H.; Kondo M.; Shu S.
CS Department of Internal Medicine, Meiji College of Oriental Medicine, 6-1
Hinotani, Honoda, Funai-gun, Kyoto 629-03, Japan
SO Biotherapy, (1996) 10/3 (259-262).
ISSN: 0914-2223 CODEN: BITPE
CY Japan
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
016 Cancer
026 Immunology, Serology and Transplantation
LA Japanese
SL English; Japanese

L4 ANSWER 93 OF 196 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS

AN 94183235 EMBASE
DN 1994183235
TI Targeting therapy for malignant ***brain*** ***tumors*** .
AU Kochi M.; Ushio Y.
CS Department of Neurosurgery, Kumamoto University Medical School, 1-1-1
Honjo, Kumamoto 860, Japan
SO Japanese Journal of Cancer and Chemotherapy, (1994) 21/6 (738-742).
ISSN: 0385-0684 CODEN: GTKRDX
CY Japan
DT Journal; Conference Article
FS 008 Neurology and Neurosurgery
016 Cancer
026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LA Japanese
SL English; Japanese

L4 ANSWER 94 OF 196 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 91196852 EMBASE
DN 1991196852
TI Biologic and immune modulating agents in the treatment of childhood
brain ***tumors*** .
AU Packer R.J.; Kramer E.D.; Ryan J.A.
CS Department of Neurology, Children's National Medical Center, 111 Michigan
Avenue, NW, Washington, DC 20010, United States
SO Neurologic Clinics, (1991) 9/2 (405-422).
ISSN: 0733-8619 CODEN: NECLEG
CY United States
DT Journal; Article
FS 016 Cancer
026 Immunology, Serology and Transplantation
037 Drug Literature Index
007 Pediatrics and Pediatric Surgery
008 Neurology and Neurosurgery
LA English
SL English

L4 ANSWER 95 OF 196 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 88219805 EMBASE
DN 1988219805
TI In vitro cytolysis of primitive neuroectodermal tumors of the posterior
fossa (medulloblastoma) by lymphokine-activated killer cells.
AU George R.E.; Loudon W.G.; Moser R.P.; Bruner J.M.; Steck P.A.; Grimm E.A.
CS Department of Neurosurgery, Baylor College of Medicine, Houston, TX,
United States
SO Journal of Neurosurgery, (1988) 69/3 (403-409).
ISSN: 0022-3085 CODEN: JONSAC
CY United States
DT Journal
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
016 Cancer
026 Immunology, Serology and Transplantation
LA English
SL English

L4 ANSWER 96 OF 196 Elsevier BIOBASE COPYRIGHT 2005 Elsevier Science B.V.
on STN
AN 1999132541 ESBIOBASE
TI Reduction of end-stage malignant glioma by injection with autologous
cytotoxic T lymphocytes
AU Tsurushima H.; Liu S.Q.; Tuboi K.; Matsumura A.; Yoshii Y.; Nose T.;
Saijo K.; Ohno T.
CS T. Ohno, RIKEN Cell Bank, Inst. Physical Chemical Res. (RIKEN), 3-1-1
Koyadai, Tsukuba Sci. City, Ibaraki 305-0074, Japan.
E-mail: ohno@rtcnex1.riken.go.jp
SO Japanese Journal of Cancer Research, (***1999***), 90/5 (536-545), 31

CODEN: JJCREP ISSN: 0910-5050

DT Journal; Article

CY Japan

LA English

SL English

L4 ANSWER 97 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 1010184463 JICST-EPlus

TI Gene therapy. Gene therapy against ***brain*** ***tumor*** .

AU NOBAYASHI MISATO; MIZUNO MASAAKI; YOSHIDA JUN

CS Nagoyadai Daigakuin'igakuenkyuka

SO Karento Terapi (Current Therapy), (2001) vol. 19, no. 1, pp. 44-48.

Journal Code: G0171B (Tbl. 1, Ref. 25)

ISSN: 0287-8445

CY Japan

DT Journal; Commentary

LA Japanese

STA New

L4 ANSWER 98 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 1000171396 JICST-EPlus

TI ***Brain*** ***Tumor*** .

AU IKUSAKA MASATOMI

CS St. Marianna Univ. Hosp.

SO Shinkei Chiryogaku (Neurological Therapeutics), (1999) vol. 16, no. 4, pp. 479-481. Journal Code: X0110A (Ref. 9)

ISSN: 0916-8443

CY Japan

DT Journal; General Review

LA Japanese

STA New

L4 ANSWER 99 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 1000112109 JICST-EPlus

TI Neurosurgery and Molecular Biology. (Series 12) Immunological Therapy for Gliomas.

AU KIJIMA HARUHIKO

SHIMIZU KEIJI

CS Kobe Ekisaikai Hosp.

Osaka Univ., Grad. Sch.

SO Neurol Surg, (1999) vol. 27, no. 12, pp. 1071-1077. Journal Code: Z0684A (Fig. 2, Ref. 40)

ISSN: 0301-2603

CY Japan

DT Journal; General Review

LA Japanese

STA New

L4 ANSWER 100 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 980970154 JICST-EPlus

TI ***Brain*** ***Tumor*** .

AU IKUSAKA MASATOMI

CS St. Marianna Univ. Hosp.

SO Shinkei Chiryogaku (Neurological Therapeutics), (1998) vol. 15, no. 4, pp. 371-373. Journal Code: X0110A (Ref. 17)

ISSN: 0916-8443

CY Japan

DT Journal; General Review

LA Japanese

STA New

L4 ANSWER 101 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 960941211 JICST-EPlus

TI The forefront of neurosurgery - malignant ***brain*** ***tumor*** . Malignant ***brain*** ***tumor*** and BRM therapy.

AU YOSHIDA TAZUKA; YOSHIDA JUN

CS Nagoya Univ., Sch. of Med.

SO Brain Nurs, (1996) vol. 12, no. 11, pp. 971-975. Journal Code: X0104A (Fig. 1, Tbl. 1, Ref. 7)

ISSN: 0910-8459

DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 102 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960289601 JICST-EPlus
TI Apoptosis-related gene products in ***brain*** . ***tumors*** and
apoptosis-inducing therapy.
AU SHIRAISHI TETSUYA
CS Saga Med. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996)
vol. 176, no. 10, pp. 651-653. Journal Code: Z0649A (Fig. 1, Tbl. 1, Ref.
10)
CODEN: IGAYAY; ISSN: 0039-2359

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 103 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960214985 JICST-EPlus
TI Cytotoxicity of OK-MC(OK-432-activated mononuclear cells) against
brain ***tumors*** is mediated by fas/fas ligand system.
AU TODA KEISUKE; SHIRAISHI TETSUYA; HIROTSU TATSUMI; FUKUYAMA KOZO; MINETA
TOSHIHIRO; KAWAGUCHI SHOJIRO; TABUCHI KAZUO
CS Saga Med. Sch.
SO Shinkei Men'eki Kenkyu (Neuroimmunological Research), (1995) vol. 8, pp.
295-297. Journal Code: L2221A (Fig. 2, Ref. 6)
ISSN: 0915-1540

CY Japan
DT Conference; Article
LA Japanese
STA New

L4 ANSWER 104 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960053289 JICST-EPlus
TI Cytokine Gene Therapy for Malignant ***Brain*** ***Tumors*** .
AU MIZUNO MASAAKI; YOSHIDA JUN
CS Nagoya Univ., Sch. of Med.
SO Tanpakushitsu Kakusan Koso (Protein, Nucleic Acid and Enzyme), (1995) vol.
40, no. 17, pp. 2709-2712. Journal Code: F0325A (Tbl. 2, Ref. 13)
CODEN: TAKKAJ; ISSN: 0039-9450

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 105 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950732439 JICST-EPlus
TI Specific immunotherapy using bispecific (BS) antibody for malignant
cerebral tumors.
AU NITTA TAIZO
CS Juntendo Univ., Sch. of Med.
SO Gan Chiryo no Ayumi (Advances in Cancer Treatment), (1995) vol. 14, pp.
83-88. Journal Code: L0679A (Fig. 5, Ref. 5)

CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 106 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950600367 JICST-EPlus
TI Involvement of Fas/Fas ligand system in OK-MC(OK-432-activated mononuclear
cells) ***adoptive*** ***immunotherapy*** for glioma.
AU TODA KEISUKE; SHIRAISHI TETSUYA; HIROTSU TATSUMI; FUKUYAMA KOZO; MINETA
TOSHIHIRO; TABUCHI KAZUO
CS Saga Med. Sch.
SO Shinkei Kagaku (Bulletin of the Japanese Society for Neurochemistry),
(1995) vol. 34, no. 2, pp. 96-97. Journal Code: Y0225A (Fig. 1, Tbl. 1,
Ref. 4)

CY Japan
DT Conference; Short Communication
LA Japanese
STA New

L4 ANSWER 107 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950353342 JICST-EPlus
TI Enhancing effect of OK-432 on the proliferation and the cytotoxicity of lymphokine-activated killer cells.
AU YAMAMOTO KIYOSHI; YOSHIDA SEIICHI; ONO KOJI; MORI HIROSHI; TANIGUCHI YOSHINORI; TANAKA RYUICHI
CS Brain Res. Inst., Niigata Univ.
SO Shinkei Men'eki Kenkyu (Neuroimmunological Research), (1994) vol. 7, pp. 274-278. Journal Code: L2221A (Fig. 6, Ref. 10)
ISSN: 0915-1540

CY Japan
DT Conference; Article
LA Japanese
STA New

L4 ANSWER 108 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950121767 JICST-EPlus
TI An immunotherapy of malignant ***brain*** ***tumor*** using bispecific (BS) antibody.
AU NITTA TAIZO
CS Juntendo Univ., Sch. of Med.
SO Rinsho to Yakubutsu Chiryo (Clinics & Drug Therapy), (1995) no. 94, pp. 60-63. Journal Code: S0115B (Fig. 5, Ref. 5)
CODEN: RYCHEI; ISSN: 0913-7505

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 109 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950060169 JICST-EPlus
TI Indication of ***adoptive*** ***immunotherapy*** for malignant glioma: computed imaging and pathological analysis.
AU MIYAGI KOICHI; MUKAWA JIRO; NAKASONE SUSUMU; MEKARU SHIN; KOGA HISASHI; HIGA YASUSHI; ISHIKAWA YASUNARI
CS Univ. of Ryukyus
SO Shinkei Men'eki Kenkyu (Neuroimmunological Research), (1993) vol. 6, pp. 336-342. Journal Code: L2221A (Fig. 3, Tbl. 3, Ref. 13)
ISSN: 0915-1540

CY Japan
DT Conference; Short Communication
LA Japanese
STA New

L4 ANSWER 110 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940983672 JICST-EPlus
TI Gene therapy and the recent progresses. Gene Therapy for Cancer.
AU NIITSU YOSHIRO; HIRAYAMA MICHIAKI; KOSHITA YOSHIKAZU
CS Sapporo Med. Coll.
SO Biotherapy (Tokyo), (1994) vol. 8, no. 10, pp. 1273-1280. Journal Code: L0028A (Fig. 6, Tbl. 4)
ISSN: 0914-2223

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 111 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940927075 JICST-EPlus
TI Gene therapy of ***brain*** ***tumor***
AU WAKABAYASHI TOSHIHIKO; YOSHIDA JUN
CS Nagoya Univ., Sch. of Med.
SO Zoketsu Inshi (Hematopoietic Factor), (1994) vol. 5, no. 4, pp. 487-490. Journal Code: L1061A (Ref. 11)
ISSN: 0915-5767

DT Journal; General Review
LA Japanese
STA New

L4 ANSWER 112 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940795317 JICST-EPlus
TI Recent Advances in Immunotherapy for Malignant ***Brain***
Tumors
AU KUBO OSAMI; TAKAKURA KINTOMO
CS Tokyo Women's Medical College, Neurological Inst.
SO Biotherapy (Tokyo), (1994) vol. 8, no. 8, pp. 1021-1025. Journal Code:
L0028A (Fig. 1, Tbl. 1, Ref. 18)
ISSN: 0914-2223

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 113 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940528024 JICST-EPlus
TI New therapy for ***brain*** ***tumors*** Bispecific antibodies.
AU NITTA TAIZO
CS Juntendo Univ.
SO Clin Neurosci, (1994) vol. 12, no. 6, pp. 676-677. Journal Code: X0621A
(Fig. 4, Ref. 12)
ISSN: 0289-0585

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 114 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930938811 JICST-EPlus
TI Results of ***Adoptive*** ***Immunotherapy*** for a Glioblastoma.
A case report.
AU KIKUCHI TETSUO; NAKAMURA NORIO; WATANABE MICHIKO; ONO NORIYA
CS Jikei Univ. School of Medicine
SO Gan no Rinsho (Japanese Journal of Cancer Clinics), (1993) vol. 39, no.
10, pp. 1125-1127. Journal Code: Z0928A (Fig. 4, Ref. 8)
ISSN: 0021-4949

CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L4 ANSWER 115 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930447706 JICST-EPlus
TI A research on a treatment system establishment of central neuron tumor.
AU NOMURA KAZUHIRO
CS National Cancer Center
SO Koseisho Gan Kenkyu Joseikin ni yoru Kenkyu Hokokushu (Annual Report of
the Cancer Research, Ministry of Health and Welfare), (1990) vol. 1989,
pp. 591-593. Journal Code: Y0184A

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 116 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 920603619 JICST-EPlus
TI A History and Prospect of ***Adoptive*** ***Immunotherapy***
Against Malignant Glioma. Past, Now and Future.
AU NITTA TAIZO
CS Juntendo Univ., School of Medicine
SO Brain Nerve, (1992) vol. 44, no. 7, pp. 605-613. Journal Code: Z0685A
(Fig. 6, Tbl. 4, Ref. 38)
ISSN: 0006-8969

CY Japan
DT Journal; General Review
LA Japanese

L4 ANSWER 117 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 920481028 JICST-EPlus
TI Cytokine therapy. Searching for the new possibility. History and view of
 adoptive ***immunotherapy*** for malignant ***brain***
 tumor
AU NITTA TAIZO; SATO KIYOSHI
CS Juntendo Univ., School of Medicine
SO Shindan to Chiryo (Diagnosis and Treatment), (1992) vol. 80, no. 6, pp.
 987-992. Journal Code: Z0941A (Fig. 2, Tbl. 2, Ref. 10)
 ISSN: 0370-999X
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 118 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 910594038 JICST-EPlus
TI An immunotherapy using chimeric antibody for malignant ***brain***
 tumor , especially glioblastoma.
AU IKEDA MASAHIRO; NITTA TAIZO; SATO KIYOSHI
CS Juntendo Univ., School of Medicine
SO Gan Chiryo no Ayumi (Advances in Cancer Treatment), (1990) vol. 10, pp.
 63-69. Journal Code: L0679A (Fig. 5, Tbl. 2, Ref. 8)
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 119 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 910214439 JICST-EPlus
TI Therapeutic result and prospects of LAK therapy for ***brain***
 tumor patient.
AU SHIMIZU KEIJI
CS Osaka Univ., Medical School
SO Nippon Yuketsu Gakkai Zasshi (Journal of the Japan Society of Blood
Transfusion), (1990) vol. 36, no. 6, pp. 806-809. Journal Code: Z0301B
 (Fig. 1, Tbl. 3, Ref. 6)
 ISSN: 0546-1448
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 120 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 910079001 JICST-EPlus
TI Current studies on LAK therapy.
AU NAKAMURA HIROHIKO; TAKAKURA KINTOMO
CS Univ. of Tokyo, Faculty of Medicine
SO Biotherapy (Tokyo), (1990) vol. 4, no. 10, pp. 1627-1636. Journal Code:
L0028A (Fig. 5, Tbl. 3, Ref. 38)
 ISSN: 0914-2223
CY Japan
DT Journal; General Review
LA Japanese
STA New

L4 ANSWER 121 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900822338 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** for a medulloblastoma patient
 with the intraspinal dissemination.
AU SHIMIZU KEIJI; YAMADA MASANOBU; HONOKI HIROAKI; TAMURA KAZUYOSHI; MATSUI
YUTAKA; OKAMOTO HIROSHI; MORIUCHI HIDEYOSHI; MAGUCHI EIICHIRO; MOGAMI
HEITARO
CS Osaka Univ.
SO Shoni Gan (Japanese Journal of Pediatric Oncology), (1990) vol. 27, no. 1,
 pp. 440-443. Journal Code: X0797A (Tbl. 1, Ref. 11)
 ISSN: 0389-4525
CY Japan
DT Journal; Article

STA New

L4 ANSWER 122 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900786399 JICST-EPlus
TI ***Brain*** ***tumors*** . Addenda to the topics of oncogene,
cytokine and immunotherapy.
AU NAGAI MASAKATSU
CS Dokkyo Univ. School of Medicine
SO Neurosurgeons, (1989) vol. 8(1988), pp. 252-255. Journal Code: S0136B
(Tbl. 1, Ref. 30)
ISSN: 0285-7936
CY Japan
DT Conference; Commentary
LA Japanese
STA New

L4 ANSWER 123 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900630537 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** in patients with ***brain***
tumor by intra-tumor injection with LAK cells.
AU KOMATSU FUMIO; OGAMI KAZUO
CS Tokyo Medical and Dental Univ.
SO Nippon Yuketsu Gakkai Zasshi (Journal of the Japan Society of Blood
Transfusion), (1990) vol. 36, no. 1, pp. 63-67. Journal Code: Z0301B (Fig.
4, Tbl. 1, Ref. 12)
ISSN: 0546-1448
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 124 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900585267 JICST-EPlus
TI Analysis of cytolytic activity and cell surface phenotypes of lymphokine
activated killer cells stimulated with r-IL2 and an anti-CD3 antibody.
AU KIKUCHI TETSURO; SAKAI HARUO; NAKAMURA NORIO; WATANABE MICHIKO; ONO NORIYA
CS Jikei Univ. School of Medicine
SO Brain Nerve, (1990) vol. 42, no. 6, pp. 575-580. Journal Code: Z0685A
(Fig. 1, Tbl. 3, Ref. 17)
ISSN: 0006-8969
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 125 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900394678 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** by intra-tumor injection with
LAK cells.
AU OGAMI KAZUO; KOMATSU FUMIO
CS Tokyo Medical and Dental Univ., Faculty of Medicine
SO Biotherapy (Tokyo), (1990) vol. 4, no. 3, pp. 516-519. Journal Code:
L0028A (Fig. 2, Tbl. 1, Ref. 6)
ISSN: 0914-2223
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L4 ANSWER 126 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900394670 JICST-EPlus
TI Long-term follow-up of adoptive immuno therapy with lymphokine-activated
killer cells for malignant ***brain*** ***tumors***.
AU SHIMIZU KEIJI; PARK K C; YAMADA MASANOBU; TAMURA KAZUYOSHI; MATSUI YUTAKA;
OKAMOTO YUTAKA; MOGAMI HEITARO
CS Osaka Univ., Medical School
SO Biotherapy (Tokyo), (1990) vol. 4, no. 3, pp. 478-482. Journal Code:
L0028A (Tbl. 3, Ref. 13)
ISSN: 0914-2223
CY Japan

LA Japanese
STA New

L4 ANSWER 127 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900394665 JICST-EPlus
TI Effects of cytokines and drugs on lymphokine-activated killer(LAK) cell generation in patients with malignant glioma.
AU NAKAMURA HIROHIKO; SHITARA NOBUYUKI; HUANG S H; TAKAKURA KINTOMO
CS Univ. of Tokyo, Faculty of Medicine
SO Biotherapy (Tokyo), (1990) vol. 4, no. 3, pp. 452-457. Journal Code: L0028A (Tbl. 5, Ref. 19)
ISSN: 0914-2223
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L4 ANSWER 128 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900159449 JICST-EPlus
TI Development of treatment methods for the improvement of clinical results for malignant gliomas.
AU TAKAKURA KIMITOMO
CS Univ. of Tokyo, Faculty of Medicine
SO Koseisho Gan Kenkyu Joseikin ni yoru Kenkyu Hokokushu (Annual Report of the Cancer Research, Ministry of Health and Welfare), (1988) vol. 1987, pp. 525-528. Journal Code: Y0184A
CY Japan
DT Journal; General Review
LA Japanese
STA New

L4 ANSWER 129 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900114658 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** using LAK cells for patients with ***brain*** ***tumors***
AU SHIMIZU KEISHI
CS Osaka Univ., Medical School
SO Brain Nurs, (1990) vol. 6, no. 1, pp. 82-88. Journal Code: X0104A (Fig. 1, Tbl. 3, Ref. 1)
ISSN: 0910-8459
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L4 ANSWER 130 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900071956 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** for three cases with medulloblastoma.
AU PARK K; SHIMIZU KEIJI; OKAMOTO YUTAKA; TAMURA KAZUYOSHI
TSUDA NOBUYUKI; MASAKI SHIN; MIZUTA TADAHISA; IWATA YOSHIKAZU
TAKIMOTO HIROSHI
CS Osaka Univ.
Suita City Hospital
Minoo City Hospital
SO Shoni no Noshinkei (Nervous System in Children), (1989) vol. 14, no. 5, pp. 387-392. Journal Code: G0347B (Fig. 7, Ref. 16)
ISSN: 0387-8023
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 131 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 890238611 JICST-EPlus
TI The basis and clinical application of ***adoptive*** ***immunotherapy*** for malignant ***brain*** ***tumors*** : Induction of lymphokineactivated killer (LAK) cells and difficulties in LAK therapy.
AU NAKAMURA HIROHIKO; SHITARA NOBUYUKI; WADA TERUMI; TAKAKURA KIMITOMO

SO Biotherapy (Tokyo), (1989) vol. 3, no. 1, pp. 175-178. Journal Code:
L0028A (Fig. 4, Tbl. 1, Ref. 9)
ISSN: 0914-2223

CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 132 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 890238600 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** for the ***brain***
tumor patients by LAK cells induced with the concentration rotary
tissue culture system.

AU SHIMIZU KEIJI; TAMURA KAZUYOSHI; PARK KAECHANG; MATSUI YUTAKA; YAMADA
MASANOBU; OKAMOTO YUTAKA; MABUCHI EIICHIRO; HAYAKAWA TORU; MOGAMI HEITARO
CS Osaka Univ., Medical School

SO Biotherapy (Tokyo), (1989) vol. 3, no. 1, pp. 108-112. Journal Code:
L0028A (Fig. 3, Tbl. 1, Ref. 8)
ISSN: 0914-2223

CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 133 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 880525039 JICST-EPlus
TI In vivo distribution of murine and human lymphokine-activated killer(LAK)
cells: implications of ***adoptive*** ***immunotherapy*** of
brain ***tumors*** .

AU SAWAMURA YUTAKA; HOSOKAWA MASUO; KOBAYASHI HIROSHI
ITOH KAZUO
CS Hokkaido Univ., School of Medicine, Cancer Inst.
Hokkaido Univ., School of Medicine

SO Biotherapy (Tokyo), (1988) vol. 2, no. 1, pp. 163-167. Journal Code:
L0028A (Fig. 6, Ref. 4)
ISSN: 0914-2223

CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 134 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 880461438 JICST-EPlus
TI The basis and clinical application of ***adoptive***
immunotherapy for malignant ***brain*** ***tumors*** .

AU NAKAMURA HIROHIKO; SHITARA NOBUYUKI; WADA TERUMI; GENKA SHIGERU; TAKAKURA
KINTOMO
CS Univ. of Tokyo, Faculty of Medicine

SO Biotherapy (Tokyo), (1987) vol. 1, no. 2, pp. 307-312. Journal Code:
L0028A (Fig. 3, Tbl. 4, Ref. 11)
ISSN: 0914-2223

CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 135 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 880045766 JICST-EPlus
TI Induction of LAK cells from rat splenocytes and an anti-tumor effect of
the LAK cells on the 9L-gliomas.

AU IMAYA HISATOSHI
CS Nippon Medical School

SO Nippon Ika Daigaku Zasshi (Journal of Nippon Medical School), (1987) vol.
54, no. 5, pp. 479-484. Journal Code: F0887A (Fig. 4, Tbl. 2, Ref. 9)
CODEN: NIDZAJ; ISSN: 0048-0444

CY Japan
DT Journal; Article
LA Japanese
STA New

AN 870483501 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** for the patients with malignant glioma.
AU YOSHIDA SEIICHI; TAKAI NOBUYUKI; SAITO TAKASHI; TANAKA RYUICHI
CS Niigatadai Noken
SO Gan to Kagaku Ryoho (Japanese Journal of Cancer and Chemotherapy), (1987)
vol. 14, no. 6 Pt 1, pp. 1930-1932. Journal Code: Z0938A (Fig. 1, Tbl. 1,
Ref. 6)
ISSN: 0385-0684
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 137 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 870481880 JICST-EPlus
TI Distribution of lymphokine-activated killer cells in the cerebrospinal space. Assessment of indium-111-labeled LAK cell scintigram.
AU MIYAO YASUYOSHI; SHIMIZU KEIJI; ISAKA YOSHINARI; OKAMOTO YUTAKA; YAMADA MASANOBU; KIMURA KAZUFUMI; IKEDA TAKUYA; MOGAMI HEITARO
CS Osaka Univ., Medical School
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1987)
vol. 141, no. 13, pp. 1015-1016. Journal Code: Z0649A (Fig. 2, Ref. 8)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L4 ANSWER 138 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 870306970 JICST-EPlus
TI Adoptive transfer of allogeneic LAK cells into a patients with medulloblastoma.
AU OKAMOTO YUTAKA; SHIMIZU KEIJI; MIYAO YASUYOSHI; YAMADA MASANOBU; TAMURA KAZUYOSHI; MATSUI YUTAKA; TSUDA NOBUYUKI; MOGAMI HEITARO HASHIMOTO MITSUO
CS Osakadai I
Hyogoken-nishinomiyabyo-in
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1987)
vol. 140, no. 11, pp. 833-834. Journal Code: Z0649A (Fig. 1, Tbl. 1, Ref. 6)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L4 ANSWER 139 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 870091004 JICST-EPlus
TI ***Adoptive*** ***immunotherapy*** of ***brain***
tumor with activated lymphoid cells. By utilizing interleukin 2-dependent tumor-specific cytotoxic T lymphocyte cell line.
AU KITAHARA TOSHIKI
CS Kumiairitsukokuhonarutobyoin
SO Juntendo Igaku (Juntendo Medical Journal), (1986) vol. 32, no. 3, pp. 282-291. Journal Code: G0715A (Fig. 5, Tbl. 5, Ref. 20)
CODEN: JUIZAG; ISSN: 0022-6769
CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 140 OF 196 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 870036654 JICST-EPlus
TI Specific ***adoptive*** ***immunotherapy*** for malignant ***brain*** ***tumors*** using cytotoxic killer T cell lines.
AU YAMASHITA JUNKO; YAMASAKI TOSHIKI; MIYATAKE SHIN'ICHI
CS Kyodai I
SO Byotai Seiri (Osaka) (Medicina Philosophica), (1986) vol. 5, no. 9, pp. 740-743. Journal Code: Y0235A (Fig. 4, Tbl. 3, Ref. 15)

CY Japan
DT Journal; Article
LA Japanese
STA New

L4 ANSWER 141 OF 196 LIFESCI COPYRIGHT 2005 CSA on STN
AN 1998:29358 LIFESCI
TI Adoptive transfer via immune T-lymphocytes of effective anti-tumor immunity against a malignant rat glioma in the brain
AU Naujocks, G.; Serwe, M.; Bayer, T.A.; Schirrmacher, V.*
CS Div. Cell. Immun., German Cancer Res. Cent., D-69120 Heidelberg, FRG
SO INT. J. ONCOL., (***19970800***) vol. 11, no. 2, pp. 249-254.
ISSN: 1019-6439.

DT Journal
FS F
LA English
SL English

L4 ANSWER 142 OF 196 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1996-0133530 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN ***Adoptive*** ***immunotherapy*** using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary ***brain*** ***tumors***
AU SANKHLA S. K.; NADKARNI J. S.; BHAGWATI S. N.
CS Bombay hosp., dep. neurosurgery, Bombay, India
SO Journal of neuro-oncology, ***(1996)***, 27(2), 133-140, 26 refs.
ISSN: 0167-594X
DT Journal; (case report, clinical case)
BL Analytic
CY Netherlands
LA English
AV INIST-20812, 354000052872980050

L4 ANSWER 143 OF 196 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:378395 PROMT
TITLE: Brain Cancer (Treatment) ***Adoptive***
Immunotherapy Slowed Some Tumor Growth
SOURCE: Vaccine Weekly, (***27 Jul 1998***) pp. N/A.
ISSN: 1074-2921.
LANGUAGE: English
WORD COUNT: 439
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 144 OF 196 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:137017 PROMT
TITLE: Neurosurgery "Induction of Human Autologous Cytotoxic T Lymphocytes Against Minced Tissues of Glioblastoma Multiforme."
SOURCE: Cancer Biotechnology Weekly, (***11 Mar 1996***) pp. N/A.
LANGUAGE: English
WORD COUNT: 255
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 145 OF 196 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 93:848506 PROMT
TITLE: Juntendo University Develops Improved Method of ***Adoptive*** ***Immunotherapy***
SOURCE: Comline Biotechnology & Medical, (***6 Oct 1993***) pp. 2.
LANGUAGE: English
WORD COUNT: 135
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L4 ANSWER 146 OF 196 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 88:108283 PROMT
TITLE: HEALTHCARE INTERNATIONAL HOSPITAL RECEIVES FDA APPROVAL TO OFFER BRAIN CANCER TREATMENT
SOURCE: News Release, (***5 Apr 1988***) pp. 1.
LANGUAGE: English

L4 ANSWER 147 OF 196 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 87:76646 PROMT
TITLE: New hope on cancer of brain
New ***adoptive*** ***immunotherapy*** gives some hope to victims of glioma brain cancer
SOURCE: New York Times (National Edition), (***25 Mar 1987***) pp. 8.
ISSN: 0362-4331.
LANGUAGE: English

L4 ANSWER 148 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2001:885702 SCISEARCH
GA The Genuine Article (R) Number: 487YH
TI Engineering of macrophages to produce IFN-gamma in response to hypoxia
AU Carta L; Pastorino S (Reprint); Melillo G; Bosco M C; Massazza S; Varesio L
CS Ist Giannina Gaslini, Mol Biol Lab, Largo G Gaslini 5, I-16147 Genoa, Italy (Reprint); Ist Giannina Gaslini, Mol Biol Lab, I-16147 Genoa, Italy; NCI, Dev Therapeut Program, Tumor Hypoxia Lab, Sci Applicat Int Corp, Frederick, MD 21702 USA
CYA Italy; USA
SO JOURNAL OF IMMUNOLOGY, (***1 MAY 2001***) Vol. 166, No. 9, pp. 5374-5380.
Publisher: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.
ISSN: 0022-1767.
DT Article; Journal
LA English
REC Reference Count: 37
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 149 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2001:653325 SCISEARCH
GA The Genuine Article (R) Number: 462FX
TI ***Adoptive*** ***immunotherapy*** for malignant ***brain*** ***tumors*** using human peripheral blood mononuclear cells activated by the streptococcal preparation OK-432 - Commentary
AU Tanaka R (Reprint)
CS Niigata Univ, Brain Res Inst, Dept Neurosurg, Niigata 95021, Japan (Reprint)
CYA Japan
SO NEUROLOGIA MEDICO-CHIRURGICA, (***AUG 2001***) Vol. 41, No. 8, pp. 392-392.
Publisher: JAPAN NEUROSURGICAL SOC, C/O AKAMON-MAE IWATA BLDG, 5-27-8 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN.
ISSN: 0387-2572.
DT Editorial; Journal
LA English
REC Reference Count: 0

L4 ANSWER 150 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:704545 SCISEARCH
GA The Genuine Article (R) Number: 353FG
TI Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma
AU Johansson M (Reprint); Henriksson R; Bergenheim A T; Koskinen L O D
CS UMEA UNIV, DEPT ONCOL, SE-90185 UMEA, SWEDEN (Reprint); UMEA UNIV, DEPT NEUROSURG, SE-90185 UMEA, SWEDEN
CYA SWEDEN
SO BRITISH JOURNAL OF CANCER, (***SEP 2000***) Vol. 83, No. 6, pp.

Publisher: CHURCHILL LIVINGSTONE, JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND.

ISSN: 0007-0920.

DT Article; Journal

FS CLIN

LA English

REC Reference Count: 37

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 151 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 2000:325996 SCISEARCH

GA The Genuine Article (R) Number: 307QT

TI Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas

AU Quattrocchi K B (Reprint); Miller C H; Cush S; Bernard S A; Dull S T; Smith M; Gudeman S; Varia M A

CS ST MARYS REG MED CTR, CTR NEUROSCI, 99 CAMPUS AVE, SUITE 303, LEWISTON, ME 04240 (Reprint); UNIV N CAROLINA, DIV NEUROSURG, CHAPEL HILL, NC; UNIV N CAROLINA, DIV RADIOL, CHAPEL HILL, NC; UNIV N CAROLINA, DEPT MED ONCOL, CHAPEL HILL, NC; UNIV N CAROLINA, DEPT RADIAT ONCOL, CHAPEL HILL, NC; UNIV CALIF DAVIS, DEPT MED PATHOL, DAVIS, CA 95616

CYA USA

SO JOURNAL OF NEURO-ONCOLOGY, (***APR 1999***) Vol. 45, No. 2, pp. 141-157.

Publisher: KLUWER ACADEMIC PUBL, SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS.

ISSN: 0167-594X.

DT Article; Journal

FS CLIN

LA English

REC Reference Count: 40

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 152 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1999:98655 SCISEARCH

GA The Genuine Article (R) Number: 159VK

TI Investigational approaches to the treatment of ***brain*** ***tumors*** in children

AU Wolff J E A (Reprint); Egeler R M

CS ALBERTA CHILDRENS PROV GEN HOSP, SO ALBERTA CHILDRENS CANC PROGRAM, 1820 RICHMOND RD SW, CALGARY, AB T2T 5C7, CANADA (Reprint); UNIV CALGARY, DEPT ONCOL, CALGARY, AB, CANADA; UNIV CALGARY, DEPT PEDIAT, CALGARY, AB T2N 1N4, CANADA; UNIV MUNSTER, DEPT ONCOL, D-4400 MUNSTER, GERMANY; UNIV MUNSTER, DEPT PEDIAT, D-4400 MUNSTER, GERMANY

CYA CANADA; GERMANY

SO MEDICAL AND PEDIATRIC ONCOLOGY, (***FEB 1999***) Vol. 32, No. 2, pp. 135-138.

Publisher: WILEY-LISS, DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012.

ISSN: 0098-1532.

DT Article; Journal

FS CLIN

LA English

REC Reference Count: 37

L4 ANSWER 153 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN

AN 1998:203540 SCISEARCH

GA The Genuine Article (R) Number: ZA538

TI Rat ***brain*** ***tumor*** models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas

AU Barth R F (Reprint)

CS OHIO STATE UNIV, DEPT PATHOL, 165 HAMILTON HALL, 1645 NEIL AVE, COLUMBUS, OH 43210 (Reprint)

CYA USA

SO JOURNAL OF NEURO-ONCOLOGY, (***JAN 1998***) Vol. 36, No. 1, pp. 91-102.

DORDRECHT, NETHERLANDS.

ISSN: 0167-594X.

DT General Review; Journal

FS CLIN

LA English

REC Reference Count: 152

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 154 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 97:902586 SCISEARCH

GA The Genuine Article (R) Number: YJ300

TI Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2

AU Kruse C A (Reprint); Cepeda L; Owens B; Johnson S D; Stears J; Lillehei K O

CS UNIV COLORADO, HLTH SCI CTR, DEPT IMMUNOL, CAMPUS BOX B184, 4200 E 9TH AVE, DENVER, CO 80262 (Reprint); UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO 80262; UNIV COLORADO, HLTH SCI CTR, DEPT SURG, DENVER, CO 80262; UNIV COLORADO, HLTH SCI CTR, DEPT RADIOL, DENVER, CO 80262

CYA USA

SO CANCER IMMUNOLOGY IMMUNOTHERAPY, (***OCT 1997***) Vol. 45, No. 2, pp. 77-87.

Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010.

ISSN: 0340-7004.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 47

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 155 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 97:554105 SCISEARCH

GA The Genuine Article (R) Number: XL365

TI Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells

AU Plautz G E (Reprint); Touhalisky J E; Shu S Y

CS CLEVELAND CLIN FDN, SURG RES CTR, 9500 EUCLID AVE, FF5, CLEVELAND, OH 44195 (Reprint)

CYA USA

SO CELLULAR IMMUNOLOGY, (***15 JUN 1997***) Vol. 178, No. 2, pp. 101-107.

Publisher: ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495.

ISSN: 0008-8749.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 34

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 156 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 95:572145 SCISEARCH

GA The Genuine Article (R) Number: RP851

TI IMPROVED LONG-TERM SURVIVAL AFTER INTRACAVITARY INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS FOR ADULTS WITH RECURRENT MALIGNANT GLIOMA

AU HAYES R L (Reprint); KOSLOW M; HIESIGER E M; HYMES K B; HOCHSTER H S; MOORE E J; PIERZ D M; CHEN D K; BUDZILOVICH G N; RANSOHOFF J

CS NYU, MED CTR, NEUROONCOL LAB RR810, 550 1ST AVE, NEW YORK, NY, 10016 (Reprint); NYU, MED CTR, DEPT NEUROSURG, NEW YORK, NY, 00000; NYU, MED CTR, DEPT MICROBIOL, NEW YORK, NY, 00000; NYU, MED CTR, DEPT NEUROL, NEW YORK, NY, 00000; NYU, MED CTR, DEPT MED, NEW YORK, NY, 00000; NYU, MED CTR, DEPT PATHOL, DIV NEUROPATHOL, NEW YORK, NY, 00000; NYU, MED CTR, KAPLAN COMPREHENS CANC CTR, BLOOD TRANSFUS SERV, NEW YORK, NY, 00000

CYA USA

SO CANCER, (***01 SEP 1995***) Vol. 76, No. 5, pp. 840-852.

ISSN: 0008-543X.

DT Article; Journal

LA ENGLISH
REC Reference Count: 72
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 157 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN
AN 95:182905 SCISEARCH
GA The Genuine Article (R) Number: QK357
TI A RAT GLIOMA MODEL, CNS-1 WITH INVASIVE CHARACTERISTICS SIMILAR TO THOSE
OF HUMAN GLIOMAS - A COMPARISON TO 9L GLIOSARCOMA
AU KRUSE C A (Reprint); MOLLESTON M C; PARKS E P; SCHILTZ P M;
KLEINSCHMIDTDEMASTERS B K; HICKEY W F
CS UNIV COLORADO, HLTH SCI CTR, DEPT SURG, CAMPUS BOX C307, 4200 E 9TH AVE,
DENVER, CO, 80262 (Reprint); UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL,
DENVER, CO, 80262; DARTMOUTH MED CTR, DEPT PATHOL, LEBANON, NH, 00000
CYA USA
SO JOURNAL OF NEURO-ONCOLOGY, (***1994***) Vol. 22, No. 3, pp. 191-200.
ISSN: 0167-594X.
DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 17
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 158 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN
AN 95:86829 SCISEARCH
GA The Genuine Article (R) Number: QC149
TI ANTITUMOR EFFECT OF EXOGENOUS ENDOGENOUS TNF (EET) THERAPY WITH
CYCLOPHOSPHAMIDE ON C6 GLIOMA IN RAT
AU OHSIRO S (Reprint); INAGAWA H; SOMA G; FUKUSHIMA T; TOMONAGA M
CS FUKUOKA UNIV, SCH MED, DEPT NEUROSURG, 45-1 7 CHOME NANAKUMA, JONAN KU,
FUKUOKA 81401, JAPAN (Reprint); TEIKYO UNIV, BIOTECHNOL RES CTR, KAWASAKI,
JAPAN
CYA JAPAN
SO CANCER BIOTHERAPY, (***WIN 1994***) Vol. 9, No. 4, pp. 359-367.
ISSN: 1062-8401.
DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 41
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 159 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN
AN 95:29942 SCISEARCH
GA The Genuine Article (R) Number: PZ268
TI TREATMENT OF EXPERIMENTAL GLIOBLASTOMA WITH A HUMAN MAJOR
HISTOCOMPATIBILITY COMPLEX NONRESTRICTED CYTOTOXIC T-CELL LINE
AU CESANO A; VISONNEAU S; SANTOLI D (Reprint)
CS WISTAR INST ANAT & BIOL, 3601 SPRUCE ST, PHILADELPHIA, PA, 19104
(Reprint); WISTAR INST ANAT & BIOL, PHILADELPHIA, PA, 19104
CYA USA
SO CANCER RESEARCH, (***01 JAN 1995***) Vol. 55, No. 1, pp. 96-101.
ISSN: 0008-5472.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 40
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 160 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN
AN 94:510808 SCISEARCH
GA The Genuine Article (R) Number: PB982
TI INTRACRANIAL ADMINISTRATIONS OF SINGLE OR MULTIPLE SOURCE ALLOGENEIC
CYTOTOXIC T-LYMPHOCYTES - CHRONIC THERAPY FOR PRIMARY ***BRAIN***
TUMORS
AU KRUSE C A (Reprint); SCHILTZ P M; BELLGRAU D; KONG Q Z;
KLEINSCHMIDTDEMASTERS B K

CY A COLORADO, HLTH SCI CTR, DEPT PATHOL, DENVER, CO, 80262; UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL IMMUNOL, DENVER, CO, 80262
USA
SO JOURNAL OF NEURO-ONCOLOGY, (***1994***) Vol. 19, No. 2, pp. 161-168.
ISSN: 0167-594X.
DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 19
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 161 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 94:500071 SCISEARCH
GA The Genuine Article (R) Number: PC402
TI GANCICLOVIR TREATMENT OF HERPES-SIMPLEX THYMIDINE KINASE-TRANSDUCED PRIMARY T-LYMPHOCYTES - AN APPROACH FOR SPECIFIC IN-VIVO DONOR T-CELL DEPLETION AFTER BONE-MARROW TRANSPLANTATION
AU TIBERGHIEN P (Reprint); REYNOLDS C W; KELLER J; SPENCE S; DESCHASEAUX M; CERTOUX J M; CONTASSOT E; MURPHY W J; LYONS R; CHIANG Y W; HERVE P; LONGO D L; RUSCETTI F W
CS CTR REG TRANSFUS SANGUINE, HISTOCOMPATIBIL & IMMUNOMOLEC THERAPEUT LAB, BUD FLEMING, F-25000 BESANCON, FRANCE (Reprint); NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD, 21702; NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD, 00000; GENET THERAPY INC, GAITHERSBURG, MD, 00000
CY A FRANCE; USA
SO BLOOD, (***15 AUG 1994***) Vol. 84, No. 4, pp. 1333-1341.
ISSN: 0006-4971.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 38

L4 ANSWER 162 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 94:44132 SCISEARCH
GA The Genuine Article (R) Number: MQ154
TI GENERATION OF CYTOTOXIC IMMUNE-RESPONSES DURING THE PROGRESSION OF A RAT GLIOMA
AU HOLLADAY F P; CHOUDHURI R; HEITZ T; WOOD G W (Reprint)
CS UNIV KANSAS, MED CTR, DEPT PATHOL, 39TH & RAINBOW BLVD, KANSAS CITY, KS, 66160 (Reprint); UNIV KANSAS, MED CTR, DEPT PATHOL, KANSAS CITY, KS, 66160; UNIV KANSAS, MED CTR, DEPT SURG, NEUROSURG SECT, KANSAS CITY, KS, 00000; UNIV KANSAS, MED CTR, DEPT ONCOL, KANSAS CITY, KS, 00000
CY A USA
SO JOURNAL OF NEUROSURGERY, (***JAN 1994***) Vol. 80, No. 1, pp. 90-96.
ISSN: 0022-3085.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 163 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 93:424077 SCISEARCH
GA The Genuine Article (R) Number: LL131
TI TREATMENT OF GLIOMA BY ENGINEERED INTERLEUKIN-4-SECRETING CELLS
AU YU J S; WEI M X; CHIOCCHI E A; MARTUZA R L; TEPPER R I (Reprint)
CS HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, CTR CANC, DEPT MED, BOSTON, MA, 02114; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT SURG, NEUROSURG SERV, BOSTON, MA, 02114; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, CTR CANC, DEPT SURG, MOLEC NEUROGENET LAB, BOSTON, MA, 02114
CY A USA
SO CANCER RESEARCH, (***01 JUL 1993***) Vol. 53, No. 13, pp. 3125-3128.
ISSN: 0008-5472.
DT Article; Journal
FS LIFE; CLIN

REC Reference Count: 29
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 164 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 93:266169 SCISEARCH
GA The Genuine Article (R) Number: KX984
TI THERAPY OF RECURRENT HIGH-GRADE GLIOMAS WITH SURGERY, AND AUTOLOGOUS
MITOGEN ACTIVATED IL-2 STIMULATED KILLER (MAK) LYMPHOCYTES .1. ENHANCEMENT
OF MAK LYtic ACTIVITY AND CYTOKINE PRODUCTION BY PHA AND CLINICAL USE OF
PHA

AU JEFFES E W B (Reprint); BEAMER Y B; JACQUES S; SILBERMAN R S; VAYUVEGULA
B; GUPTA S; COSS J S; YAMAMOTO R S; GRANGER G A

CS VET ADM HOSP LONG BEACH, 5901 E 7TH ST, LONG BEACH, CA, 90822 (Reprint);
HEALTHCARE MED CTR TUSTIN, TUSTIN, CA, 92717; UNIV CALIF IRVINE, DEPT MED,
IRVINE, CA, 92717; UNIV CALIF IRVINE, DEPT DERMATOL, IRVINE, CA, 92717;
UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA, 92717

CYA USA
SO JOURNAL OF NEURO-ONCOLOGY, (***FEB 1993***) Vol. 15, No. 2, pp.
141-155.
ISSN: 0167-594X.

DT Article; Journal
FS CLIN
LA ENGLISH

REC Reference Count: 39
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 165 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 93:266165 SCISEARCH
GA The Genuine Article (R) Number: KX984
TI SYSTEMIC CHEMOTHERAPY COMBINED WITH LOCAL ***ADOPTIVE***
IMMUNOTHERAPY CURES RATS BEARING 9L GLIOSARCOMA

AU KRUSE C A (Reprint); MITCHELL D H; KLEINSCHMIDTDEMASTERS B K; BELLGRAU D;
EULE J M; PARRA J R; KONG Q Z; LILLEHEI K O

CS UNIV COLORADO, HLTH SCI CTR, DEPT SURG, DIV NEUROSURG, CAMPUS BOX C307,
4200 E 9TH AVE, DENVER, CO, 80262 (Reprint); UNIV COLORADO, HLTH SCI CTR,
DEPT PATHOL, DENVER, CO, 80262; UNIV COLORADO, HLTH SCI CTR, DEPT
MICROBIOL IMMUNOL, DENVER, CO, 80262

CYA USA
SO JOURNAL OF NEURO-ONCOLOGY, (***FEB 1993***) Vol. 15, No. 2, pp.
97-112.
ISSN: 0167-594X.

DT Article; Journal
FS CLIN
LA ENGLISH

REC Reference Count: 55
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 166 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 93:56593 SCISEARCH
GA The Genuine Article (R) Number: KH410
TI EFFECT OF DEXAMETHASONE ON THE EFFICACY OF CHEMOTHERAPY ***ADOPTIVE***
IMMUNOTHERAPY OF RAT- ***BRAIN*** ***TUMOR***

AU FRANK J A (Reprint); EULE J M; DEMASTERS B K; KONG Q; MITCHELL D H;
LILLEHEI K O; KRUSE C A

CS UNIV COLORADO, HLTH SCI CTR, DENVER, CO, 80262

CYA USA
SO CLINICAL RESEARCH, (***FEB 1993***) Vol. 41, No. 1, pp. A31.
ISSN: 0009-9279.

DT Conference; Journal
FS LIFE
LA ENGLISH

REC No References

L4 ANSWER 167 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 92:631465 SCISEARCH
GA The Genuine Article (R) Number: JU807

AU CYTOTOXIC LYMPHOCYTES-T, BUT NOT BY LYMPHOKINE-ACTIVATED KILLER-CELLS
CS HOLLADAY F P; HEITZ T; WOOD G W (Reprint)
UNIV KANSAS, MED CTR, DEPT PATHOL, 39TH & RAINBOW BLVD, KANSAS CITY, KS,
66106; UNIV KANSAS, MED CTR, DEPT PATHOL & ONCOL, KANSAS CITY, KS, 66103;
UNIV KANSAS, MED CTR, DEPT SURG, DIV NEUROSURG, KANSAS CITY, KS, 66103

CYA USA
SO JOURNAL OF NEUROSURGERY, (***NOV 1992***) Vol. 77, No. 5, pp. 757-762.
ISSN: 0022-3085.

DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 31
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 168 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 92:564299 SCISEARCH
GA The Genuine Article (R) Number: JN834
TI SUCCESSFUL TREATMENT OF A MALIGNANT RAT GLIOMA WITH CYTOTOXIC LYMPHOCYTE-T
AU HOLLADAY F P (Reprint); HEITZ T; CHEN Y L; CHIGA M; WOOD G W; OLSON J J
CS UNIV KANSAS, MED CTR, DIV NEUROSURG, DEPT SURG, 39TH & RAINBOW BLVD,
KANSAS CITY, KS, 66103 (Reprint); UNIV KANSAS, MED CTR, DIV NEUROSURG,
DEPT PATHOL & ONCOL, KANSAS CITY, KS, 66103

CYA USA
SO NEUROSURGERY, (***SEP 1992***) Vol. 31, No. 3, pp. 528-533.
ISSN: 0148-396X.

DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 47
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 169 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 92:455778 SCISEARCH
GA The Genuine Article (R) Number: JF283
TI THE CELLULAR IMMUNOTHERAPY OF PRIMARY ***BRAIN*** - ***TUMORS***
AU HAYES R L (Reprint)
CS NYU MED CTR, DEPT NEUROSURG, 550 1ST AVE, NEW YORK, NY, 10016 (Reprint)

CYA USA
SO REVUE NEUROLOGIQUE, (***1992***) Vol. 148, No. 6-7, pp. 454-466.
ISSN: 0035-3787.

DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 130
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 170 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

AN 91:258516 SCISEARCH
GA The Genuine Article (R) Number: FJ152
TI IMMUNOTHERAPY OF GLIOBLASTOMA WITH INTRATUMORAL ADMINISTRATION OF
AUTOLOGOUS LYMPHOCYTES AND HUMAN LYMPHOBLASTOID INTERFERON - A FURTHER
CLINICAL-STUDY

AU VAQUERO J (Reprint); MARTINEZ R; RAMIRO J; SALAZAR F G; BARBOLLA L;
REGIDOR C
CS AUTONOMOUS UNIV MADRID, PUERTA HIERRO CLIN, DEPT NEUROSURG, MADRID, SPAIN;
AUTONOMOUS UNIV MADRID, PUERTA HIERRO CLIN, DEPT HEMATOL, MADRID, SPAIN;
HOSP GREGORIO MARANON, MADRID, SPAIN

CYA SPAIN
SO ACTA NEUROCHIRURGICA, (***1991***) Vol. 109, No. 1-2, pp. 42-45.

DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 30
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 171 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN

GA The Genuine Article (R) Number: FA033
TI COMPARISON OF LYMPHOKINE-ACTIVATED KILLER ACTIVITIES BETWEEN THYMOCYTES
AND SPLENOCYTES IN RATS WITH ***BRAIN*** - ***TUMORS***
AU MATSUURA H (Reprint); IMAYA H
CS SAITAMA NEUROSURG INST, NEUROSURG, 664-1 KAMIYA, KOHNOSU, SAITAMA 365,
JAPAN (Reprint); NIPPON MED COLL, DEPT NEUROSURG, TOKYO 113, JAPAN
CYA JAPAN
SO CANCER IMMUNOLOGY IMMUNOTHERAPY, (***1991***) Vol. 33, No. 1, pp.
50-53.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 18
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 172 OF 196 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation
on STN
AN 87:511454 SCISEARCH
GA The Genuine Article (R) Number: J8400
TI ***ADOPTIVE*** ***IMMUNOTHERAPY*** OF ***BRAIN*** -
TUMORS
AU SHIMIZU K (Reprint); OKAMOTO Y; MIYAO Y; TAMURA K; YAMADA M; USHIO Y;
HAYAKAWA T; MOGAMI H
CS OSAKA UNIV, DEPT NEUROSURG, OSAKA, JAPAN
CYA JAPAN
SO JOURNAL OF NEURO-ONCOLOGY, (***1987***) Vol. 5, No. 2, pp. 182.
DT Conference; Journal
FS CLIN
LA ENGLISH
REC No References

L4 ANSWER 173 OF 196 USPATFULL on STN
AN 2001:199741 USPATFULL
TI Cancer immunotherapy using autologous tumor cells combined with cells
expressing a membrane cytokine
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
PI US 2001038841 A1 20011108 <--
AI US 2001-875349 A1 20010605 (9)
RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.
No. US 6277368
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility
FS APPLICATION
LN.CNT 2638
INCL INCLM: 424/130.100
INCLS: 424/277.100; 435/368.000
NCL NCLM: 424/130.100
NCLS: 424/277.100; 435/368.000
IC [7]
ICM: A61K039-395
ICS: A61K039-00; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 174 OF 196 USPATFULL on STN
AN 2001:193945 USPATFULL
TI Cancer immunotherapy using autologous tumor cells combined with cells
expressing a membrane cytokine
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
PI US 2001036458 A1 20011101 <--
AI US 2001-875823 A1 20010605 (9)
RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.
No. US 6276923
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility

LN.CNT 2634
INCL INCLM: 424/130.100
INCLS: 424/277.100; 435/368.000
NCL NCLM: 424/130.100
NCLS: 424/277.100; 435/368.000
IC [7]
ICM: A61K039-395
ICS: A61K039-00; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 175 OF 196 USPATFULL on STN
AN 2001:145077 USPATFULL
TI Protein which induces interferon-gamma production by immunocompetent cell
IN Akita, Kenji, Okayama, Japan
Nukada, Yoshiyuki, Okayama, Japan
Fujii, Mitsukiyo, Okayama, Japan
Tanimoto, Tadao, Okayama, Japan
Kurimoto, Masashi, Okayama, Japan
PA KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO, Okayama-shi, Japan (non-U.S. corporation)
PI US 2001018212 A1 20010830 <--
US 6441138 B2 20020827
AI US 2001-752510 A1 20010103 (9)
RLI Division of Ser. No. US 1997-832198, filed on 8 Apr 1997, GRANTED, Pat. No. US 6242255 Division of Ser. No. US 1996-721018, filed on 26 Sep 1996, ABANDONED
PRAI JP 1995-270725 19950926
JP 1996-67434 19960229
JP 1996-10050403 19960920
DT Utility
FS APPLICATION
LN.CNT 1070
INCL INCLM: 435/366.000
INCLS: 424/085.200; 530/351.000
NCL NCLM: 530/351.000
NCLS: 530/324.000; 530/350.000
IC [7]
ICM: A61K038-20
ICS: C07K014-54; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 176 OF 196 USPATFULL on STN
AN 2001:136403 USPATFULL
TI DNA molecule encoding interferon-gamma (IFN-.lambda.) inducing factor (IGIF, IL-18) and DNA fragment thereof
IN Okamura, Haruki, Osaka, Japan
Tanimoto, Tadao, Okayama, Japan
Torigoe, Kakaji, Okayama, Japan
Kunikata, Toshio, Okayama, Japan
Taniguchi, Mutsuko, Okayama, Japan
Kohno, Keizo, Okayama, Japan
Kurimoto, Masashi, Okayama, Japan
PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan (non-U.S. corporation)
PI US 6277598 B1 20010821 <--
AI US 1999-251911 19990219 (9)
RLI Continuation of Ser. No. US 1997-908005, filed on 11 Aug 1997, now patented, Pat. No. US 5914253 Division of Ser. No. US 1995-502535, filed on 14 Jul 1995, now patented, Pat. No. US 5912324
PRAI JP 1994-184162 19940714
JP 1995-45057 19950210
DT Utility
FS GRANTED
LN.CNT 1628
INCL INCLM: 435/069.520
INCLS: 435/069.500; 435/320.100; 435/252.300; 435/325.000; 435/254.110;
435/006.000; 536/023.100; 536/024.310; 536/024.330
NCL NCLM: 435/069.520
NCLS: 435/006.000; 435/069.500; 435/252.300; 435/254.110; 435/320.100;

IC [7]
ICM: C12N015-24
ICS: C07K014-54
EXF 536/23.1; 536/24.31; 435/320.1; 435/325; 435/252.3; 435/252.33;
435/254.11; 435/69.1; 435/69.5; 435/69.52; 435/320
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 177 OF 196 USPATFULL on STN
AN 2001:136177 USPATFULL
TI Cancer immunotherapy using autologous tumor cells combined with cells
expressing a membrane cytokine
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6277368 B1 20010821 <--
AI US 1997-901225 19970724 (8)
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility
FS GRANTED
LN.CNT 2892
INCL INCLM: 424/093.210
INCLS: 424/093.100; 424/093.300; 424/093.700; 424/093.710; 424/085.100;
424/085.200; 424/085.600; 424/277.100; 435/325.000
NCL NCLM: 424/093.210
NCLS: 424/085.100; 424/085.200; 424/085.600; 424/093.100; 424/093.300;
424/093.700; 424/093.710; 424/277.100; 435/325.000
IC [7]
ICM: A01N063-00
ICS: C12N015-85; A61K035-12; A61K035-19
EXF 424/93.21; 424/93.1; 424/93.3; 424/93.7; 424/93.71; 424/85.1; 424/85.2;
424/85.4; 424/277.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 178 OF 196 USPATFULL on STN
AN 2001:131421 USPATFULL
TI Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) and peptide
fragment thereof
IN Okamura, Haruki, Osaka, Japan
Tanimoto, Tadao, Okayama, Japan
Torigoe, Kakaji, Okayama, Japan
Kunikata, Toshio, Okayama, Japan
Taniguchi, Mutsuko, Okayama, Japan
Kohno, Keizo, Okayama, Japan
Kurimoto, Masashi, Okayama, Japan
PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan
(non-U.S. corporation)
PI US 6274709 B1 20010814 <--
AI US 1999-253523 19990219 (9)
RLI Continuation of Ser. No. US 1995-502535, filed on 14 Jul 1995, now
patented, Pat. No. US 5912324
PRAI JP 1994-184162 19940714
JP 1995-4505 19950210
DT Utility
FS GRANTED
LN.CNT 1627
INCL INCLM: 530/351.000
INCLS: 530/350.000; 530/324.000; 514/002.000; 514/012.000; 424/085.200
NCL NCLM: 530/351.000
NCLS: 424/085.200; 530/324.000; 530/350.000
IC [7]
ICM: C07K001-00
EXF 530/350; 530/324; 530/351; 514/2; 514/12; 424/85.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 179 OF 196 USPATFULL on STN
AN 2001:105012 USPATFULL
TI Treating tumors using implants comprising combinations of allogeneic

IN Hiserodt, John C., Huntington Beach, CA, United States
Arthur, Gale A., Laguna Beach, CA, United States
PI US 2001006631 A1 20010705 <--
AI US 2001-771263 A1 20010126 (9)
RLI Continuation-in-part of Ser. No. US 1998-169561, filed on 9 Oct 1998,
GRANTED, Pat. No. US 6203787
PRAI US 1997-61766P 19971010 (60)
DT Utility
FS APPLICATION
LN.CNT 2370
INCL INCLM: 424/093.300
NCL NCLM: 424/093.300
IC [7]
ICM: A01N063-00

L4 ANSWER 180 OF 196 USPATFULL on STN
AN 2001:93486 USPATFULL
TI Method for gene therapy using nucleic acid loaded polymeric
microparticles
IN Mathiowitz, Edith, Brookline, MA, United States
Jong, Yong S., Warwick, RI, United States
Carino, Gerardo, Providence, RI, United States
Jacob, Jules S., Taunton, MA, United States
PA Brown University Research Foundation, Providence, RI, United States
(U.S. corporation)
PI US 6248720 B1 20010619 <--
AI US 1996-675454 19960703 (8)
DT Utility
FS GRANTED
LN.CNT 1572
INCL INCLM: 514/044.000
INCLS: 424/489.000; 424/490.000; 424/497.000; 435/320.100; 435/455.000
NCL NCLM: 514/044.000
NCLS: 424/489.000; 424/490.000; 424/497.000; 435/320.100; 435/455.000
IC [7]
ICM: A61K048-00
ICS: C12N015-11
EXF 424/489; 424/490; 424/497; 514/44; 514/951; 935/52; 935/54; 536/23.1;
435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 181 OF 196 USPATFULL on STN
AN 2001:82580 USPATFULL
TI Protein which induces interferon-gamma production by immunocompetent
cell
IN Akita, Kenji, Okayama, Japan
Nukada, Yoshiyuki, Okayama, Japan
Fujii, Mitsukiyo, Okayama, Japan
Tanimoto, Tadao, Okayama, Japan
Kurimoto, Masashi, Okayama, Japan
PA Kabushiki Kaisha Hayashibara Seibutsu Kegaku Kenkyujo, Okayama, Japan
(non-U.S. corporation)
PI US 6242255 B1 20010605 <--
AI US 1997-832198 19970408 (8)
RLI Division of Ser. No. US 1996-721018, filed on 26 Sep 1996, now abandoned
PRAI JP 1995-270725 19950926
JP 1996-67434 19960229
JP 1996-269105 19960920
DT Utility
FS Granted
LN.CNT 1045
INCL INCLM: 435/366.000
INCLS: 435/325.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000
NCL NCLM: 435/366.000
NCLS: 435/325.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000
IC [7]
ICM: C12N005-08
EXF 514/12; 514/15; 514/14; 514/2; 514/21; 530/300; 530/350; 530/412;
530/324; 435/68.1; 435/69.1; 435/252.3; 435/320.1; 435/325; 435/366;
536/23.1; 536/23.5; 424/85.2

L4 ANSWER 182 OF 196 USPATFULL on STN
AN 2001:55742 USPATFULL
TI Adjuvant incorporation into antigen carrying cells: compositions and methods
IN Ravindranath, Mepur H., Los Angeles, CA, United States
Morton, Donald L., Malibu, CA, United States
PA John Wayne Cancer Institute, Santa Monica, CA, United States (U.S. corporation)
PI US 6218166 B1 20010417 <--
AI US 1995-462106 19950605 (8)
RLI Continuation-in-part of Ser. No. US 1994-353549, filed on 9 Dec 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5039
INCL INCLM: 435/240.200
INCLS: 424/240.100; 424/277.100; 424/283.100; 424/184.100; 424/078.310;
424/278.100; 424/179.100; 424/174.100; 424/150.100; 424/201.100
NCL NCLM: 435/366.000
NCLS: 424/078.310; 424/150.100; 424/174.100; 424/179.100; 424/184.100;
424/201.100; 424/240.100; 424/277.100; 424/278.100; 424/283.100;
435/325.000; 435/354.000; 435/372.000
IC [7]
ICM: A61K039-00
ICS: A61K045-00; A61K039-40; A61K039-395
EXF 424/240.1; 424/277.1; 424/283.1; 424/184.1; 424/78.31; 424/278.1;
424/179.1; 424/150.1; 424/201.1; 424/174.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 183 OF 196 USPATFULL on STN
AN 2001:44199 USPATFULL
TI Pharmaceutical composition containing IFN-.gamma. inducing polypeptide or factor for treating and/or preventing IFN-.gamma. susceptible diseases
IN Torigoe, Kakaji, Okayama, Japan
Tanimoto, Tadao, Okayama, Japan
Fukuda, Shigeharu, Okayama, Japan
Kurimoto, Masashi, Okayama, Japan
PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan (non-U.S. corporation)
PI US 6207641 B1 20010327 <--
AI US 1997-974469 19971120 (8)
RLI Continuation of Ser. No. US 1996-599879, filed on 14 Feb 1996, now abandoned Continuation-in-part of Ser. No. US 1995-558190, filed on 15 Nov 1995, now abandoned
PRAI JP 1995-78357 19950310
JP 1995-274988 19950929
DT Utility
FS Granted
LN.CNT 818
INCL INCLM: 514/012.000
INCLS: 514/021.000; 514/002.000; 530/351.000; 530/350.000; 530/324.000
NCL NCLM: 514/012.000
NCLS: 514/002.000; 514/021.000; 530/324.000; 530/350.000; 530/351.000
IC [7]
ICM: A61K038-17
ICS: C07K014-00
EXF 514/12; 514/21; 514/2; 530/351; 530/350; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 184 OF 196 USPATFULL on STN
AN 2001:43705 USPATFULL
TI Cancer immunotherapy using tumor cells combined with mixed lymphocytes
IN Hiserodt, John C., Huntington Beach, CA, United States
Thompson, James A., Aliso Viejo, CA, United States
Granger, Gale A., Laguna Beach, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6207147 B1 20010327 <--
AI US 1997-948939 19971010 (8)

DT Utility
FS Granted
LN.CNT 3189
INCL INCLM: 424/093.100
INCLS: 424/093.300; 435/363.000; 435/366.000; 435/372.000; 435/373.000;
435/347.000; 435/374.000
NCL NCLM: 424/093.100
NCLS: 424/093.300; 435/347.000; 435/363.000; 435/366.000; 435/372.000;
435/373.000; 435/374.000
IC [7]
ICM: A01N063-00
ICS: C12N005-06; C12N005-08; C12N005-02
EXF 424/93.1; 424/93.3; 435/325; 435/277.1; 435/363; 435/366; 435/372;
435/373; 435/347; 435/374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 185 OF 196 USPATFULL on STN
AN 2001:40003 USPATFULL
TI Treating tumors using implants comprising combinations of allogeneic
cells
IN Thompson, James A., Alliso Viejo, CA, United States
Granger, Gale A., Laguna Beach, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6203787 B1 20010320 <--
AI US 1998-169561 19981009 (9)
PRAI US 1997-61766P 19971010 (60)
DT Utility
FS Granted
LN.CNT 2308
INCL INCLM: 424/093.300
INCLS: 424/093.700; 424/093.710; 435/325.000; 435/347.000; 435/366.000;
435/372.000; 435/373.000; 435/383.000
NCL NCLM: 424/093.300
NCLS: 424/093.700; 424/093.710; 435/325.000; 435/347.000; 435/366.000;
435/372.000; 435/373.000; 435/383.000
IC [7]
ICM: A01N063-00
ICS: C12N005-06; C12N005-08
EXF 424/93.3; 424/93.7; 424/93.71; 435/373; 435/325; 435/347; 435/366;
435/372; 435/383

L4 ANSWER 186 OF 196 USPATFULL on STN
AN 2000:150137 USPATFULL
TI Pharmaceutical composition and method for immunoenhancement therapy
IN Hill, Albert Fay, Denver, CO, United States
PA Hill Medical Corporation, La Jolla, CA, United States (U.S. corporation)
PI US 6143717 20001107 <--
AI US 1998-198354 19981124 (9)
RLI Division of Ser. No. US 1997-790683, filed on 28 Jan 1997, now patented,
Pat. No. US 5840770 which is a continuation of Ser. No. US 1995-426088,
filed on 21 Apr 1995, now abandoned which is a continuation-in-part of
Ser. No. US 1993-111288, filed on 24 Aug 1993, now patented, Pat. No. US
5449522
DT Utility
FS Granted
LN.CNT 1663
INCL INCLM: 514/003.000
INCLS: 514/023.000; 514/397.000; 424/610.000
NCL NCLM: 514/003.000
NCLS: 424/610.000; 514/023.000; 514/397.000
IC [7]
ICM: A61K038-28
ICS: A61K031-70; A61K031-415; A61K033-00
EXF 514/3; 514/23; 514/397; 424/610; 424/686; 424/717
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 187 OF 196 USPATFULL on STN
AN 2000:98017 USPATFULL
TI Methods and compositions useful for administration of chemotherapeutic

IN Desai, Neil P., Los Angeles, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S.
corporation)
PI US 6096331 20000801 <--
AI US 1997-926155 19970909 (8)
RLI Continuation-in-part of Ser. No. US 1996-720756, filed on 1 Oct 1996,
now patented, Pat. No. US 5916596 which is a continuation-in-part of
Ser. No. US 1995-485448, filed on 7 Jun 1995, now patented, Pat. No. US
5665382 which is a continuation-in-part of Ser. No. US 1994-200235,
filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a
continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993,
now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No.
US 1993-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478
DT Utility
FS Granted
LN.CNT 1787
INCL INCLM: 424/422.000
INCLS: 424/489.000; 424/426.000; 424/455.000; 424/428.000
NCL NCLM: 424/422.000
NCLS: 424/426.000; 424/428.000; 424/455.000; 424/489.000
IC [7]
ICM: A61K009-127
EXF 424/450; 424/422; 424/489; 424/426; 424/491; 424/497; 514/44; 514/359;
514/358

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 188 OF 196 USPATFULL on STN
AN 1999:69642 USPATFULL
TI Recombinant production of murine interferon--.gamma. (IFN-.gamma.)
inducing factor (IGIF, IL-18)
IN Okamura, Haruki, Osaka, Japan
Tanimoto, Tadao, Okayama, Japan
Torigoe, Kakaji, Okayama, Japan
Kunikata, Toshio, Okayama, Japan
Taniguchi, Mutsuko, Okayama, Japan
Kohno, Keizo, Okayama, Japan
Kurimoto, Masashi, Okayama, Japan
PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan
(non-U.S. corporation)
PI US 5914253 19990622 <--
AI US 1997-908005 19970811 (8)
RLI Division of Ser. No. US 1995-502535, filed on 14 Jul 1995
PRAI JP 1994-184162 19940714
JP 1995-45057 19950210
DT Utility
FS Granted
LN.CNT 1721
INCL INCLM: 435/069.520
INCLS: 536/023.500; 435/069.500; 435/325.000; 435/252.300; 435/252.330;
435/320.100
NCL NCLM: 435/069.520
NCLS: 435/069.500; 435/252.300; 435/252.330; 435/320.100; 435/325.000;
536/023.500
IC [6]
ICM: C12N015-24
ICS: C07K014-54; A61K038-20
EXF 536/23.5; 435/69.5; 435/69.52; 435/325; 435/252.3; 435/252.33; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 189 OF 196 USPATFULL on STN
AN 1999:67343 USPATFULL
TI Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) purified
from murine liver
IN Okamura, Haruki, Osaka, Japan
Tanimoto, Tadao, Okayama, Japan
Torigoe, Kakaji, Okayama, Japan
Kunikata, Toshi, Okayama, Japan
Taniguchi, Mutsuko, Okayama, Japan
Kohno, Keizo, Okayama, Japan

PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan
(non-U.S. corporation)
PI US 5912324 19990615
AI US 1995-502535 19950714 (8) <--
PRAI JP 1994-184162 19940714
JP 1995-45057 19950210
DT Utility
FS Granted
LN.CNT 1667
INCL INCLM: 530/351.000
INCLS: 530/413.000; 435/069.520; 424/085.100; 424/085.200
NCL NCLM: 530/351.000
NCLS: 424/085.100; 424/085.200; 435/069.520; 530/413.000
IC [6]
ICM: C07K014-54
ICS: C12N015-24
EXF 530/350; 530/351; 530/413; 530/388.2; 530/388.23; 435/69.1; 435/69.5;
435/7.9; 435/332; 435/335; 435/337; 435/70.21; 435/69.52; 514/2;
424/85.1; 424/85.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 190 OF 196 USPATFULL on STN
AN 1999:24526 USPATFULL
TI Process for induction culture of cytotoxic T lymphocytes having killing
activity against tumor cells
IN Ohno, Tadao, Ibaraki, Japan
Liu, Shu Qin, Ibaraki, Japan
Todoroki, Takeshi, Ibaraki, Japan
PA The Institute of Physical and Chemical Research, Saitama, Japan
(non-U.S. corporation)
PI US 5874307 19990223 <--
AI US 1995-492585 19950620 (8)
PRAI JP 1994-145908 19940628
DT Utility
FS Granted
LN.CNT 560
INCL INCLM: 435/372.300
INCLS: 435/373.000; 435/383.000; 435/325.000; 424/093.710; 424/534.000
NCL NCLM: 435/372.300
NCLS: 424/093.710; 424/534.000; 435/325.000; 435/373.000; 435/383.000
IC [6]
ICM: C12N005-08
ICS: C12N005-00; A61K035-14
EXF 435/373; 435/383; 435/325; 435/372.3; 424/93.71; 424/534

L4 ANSWER 191 OF 196 USPATFULL on STN
AN 1999:18709 USPATFULL
TI Methods and compositions for inducing complement destruction of tissue
IN Link, Jr., Charles J., Clive, IA, United States
Levy, John P., West Des Moines, IA, United States
PA Human Gene Therapy Research Institute, Des Moines, IA, United States
(U.S. corporation)
PI US 5869035 19990209 <--
AI US 1996-748344 19961113 (8)
DT Utility
FS Granted
LN.CNT 1951
INCL INCLM: 424/093.700
INCLS: 514/044.000; 424/277.100; 424/093.210; 435/240.200; 435/320.100
NCL NCLM: 424/093.700
NCLS: 424/093.210; 424/277.100; 435/320.100; 514/044.000
IC [6]
ICM: A01N043-04
ICS: A01N063-00; A61K039-00; C12N015-00
EXF 514/44; 424/93.7; 424/277.1; 424/93.21; 435/320.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 192 OF 196 USPATFULL on STN
AN 1998:147485 USPATFULL
TI Method of killing tumor cells

PA Hill Medical Corporation, La Jolla, CA, United States (U.S. corporation)
PI US 5840770 19981124 <--
AI US 1997-790683 19970128 (8)
RLI Continuation of Ser. No. US 1995-426088, filed on 21 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-111288, filed on 24 Aug 1993, now patented, Pat. No. US 5449522
DT Utility
FS Granted
LN.CNT 1693
INCL INCLM: 514/885.000
INCLS: 424/278.100; 424/722.000; 514/003.000; 514/004.000
NCL NCLM: 514/003.000
NCLS: 424/278.100; 424/722.000; 514/004.000; 514/023.000
IC [6]
ICM: A61K038-28
ICS: A61K033-14; A61K045-05
EXF 514/885; 514/883; 514/908; 514/3; 514/4; 514/23; 514/397; 424/568;
424/679; 424/717; 424/722; 424/278.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 193 OF 196 USPATFULL on STN
AN 96:108687 USPATFULL
TI Therapeutic use of vataletheine modulators in neoplasia
IN Knight, Galen D., Albuquerque, NM, United States
Scallen, Terence J., Albuquerque, NM, United States
PA The University of New Mexico, Albuquerque, NM, United States (U.S. corporation)
PI US 5578313 19961126 <--
AI US 1994-317548 19941004 (8)
RLI Division of Ser. No. US 1992-928725, filed on 13 Aug 1992, now patented, Pat. No. US 5370868 which is a continuation-in-part of Ser. No. US 1990-549440, filed on 6 Jul 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1906
INCL INCLM: 424/423.000
INCLS: 514/908.000
NCL NCLM: 424/423.000
NCLS: 514/908.000
IC [6]
ICM: A61K031-185
EXF 424/78.08; 424/423; 562/106; 514/553; 514/576; 514/578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 194 OF 196 USPATFULL on STN
AN 95:82121 USPATFULL
TI Pharmaceutical composition for immunoenhancement therapy
IN Hill, Albert F., 1755 Monaco Pkwy., Denver, CO, United States 80220 <--
PI US 5449522 19950912
AI US 1993-111288 19930824 (8)
DT Utility
FS Granted
LN.CNT 1621
INCL INCLM: 424/722.000
INCLS: 424/679.000; 424/717.000; 424/568.000; 514/004.000; 514/023.000;
514/397.000
NCL NCLM: 424/722.000
NCLS: 424/568.000; 424/679.000; 424/717.000; 514/004.000; 514/023.000;
514/397.000
IC [6]
ICM: A61K033-14
ICS: A61K035-55
EXF 514/885; 514/4; 514/23; 514/397; ; 424/679; 424/717; 424/722; 424/400;
424/568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 195 OF 196 USPATFULL on STN
AN 94:106570 USPATFULL
TI Therapeutic use of vataletheine modulators in neoplasia
IN Knight, Galen D., Albuquerque, NM, United States

PA University of New Mexico, Albuquerque, NM, United States (U.S.
corporation)
PI US 5370868 19941206 <--
AI US 1992-928725 19920813 (7)
RLI Continuation-in-part of Ser. No. US 1990-549440, filed on 6 Jul 1990,
now abandoned
DT Utility
FS Granted
LN.CNT 1756
INCL INCLM: 424/078.080
INCLS: 424/078.370; 514/563.000
NCL NCLM: 424/078.080
NCLS: 424/078.370; 514/563.000
IC [5]
ICM: A61K031-785
ICS: A61K031-795; A61K031-16
EXF 424/78.08; 424/78.35; 424/78.37
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 196 OF 196 USPATFULL on STN
AN 90:13026 USPATFULL
TI Implantable immunotherapy system using stimulated cells
IN Ingram, Marylou, 371 Patrician Way, Pasadena, CA, United States 91105
PI US 4902288 19900220 <--
AI US 1985-804068 19851203 (6)
DT Utility
FS Granted
LN.CNT 451
INCL INCLM: 604/891.100
INCLS: 424/095.000; 424/423.000; 424/085.100; 424/085.800; 604/890.100
NCL NCLM: 604/891.100
NCLS: 424/085.100; 424/093.710; 424/423.000; 424/534.000; 604/890.100
IC [4]
ICM: A61K009-22
ICS: A61K035-12
EXF 424/95; 424/85.1; 424/85.8; 435/240.2; 604/891.1
STN INTERNATIONAL LOGOFF AT 16:34:33 ON 03 MAR 2005